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Since the biomedical revolution there is a growing demand for pharmaceuticals proteins, so-
called biopharmaceuticals. These proteins are isolated from a natural resource or, more often, 
made using cell-based fermentation systems (heterologous expression systems), as the isolation 
from humans or other mammals does often not suffice in terms of quantity or quality. Plants 
provide a good alternative production platform that has unique advantages compared to the 
currently used heterologous expression systems.  
 
 
Genetic manipulation of plants 
 
Today, many plant species can be easily manipulated genetically. In 1982 the first plant was 
transformed with exogenous genes [1]. The gene transfer was accomplished by exploiting the 
soil-born bacterium Agrobacterium tumefaciens. A. tumefaciens can infect many plant species 
causing crown-gall disease. Upon infection the bacteria induces the formation of tumours that 
provide the bacteria with nutrients. To induce these tumours A. tumefaciens carries genes that 
lead to synthesis of plant hormones and metabolites in the plant on a plasmid called the 
tumour inducing (Ti) plasmid. The part of the plasmid that carries these genes, called the T-
DNA, is actively integrated in the plant genome. Subsequent expression of the integrated genes 
induces tumour formation. The genes encoding the enzymes to synthesise hormones and other 
metabolites can be easily replaced by (an)other gene(s) and does not affect the transformation 
potency of A. tumefaciens. When in 1985 a simple protocol for Agrobacterium-mediated 
transformation and regeneration of plants from leaf disks was described [2], this quickly 
became a widely used technique. Later a very efficient procedure to transform the model plant 
Arabidopsis thaliana involved only the simple dipping of the plant’s flowers in Agrobacterium 
suspension where after transformation results in transgenic seeds [3].  
Unfortunately A. tumefaciens has a specific host range. Although plant-bacterium 
incompatibility can sometimes be overcome using specialised tissue culture techniques, A. 
tumefaciens cannot be used for transformation of all plant species such as many monocots. 
Therefore direct gene transfer methods were also developed based on the introduction of 
naked DNA involving the ‘shooting’ of DNA coated gold or tungsten particles into plant cells 
[4] or chemical transformation or electroporation of protoplasts, where after integration into 
the plant genome occurs by chance. But, despite these alternatives being available 
Agrobacterium-mediated transformation has always been greatly preferred, because it has a 
great advantage. The use of A. tumefaciens ensures that the gene of interest is more often 
integrated at a location that allows transcription, as it makes use of the plant’s own DNA repair 
system for integration and DNA repair is most often needed in transcriptionally active sites.  
After transformation and plant regeneration, repeated selfing can create a stable 
transgenic plant as the transformed genes are transferred to the plant’s offspring in a Mendelian 
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fashion. However, the creation of stable transgenic plants is a lengthy and laborious process. 
Alternatively, plant transformation can be performed transiently. Expression of introduced 
genes upon transformation does not depend on integration into the genome [5-7]. Because the 
introduced genes that are not integrated are eventually broken down, the transformation is 
referred to as transient. Transient expression is often used as a pre-screen to evaluate the effect 
of expression of the gene or to obtain higher expression of the transformed gene, because in 
transient transformation there is no limit on expression imposed by the site of integration.  
A currently widely used technique based on transient expression is the Agrobacterium-
mediated transient transformation assay (ATTA). This technique includes the infiltration of an 
Agrobacterium suspension through the stomata into the spongy parenchyma of plant leaves 
using either a needle-less syringe (Figure 1) or by applying vacuum. Commonly used plant 
species for this technique include tobacco, tomato and potato. Gene expression can be 
detected from one day post infiltration (dpi) onwards. The peak of recombinant protein 
accumulation usually lies between 3 and 20 dpi dependent on the size and stability of the 
protein, whether or not a viral vector is used and whether or not gene silencing is triggered. 
Gene silencing is the natural mechanism of plants to combat viruses. As a response some plant 
viruses encode a silencing inhibitor in their genetic material. Co-expression of the silencing 
inhibitor p19 of tomato bushy stunt virus is often used to avoid gene silencing during transient 
expression. Due to the high levels of expression that can be obtained using transient 
transformation the ATTA technique may become the standard for recombinant protein 
production.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 1 !  Agrobacterium transient transformation assay. 
 
Antistoffen maken tegen menselijke ziekten, daar worden
planten steeds beter in. Hester van Santen
Patiënten met de ziek-te van Gaucher, een do-delijke en zeer zeldza-me stofwisselingsziek-te, krijgen sinds vorig
jaar medicijnen uit wortels – de oran-
je groente dus. In de plantencellen is
een menselijk gen ingebouwd, waar-
door de wortels het enzym maken dat
de patiënten missen.
Die wortelcellen zijn niet het enige
voorbeeld van deze techniek. Steeds
ingewikkelder menselijke eiwitten
kunnen gemaakt worden door plan-
ten. En dat begint, zeggen plantenon-
derzoekers, na twintig jaar onder-
zoek eindelijk vruchten af te werpen.
De Duitse plantentechnoloog Stefan
Schillberg zegt het zo: „Het aantal
mensen dat in de branche actief is
neemt af. Maar degenen die over zijn,
krijgen nu de technologie onder de
knie.”
Het gaat daarbij niet alleen meer om
enzymen, maar ook om speciaal ont-
wikkelde antistoffen. Een voorbeeld
daarvan stond deze week in het tijd-
schrift Proceedings of the National Acade-
my of Sciences. Arizona State University
maakte een werkend antilichaam te-
gen het westnijlvirus – in tabak.
Antistoffen, oftewel antilichamen,
zijn complexe eiwitten van het im-
muunsysteem. Antilichamen binden
zich aan bepaalde (lichaamsvreemde)
eiwitten en maken die zo onschade-
lijk. Dat kunnen eiwitten van het
westnijlvirus zijn bijvoorbeeld, of van
een tumor. De mogelijke toepassin-
gen zijn dus legio, maar in de praktijk
zijn antilichamen vooral in zwang als
dure kankerbehandelingen. Het afge-
lopen decennium waren antilicha-
men het snelst groeiende marktseg-
ment in de farma-industrie.
INSULINE Want: kunstmatige antili-
chamen zijn kostbaar. De antilicha-
men, die uit vier stukken eiwit be-
staan, kunnen niet via chemische weg
gemaakt worden, en evenmin in bac-
teriën. Dat laatste gebeurt bijvoor-
beeld wel met insuline. Farmaceuti-
sche bedrijven produceren de antili-
chamen in genetisch gemanipuleerde
zoogdiercellen. Om precies te zijn: in
celkweken van de eierstokken van
Chinese dwerghamsters. Dat gaat in
fabrieken in grote tanks, tot 20.000 li-
ter, vol met cellen.
De afgelopen twintig jaar is de op-
brengst per liter sterk verbeterd. Die
werd tien tot honderd keer zo groot.
Maar biotechnologen discussiëren
ook over alternatieven voor de gene-
tisch gemanipuleerde hamstercellen.
Er is veel kennis over de kweek, de op-
brengsten zijn prachtig, maar de ge-
netisch gemanipuleerde cellen wer-
ken niet altijd goed en de kweekme-
dia zijn duur. Er moet ook met andere
soorten cellen gewerkt worden, vin-
den zij. Insectencellen, gisten, toch
bacteriën misschien. Of planten.
“Met planten kun je die antilichamen
veel goedkoper produceren”, zegt
Qiang Chen. Chen, onderzoeker aan
Arizona State University, maakten in
tabaksplanten de antilichamen die
het westnijlvirus aanvallen. Muizen
die met het virus waren geïnfecteerd,
gingen niet dood als ze daarna een
dosis ‘plantaardig’ antiserum kregen.
“Dit is het eerste antilichaam dat
werkt bij de behandeling van een
ziekte”, zegt Chen.
Plantentechnologen zijn eensgezind
over de voordelen. Ten eerste: massa-
productie is alleen een kwestie van
een grote broeikas bouwen. Chen
schat dat hij op één vierkante meter
kas planten kan kweken voor vier pa-
tiënten. Wel moet eerst nog blijken
dat zijn antilichaam ook patiënten
geneest – dat is allerminst vanzelf-
sprekend. Zo ja, dan is de hoop dat
planten antilichaambehandelingen
beschikbaar maken voor een grote
groep minder kapitaalkrachtige
mensen. De plantkundigen denken
aan patiënten in ontwikkelingslan-
Met tabak
Eén vierkante
meter met planten
kan vier
patiënten helpen
den, lijdend aan infecties
zoals westnijlvirus. De
Duitse plantentechnoloog
Schillberg verbouwt ta-
baksplanten die antilicha-
men maken voor een expe-
rimentele vaginale gel te-
gen aids. Ze staan in een kas
van het biologische Fraun-
hofer-Institut IME in
Aken.“Er zijn veel patiën-
ten, en dus wil je veel antili-
chamen produceren.”
Een tweede mogelijk voor-
deel van antilichamen uit
planten is de veiligheid van
de productie. Planten zijn
doorgaans geen drager van
menselijke ziekteverwek-
kers. Dat is de reden waar-
om patiënten met de ziekte
van Gaucher nu met een
menselijk eiwit uit planten
behandeld worden. De
tienduizenden patiënten
die er van afhankelijk zijn,
kregen hun enzym tot vo-
rig jaar van fabrikant Gen-
zyme. Dat bedrijf moest de
productie echter stilleggen
nadat een virus de hamster-
cellen had geïnfecteerd. De
Amerikaanse geneesmid-
delenautoriteit verleende
daarom toestemming aan
de Israëlische fabrikant
Protalix om hun experi-
mentele enzym uit peen
versneld te leveren.
Het succes van Protalix
gonst rond in de plantenbi-
otechnologie. Maar het
vakgebied kent nog geen
rijke oogst van toepassin-
gen. „De productie in plan-
ten heeft ook nadelen”,
zegt de Wageningse plant-
kundige dr. Arjen Schots.
Schots werkt aan plantaar-
dige productie van mense-
lijke antilichamen, in op-
dracht van de farmaceuti-
sche industrie. Hij wil niet zeggen
wát hij maakt, en voor wie – dat is
commercieel gevoelig. Hij wil wel
vertellen hoe het vakgebied vordert.
S U I K E R S TA A R T E N Een van de belang-
rijkste problemen heeft te maken met
de ‘suikerstaart’ van de eiwitten, zegt
hij. Plantaardige en dierlijke eiwitten
zijn beide voorzien van typische sui-
kerketens die aan het eiwit vastzitten.
Helaas zijn de suikers bij planten en
dieren niet gelijk. Planten kunnen de
‘m e n s e l ij k e ’ suikerstaarten niet aan
de antilichamen vastmaken (‘glycosy-
leren’). Dat kan de werking verslech-
teren, en de plantensuikers kunnen
allergische reacties veroorzaken.
Chen hoefde dat in zijn studie naar
westnijlvirus niet op te lossen. Zijn
antilichaam bleek ook met plantaar-
dige suikerstaarten te werken. En de
eiwitten voor Schillbergs vaginale gel
werken niet ín, maar óp het lichaam
(als de vagina als de buitenkant van
het lijf beschouwd wordt). “Ve r g e l e -
ken met een antilichaam dat geïnjec-
teerd wordt, is dit gemakkelijker.”
Meerdere onderzoeksgroepen – on-
der andere in Wageningen – hebben
de afgelopen jaren zogeheten ‘gehu-
maniseerde’ planten gekweekt waar-
in de aanmaak van bepaalde plantaar-
dige suikerstaarten is uitgeschakeld.
Schots: “Voor het ene antilichaam
werkt het beter dan het andere. Als
we wisten waaraan het lag, waren we
al een eind verder.” Dat vakgebied is
sterk in ontwikkeling, en niet alleen
bij planten. Er zijn al antilichamen
geproduceerd in ‘gehumaniseerde’
gisten, en zelfs wordt gewerkt aan
bacteriën die de menselijke glycosyle-
ring kunnen nabootsen.
Als die horde genomen is, is er nog
tijd en geld nodig om zo’n plantaar-
dig antilichaam op de markt te krij-
gen. Het tijdschrift Nature schreef er
vorig jaar een verontwaardigd hoofd-
redactioneel commentaar over. Bin-
nen het Europese samenwerkingsver-
band Pharma-Planta werken univer-
siteiten aan medicijnen uit transgene
planten. De Europese geneesmidde-
lenautoriteit EMEA, deed te weinig
om de kwaliteitscontroles aan te pas-
sen aan de productie in planten, vond
Nature. ‘EM EA moet proactiever
worden’, schreef het blad.
“Je moet opboksen tegen de gevestig-
de orde”, zegt Schots. Hij denkt dat er
wel degelijk plaats is voor een plant-
aardig systeem. “We staan er absoluut
beter voor dan tien jaar geleden. Het
moet alleen nog nét een tikkeltje be-
t e r. ”.
aids bestrijde
Een tabaksplant wordt geïnfiltreerd met bacteriën waarin DNA zit dat leidt tot de productie van medicinale
eiwitten. Het DNA wordt opgenomen in het genoom van de plant. Later kan dan het gewenste eiwit
worden geoogst. FOTO RIEN ZILVOLD
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Plants as a production platform for biopharmaceuticals 
 
Of the biopharmaceuticals that are produced in heterologous expression systems and are 
approved for medical use in humans in 2010, 17 were produced in the bacterium Escherichia 
coli, 4 in the yeast Saccharomyces cerevisiae and 32 in mammalian cell lines (mainly in 
Chinese hamster ovarian (CHO) and murine myeloma (SP2/0) cells) [8]. The use of E. coli is 
most cost effective, because relatively simple media and culture conditions are sufficient to 
support its growth. However, E. coli is a prokaryote and of all expression platforms is the most 
distantly related to humans and cannot produce all human proteins with the same quality as 
the original. Yeasts are single-cell eukaryotic organisms and are often able to properly fold 
proteins and carry out post-translational modifications, but have a tendency to hyper-
glycosylate [9]. Mammalian cells produce the highest quality of proteins with regard to 
similarity to human proteins, but are the most expensive to maintain.  
Plants have been demonstrated to be a good alternative production platform [10-13]. 
Plants are higher eukaryotes and have the ability to correctly fold complex proteins, assemble 
heteromultimeric protein complexes [14] and carry out post-translational modifications. While 
they have the same capabilities as mammalian cells, they require much less specialized care 
and are therefore much cheaper to maintain. The production of insulin in safflower 
demonstrated that plants could even be cheaper than the use of E. coli [15]. Insulin production 
could be easily scaled up in safflower, with an estimated production of 2,5 kilo of insulin per 
hectare. Thus, for the worldwide demand only 65 square kilometre of land, i.e. 3 commercial 
farms in North America, is required [16].  
The speed of protein production in plants using transient expression is exploited in a 
personalized medicine approach used to treat Non-Hodgkin lymphoma (NHL). NHL is 
characterized by the uninhibited clonal proliferation of a B-cell. Because each B-cell is unique 
in the membrane-bound antibodies it carries, an anti-idiotype immune response against this 
antibody could help clear the malignant B-cells from the body. Thereto the variable domain of 
the antibody should be sequenced to allow synthetic gene synthesis followed by production of 
the antibody for immunization of the patient. Thus, each patient requires a personalized anti-
idiotype ‘vaccine’. Grams of antibody can be produced in plants in a matter of weeks using the 
ATTA technique. Because no expression platform can compete with plants in the terms of 
speed [17], it is the production platform of choice for production of the NHL-vaccine. The 
company Icon Genetics has recently announced the successful completion of the Phase I 
clinical study with plant-produced personalized NHL-vaccines whereby 73% of the patients 
were found to have mounted a tumour-specific immune response [18].  
The ATTA technique is also used for large-scale production of biopharmaceuticals [19]. 
The production strategy of the company Kentucky Bioprocessing involves the large-scale 
growth of Nicotiana benthamiana plants in green houses and automated vacuum-infiltration of 
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Agrobacterium and plant harvest. Kentucky Bioprocessing focuses mainly on the production of 
monoclonal antibodies for use as microbiocides and mucosal vaccines to prevent infection 
with pathogens such as Clostridium difficile, Papillomavirus, HIV, Parvovirus, Rabies virus and 
Ebola virus. They have also demonstrated the feasibility to rapidly deliver large quantities of 
purified recombinant protein needed as vaccine in case of a pandemic threat. An important 
fact, as for instance the production of influenza-viruses in current egg based vaccine 
production systems has limited capacity and speed to respond to pandemic threats [20]. 
The company Protalix Biotherapeutics produces the first approved biopharmaceutical 
for clinical use in humans. This company exploits the fact that plants can produce the enzyme 
glucocerebrosidase with N-glycans terminating in mannoses, which is sold as Taliglucerase 
alfa. Glucocerebrosidase is a lysosomal enzyme that catalyses the hydrolysis of 
glycosylceramide. In patients suffering from Gaucher disease a genetic defect renders this 
enzyme non-functional leading to accumulation of glycosylceramide in lysosomes. Associated 
symptoms include bruising, fatigue, anaemia, low blood platelets, and enlargement of the liver 
and spleen. Gaucher disease is treated with life-long enzyme-replacement therapy. It has been 
shown that uptake of the enzyme by macrophages relieves the symptoms associated with 
Gaucher disease to a major extent. To ensure uptake of glucocerebrosidase by macrophages 
the enzyme needs to carry N-glycans with terminal mannose residues to enable endocytosis by 
the cell through the mannose receptor. Because glucocerebrosidase produced in mammalian 
cells does not carry N-glycans with terminal mannoses, it needs to undergo several 
deglycosylation steps in vitro. In plants N-glycans with terminal mannoses can be achieved in 
vivo. Thereto, Protalix expressed glucocerebrosidase in carrot cells with a vacuolar targeting 
signal [21]. This plant-based glucocerebrosidase was demonstrated to perform better than its 
mammalian-cell produced counterpart as in vitro deglycosylation leads to a heterogeneous 
population of N-glycans often without the required terminal mannoses. Therefore, 
Taliglucerase alfa is considered a ‘bio-better’ as opposed to a ‘bio-similar’. The approval for 
Taliglucerase alfa was accelerated because Genzyme, the only company that produced 
glucocerebrosidase in CHO cells (trade name Cerezyme) at the time, had manufacturing 
difficulty due to contamination with Vesivirus 2117 [22]. While this virus is not harmful for 
humans, it hampers the growth of CHO cells. This illustrates another important advantage of 
plants as a production platform for biopharmaceuticals, namely their low risk of contamination 
with mammalian pathogens, especially human viruses as these cannot replicate in plant cells.  
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Engineering of the N-glycosylation pathway in plants 
 
The chance of other plant-based biopharmaceuticals reaching the market is greatly enhanced 
by the capability of plants, upon engineering of the glycosylation pathway, to produce proteins 
with homogeneous human-like N-glycan profiles. The biological role of N-glycans is to aid in 
protein folding, provide protein stability and enable (sub)cellular protein trafficking and 
receptor mediated signalling. In all eukaryotes N-glycosylation occurs co-translational when 
the oligosaccharyl transferase complex encounters a N-glycosylation signal. The signal for N-
glycosylation is the amino acid sequence asparagine-X-serine/threonine, whereby X can be 
any amino acid except proline. A common N-glycan precursor is than attached to the 
asparagine in the endoplasmic reticulum. In the Golgi several sugar residues are removed from 
the precursor by glycosylhydrolases whereas other sugar residues are attached by 
glycosyltransferases, thereby creating a specific N-glycan type dependent on species, tissue, 
environment and the protein itself.  
The plant repertoire of glycan modifying enzymes is limited, because plants are less 
complex organisms and use N-glycosylation for protein folding and stability and not or to a 
minor extent for cellular protein trafficking and receptor mediated signalling. Unsurprisingly, 
plants do not produce N-glycans that are identical to human/mammalian N-glycans (Figure 2). 
Differences in N-glycan type can lead to a reduced protein half-life, loss of function and 
increased immunogenicity [23]. Increased immunogenicity is one of the main concerns of 
regulatory bodies when dealing with biopharmaceuticals. An immune response against the 
therapeutic protein may lead to allergic symptoms or even septic shock. Therefore, the N-
glycosylation pathway of plants has been engineered to produce proteins carrying human N-
glycan types [24].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 !  Schematic representation of typical plant and mammalian N-glycans. 
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The majority of secreted plant proteins carry a diantennary N-glycan structure with 
terminal N-acetylglucosamine or paucimannosidic oligosaccharides (Figure 2), both with β1,2-
xylose and core α1,3-fucose, abbreviated as GnGnXF3 and MMXF3, respectively [25-28]. Only 
the β1,2-xylose and the core α1,3-fucose do not occur on human N-glycans. Because these 
sugar residues are potentially immunogenic, the glycosyltransferases responsible for the 
addition of these sugar residues were either silenced or mutated successfully in several plant 
species [26-31]. Human N-glycans often carry a core α1,6-fucose. This sugar residue was 
added to the N-glycans on a plant-produced antibody by co-expression of α1,6-
fucosyltransferase 8 [32, 33]. Next to that, the antennae of human N-glycans are often 
extended with terminal β1,4-galactose and/or sialic acid. In planta β1,4-galactosylation and 
sialylation has also been achieved [25, 34-37]. Furthermore, while plants only produce 
diantennary N-glycans, human N-glycans can be bisected or branched (Figure 2). Plant 
expression of N-acetylglucosaminyltransferases III, IV and V resulted in the synthesis of 
different bisected and branched complex N-glycans [38, 39].  
Engineering of human-like N-glycans in plants is in part successful due to the fact that 
plants rarely show aberrant phenotypes upon engineering of the N-glycosylation pathway. 
Furthermore, antibodies produced in glyco-engineered plants were even shown to be more 
homogeneously glycosylated compared to CHO cell produced antibodies, which improved 
antibody functioning [28, 36]. A more homogenous glycosylation pattern is most likely due to 
the fact that the plant repertoire of glycan modifying enzymes is limited. The advances of 
glyco-engineering cover over a decade of research and now lead to possibilities to engineer 
virtually any N-glycan. Potentially interesting N-glycan types with regards to immunogenicity 
and cellular targeting may be identified and exploited for biopharmaceutical and vaccination 
purposes [40]. 
 
 
Biopharmaceuticals for the treatment of inflammatory disorders  
 
Currently, biopharmaceuticals are commonly used in the treatment of autoimmune diseases 
such as diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis and other chronic 
inflammatory disorders such as inflammatory bowel diseases. In autoimmune diseases and 
inflammatory disorders the immune system reacts to, respectively, self-antigens or harmless 
non-self molecules causing chronic inflammation and tissue damage. High serum 
concentrations of signalling molecules used by the immune system characterize chronic 
inflammation. The largest group of signalling molecules of the immune system is the cytokines. 
During the onset of an infection, cells of the innate immune system (such as dendritic cells and 
macrophages) recognize the pathogen and start secreting pro-inflammatory cytokines such as 
tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-12 and IL-23. Depending on the 
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type of pathogen, specific cytokines are secreted by antigen presenting cells that drive the 
proliferation of a specific T helper (Th) cell subset of the adaptive immune system. Generally, 
intracellular pathogens such as viruses and intracellular microbes trigger a Th1 response, while 
extracellular parasites trigger Th2 cell proliferation. More recently, the Th17 subset was 
characterized and shown to proliferate upon infection with extracellular bacteria and fungi, 
including mucosal bacteria upon breaching epithelial mucosae. Dependent on the Th subset 
specific immune cells of both the innate and adaptive immune system are activated and B cells 
are induced to secrete specific immunoglobulin isotypes that are best equipped to eliminate 
the invading pathogen. These effects are also mediated by cytokines. Th1 cells predominantly 
secrete interferon (IFN)-γ and lymphotoxin (LT), while Th2 cells secrete IL-4, IL-5, and IL-13. 
Th17 cells secrete IL-17, IL-21 and IL-22. After the pathogen is cleared the immune system 
returns to homeostasis through the secretion of cytokines such as IL-10 and transforming 
growth factor (TGF)-β, which are mainly secreted by innate immune cells and T regulatory 
cells. Cytokines are pleiotropic, meaning that they can exert many different functions. 
Dependent on the environment and stimuli given, some cytokines, like TGF-β and IL-22, exert 
either pro- or anti-inflammatory responses.  
Autoimmune diseases are often associated with the activation and proliferation of Th1 
and Th17 cells, whereas Th2 cells dominate allergic responses. Current therapies to treat 
chronic inflammation often include the use of antibodies that can neutralize pro-inflammatory 
cytokines or immune receptors that support inflammation. The largest share of the global 
biopharmaceutical market ($99 billion in 2009) belong to antibody-based biopharmaceuticals, 
mainly antibodies that neutralize TNF-α ($18 billion in 2009) [8]. 
 
 
Outline of this thesis 
 
This thesis describes the use of Nicotiana benthamiana as a production platform for 
biopharmaceuticals that are currently or may be used in the future to treat autoimmune 
diseases and inflammatory disorders. In Chapter 2 we describe the expression of the cytokine 
IL-10. This cytokine was suggested to have great anti-inflammatory potential as it can reduce 
the activity of macrophages, inhibit antigen presentation by dendritic cells and inhibit the 
production of pro-inflammatory cytokines by innate immune cells and adaptive immune cells, 
such as T and B cells [41-44]. The yield of cytokines expressed in heterologous hosts is often 
poor. The suggested reason for this is that cytokines must be inherently unstable as they often 
have a short half-life in vivo. We demonstrated that for IL-10 the major yield-limiting factor is 
not intrinsic instability, but its ability to swap domains intended to result in dimers. Upon 
expression in planta this so-called ‘3D domain swapping’ lead to large multimers, which were 
visible as intracellular granules of organelle size. By protein engineering we were able to 
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prevent multimerisation of IL-10 and increase its yield 30-fold. 
In Chapter 3 we compared the plant-based expression of IgA with IgG. The use of the 
IgG antibody isotype is the standard in the clinic today. But, other isotypes such as IgE and IgA 
may offer, yet unexplored, advantages. IgA naturally blocks pro-inflammatory responses 
mediated by IgG and IgE. This would be an interesting ‘bonus’ trait for an antibody used to 
reduce inflammation. Although ample experience with expression of IgG exists, reports on the 
production of IgA are scarce. We expressed IgA variants of the three antibodies Infliximab, 
Adalimumab and Ustekinumab, which are used as immunosuppressors in the clinic today, and 
compared it with the expression of the original IgG variants. Infliximab (trade name Remicade) 
and Adalimumab (trade name Humira) both neutralize TNF-α. Ustekinumab (trade name 
Stelara) is directed against the p40 subunit shared by IL-12 and IL-23 and able to neutralize 
these pro-inflammatory cytokines. We demonstrate that IgA can be produced equally well in 
plants in terms of yield and binding capacity, but receives a different N-glycan. The type of N-
glycan a protein receives upon expression in Nicotiana benthamiana can be determined by 
protein intrinsic properties, in this case the antibody isotype.  
In Chapter 4 we continue our research on IgA and transiently express secretory (s)IgA, 
a heteromultimeric protein complex. sIgA consists of two IgA molecules that are kept together 
by the joining chain and this dimeric IgA is enveloped by a part of the polymeric-Ig-receptor 
called the secretory component. The challenge in transient expression of a heteromultimeric 
protein is to achieve expression of all necessary genes simultaneously in as many cells as 
possible and in the most efficient ratio that reflects the stoichiometry of the protein complex. 
Use of a multi-gene expression vector increased sIgA yield compared to co-infiltration of 
separate vectors. However, the transformation method turned out not to be the production 
bottleneck. We demonstrated that not joining chain expression, but its incorporation in the 
protein complex is the limiting factor for sIgA yield. We hypothesize that the partial N-
glycosylation of the tailpiece of the alpha heavy chain and/or the joining chain are the cause 
of this inefficient incorporation.  
In Chapter 5 we study the plant-based expression of a helminth protein. Parasitic 
helminths have often evolved such that they employ immune modulatory proteins to evade the 
host’s immune system to sustain infection. Their ability to control the immune system has even 
been exploited in treatment of inflammatory bowel disease and allergies [45]. In this chapter 
we focused on omega-1, a Schistosoma mansoni egg antigen. Omega-1 is a T2 RNase that 
modifies the activity of dendritic cells and upon antigen presentation polarizes T helper cells 
towards a Th2-phenotype. This effect is not only facilitated by its enzymatic activity, but also 
by its N-glycosylation that ensures internalisation by the dendritic cell. Upon expression in 
Nicotiana benthamiana the majority of omega-1 was secreted to the apoplast. Isolation of 
apoplast proteins was a good starting point for purification, as little ‘contaminating’ proteins 
reside in this extracellular compartment. Although plant-produced omega-1 was shown to 
predominantly carry the typical plant N-glycan MMXF3, omega-1 from S. mansoni 
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predominantly carries N-glycan types with terminal Lewis-X motifs. Lewis-X motifs consist of a 
β1,4-galactose and α1,3-fucose on the terminal N-acetylglucosamine. To be able to investigate 
the influence of these Lewis-X motifs on the function of omega-1 we co-expressed omega-1 
with α1,3-fucosyltransferase 9a from Tetraodon nigriviridus and β1,4-galactosyltransferase 1 
from Danio rerio. Controlled expression of these glycosyltransferases resulted in the production 
of omega-1 with a significant proportion carrying N-glycans with one or two terminal Lewis-X 
motifs. This demonstrated the potential of plants to produce, often immune-modulatory, 
helminth proteins to elucidate their biological function. Research on these proteins may reveal 
new therapeutic candidates.  
Finally, when expressing genes heterologously, matching of the codon use of the gene 
of interest to the codon use of the production host can boost protein yield tremendously. 
Although this is a widely known fact, a general codon optimisation strategy has never been 
described and the results with the various published strategies are highly variable. We 
developed a strategy based on a general expression-linked codon bias found across plant 
species and turned out to be robustly successful. This encouraged the research described in 
Chapter 6 wherein we demonstrate that codon optimisation of heterologously expressed genes 
can improve protein yield by increasing mRNA stability as well as translatability. To support 
our experimental data we employed a large database study on the codon use of several 
species. We demonstrate that this general codon bias found in plants extends to other 
kingdoms of life. In our investigations to explain this general codon bias we found that 
structural mRNA characteristics are correlated with expression. The mRNA molecules of highly 
expressed genes are generally more stable due to an increased amount of nucleotide bonds, 
but also display a more equal distribution of these bonds over the molecule, making the 
mRNA structure more ‘airy’ to allow efficient translation.  
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Abstract 
 
Heterologous expression platforms of biopharmaceutical proteins have been significantly 
improved over the last decade. Further improvement can be established by examining the 
intrinsic properties of proteins. Interleukin-10 (IL-10) is an anti-inflammatory cytokine with a 
short half-life that plays an important role in re-establishing immune homeostasis. This 
homodimeric protein of 36 kDa has significant therapeutic potential to treat inflammatory and 
autoimmune diseases. In this study we show that the major production bottleneck of human 
IL-10 is not protein instability as previously suggested, but extensive multimerisation due to its 
intrinsic 3D domain swapping characteristic. Extensive multimerisation of human IL-10 could 
be visualised as granules in planta. On the other hand, mouse IL-10 hardly multimerised, 
which could be largely attributed to its glycosylation. By introducing a short glycine-serine-
linker between the fourth and fifth alpha helix of human IL-10 a stable monomeric form of IL-
10 (hIL-10mono) was created that no longer multimerised and increased yield 30-fold. However, 
hIL-10mono no longer had the ability to reduce pro-inflammatory cytokine secretion from 
lipopolysaccharide-stimulated macrophages. Forcing dimerisation restored biological activity. 
This was achieved by fusing human IL-10mono to the C-terminal end of constant domains 2 and 
3 of human immunoglobulin A (Fcα), a natural dimer. Stable dimeric forms of IL-10, like Fcα-
IL-10, may not only be a better format for improved production, but also a more suitable 
format for medical applications. 
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Introduction  
 
Recombinant DNA technology has revolutionized the production and application of 
pharmaceutical proteins. Current heterologous production hosts include bacteria, yeasts, insect 
and mammalian cells, and, more recently, plants. Most expression systems have been rapidly 
improved in terms of yield and cost efficiency in the last decades. However, these advances 
have mainly been achieved with antibodies and hormones, which are relatively stable 
proteins. Recently more attention in optimizing the production of biopharmaceutical proteins 
is directed to their intrinsic properties that result of post-translational modifications and folding 
processes. Improved insight in these processes may increase the yield of still poorly expressed 
proteins.  
Many cytokines have a promising therapeutic potential. However, several cytokine 
families show a short half-life in vivo and are poorly expressed in heterologous hosts. Human 
interleukin-10 (IL-10) is such a cytokine that may be used for treatment of many inflammatory 
and autoimmune diseases due to its immunosuppressive properties [1, 2]. Generally, IL-10 
facilitates the return of the immune system to homeostasis after clearance of antigen and plays 
an important role in conferring oral tolerance. It exerts its function through reduction of the 
activity of macrophages, inhibition of antigen presentation by dendritic cells and inhibition of 
the production of pro-inflammatory cytokines by antigen presenting cells and T lymphocytes 
[3-6]. The human IL-10 gene encodes a 178 amino acid protein including a N-terminal signal 
peptide for secretion. An IL-10 monomer consists of six alpha helices (A-F) with two internal 
disulphide bridges (Cys30-Cys126 and Cys80-Cys132). Two monomers are stabilized into a 
biologically active dimer by exchanging their C-terminal domains composed of the helices E 
and F, a process called 3D domain swapping [7-9]. 
Human interleukin-10 has previously been produced in bacterial systems for medical 
purposes [10, 11], and in insect and mammalian cells for research purposes. The use of plants 
as a production platform for IL-10 provides a cheap alternative compared to bacterial, insect 
and mammalian expression systems. As plants are eukaryotes they can correctly fold and 
assemble proteins, and are able to perform complex post-translational processes, such as 
glycosylation. Plants as production hosts for IL-10 offer an extra advantage as they have a low 
risk of contamination with human pathogens, especially relevant when producing 
immunosuppressive molecules for medical application. Human IL-10 was produced for the 
first time in planta by stable transformation of a low-alkaloid Nicotiana tabacum variety [12]. 
High transcript levels were contrasted by low protein levels with a maximum of 0.000069% of 
total soluble protein (TSP). Biological activity of plant-derived human IL-10 was shown in vitro 
and in vivo without the need for purification [12, 13]. Yield could be increased to 0.55% of 
TSP by transient expression of human IL-10 fused to an elastin-like polypeptide combined with 
retention in the endoplasmic reticulum (ER), but biological activity was not confirmed [14]. 
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From these experiments it was concluded that protein instability is a major bottleneck for 
human IL-10 production.  
We show that 3D domain swapping is an important bottleneck for human IL-10 
production in Nicotiana benthamiana. Human IL-10 multimerises extensively as was visualised 
in situ using GFP fusions. Domain swapping could be prevented by engineering a stable 
monomer [15] that regained biological activity through fusion to the Fc portion of IgA, a 
natural dimer. Identification of this expression bottleneck enabled us to increase yield 
considerably to levels that approach the economic threshold. 
 
 
Results  
 
Yield of mouse IL-10 is significantly higher compared to human IL-10 
To determine the maximum yield of human (h) and mouse (m) IL-10 in a transient expression 
system, leaves of 5-6 weeks-old Nicotiana benthamiana plants were agro-infiltrated. The 
expression vector contained the complete native coding sequence of the human or mouse IL-
10 gene with or without a 3’ tag coding for a thrombin cleavage site, a 6xHis-tag and the ER 
retention sequence KDEL (thk) (Figure 1a). Adequate transcription of the constructs was 
confirmed two and three days post infiltration (dpi) through determination of mRNA levels by 
means of quantitative PCR. Similar relative transcription levels (around 1000 transcripts of IL-
10 per β-actin transcript) were found for all four constructs on both days (Figure 1b). Human 
and mouse IL-10 yield was determined on 1-6 dpi using a sandwich ELISA (Figure 1c and 1d). 
Maximum human and mouse IL-10 yield was obtained between 2-4 dpi. Although maximum 
yields were similar for native and ER-retained IL-10, expression levels of ER-retained IL-10 
remained higher over time. Considering average yields from 2 to 5 dpi showed that ER-
retained IL-10 resulted in 11 and 10-fold more protein for human and mouse IL-10 
respectively. More striking was the observation that even though mRNA transcript levels were 
comparable, mouse IL-10 yield was significantly higher when compared to human IL-10 
(P=0.043), regardless of ER-retention (P=0.003). The average yield of mIL-10 was 19 and 17-
fold higher for secreted and ER-retained IL-10 respectively. Retention of a protein in the ER can 
lead to increased yield due to the presence of chaperones that assist protein folding and the 
absence of many proteases explaining reduced degradation over time [16]. However, as the 
difference in expression level between human and mouse IL-10 was significant despite ER-
retention another factor than protein degradation supposedly influences yield.  
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Figure 1 !  Expression data of human and mouse IL-10 in transiently transformed Nicotiana benthamiana 
leaves. Use of the thk-tag gives an increasing boost in yield for both human and mouse IL-10 from 2 days 
post infiltration (dpi). Strikingly, mouse IL-10 yield was significantly higher compared to human IL-10, 
regardless of ER-retention. Differences in yield could not be explained by differences in mRNA transcript 
levels. A Schematic representation of expression cassettes and vector used. Expressed genes include the 
native coding sequence of the human (h) or mouse (m) IL-10 gene including signal peptide for secretion 
(SP) with or without a 3’ tag coding for a thrombin cleavage site, a 6xHis-tag and the ER retention 
sequence KDEL (thk). All expression cassettes include the 35S promoter of the Cauliflower mosaic virus 
with duplicated enhancer (d35S), 5’ leader sequence of the Alfalfa mosaic virus RNA 4 (AlMV) and 
Agrobacterium tumefaciens nopaline synthase transcription terminator (Tnos). B Relative transcript levels 
of IL-10 versus actin as determined by Q-PCR on 2 and 3 dpi (n=3, error bars indicate standard error). C/D 
Human and mouse IL-10 yield in crude extracts (1 to 6 dpi) in µg per mg total soluble protein (TSP) as 
determined by ELISA (n=3, error bars indicate standard error).  
 
 
 
Human IL-10 accumulates in granules  
To investigate the cellular fate of human and mouse IL-10 in planta, GFP was fused C- and N-
terminally to both proteins and expression was monitored by confocal microscopy. Plants 
expressing hIL-10-GFP showed fluorescent globular structures up to 5 m in size (Figure 2b). 
These granules resembled Golgi-bodies and were, regardless of their size, highly mobile as 
they travelled along ER strands. In contrast, mIL-10-GFP showed no or negligible signs of this 
phenomenon (Figure 2c). For both proteins, fluorescence was observed in the nuclear 
envelope, the ER and, putatively, the apoplast as expected for a secretory protein (Figure 2a). 
The results of C-terminal GFP fusions harbouring the native IL-10 signal peptides, like the 
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unfused variants, are shown. N-terminal GFP fusions gave similar results (data not shown). 
Formation of granules may be caused by aggregation of folding intermediates or extensive 
multimerisation of human IL-10. Since mouse IL-10 did not show granules as observed for 
human IL-10, we assumed that formation of granules hinders yield of biologically active IL-10.  
 
Figure 2 !  Whole mount confocal microscopy output of leaves expressing human or mouse IL-10 fused 
to GFP. Highly mobile globular granules of up to 5µm in size were observed traveling along cytoplasmic 
and/or ER strands for SP-hIL-10-GFP only. A GFP preceded by the Arabidopsis thaliana chitinase signal 
peptide for secretion (SP-GFP). B/C The native open reading frame of human (h) and mouse (m) IL-10 
including the native signal peptide (SP) with GFP fused C-terminally.  
 
 
Glycosylation of IL-10 hinders granulation 
Human and mouse IL-10 have a homology of 73% at amino acid level. The most apparent 
difference between human and mouse IL-10 during post-translational processing is the 
glycosylation of mouse IL-10. Both proteins have one potential N-glycosylation site (Asn134) 
that is not glycosylated, while mouse IL-10 has yet another site that is glycosylated (Asn29). As 
glycosylation can stabilize a protein and influence protein folding by mediating interaction 
with chaperones, it may explain the difference in protein processing between human and 
mouse IL-10. To investigate the influence of glycosylation of IL-10 on granulation, the 
glycosylation site of mouse IL-10 was introduced in human IL-10 and removed from mouse IL-
10. In both cases this was done by a single nucleotide mutation causing the serine of human 
IL-10 on position 29 to change into an asparagine and vice versa (hIL-10S29N and mIL-10N29S). 
Figures 3a and 3d show a micrograph of GFP fused C-terminally to hIL-10S29N and mIL-10N29S, 
respectively. Granulation of hIL-10S29N-GFP was greatly reduced, however, never completely 
absent. For mIL-10N29S-GFP granulation was induced, however, never reached the same extent 
as seen for hIL-10-GFP. 
To confirm the presence of a N-glycan on hIL-10S29N and the absence on mIL-10N29S, 
all non-GFP fused variants were analysed by Western blot (Fig 3b and 3e). E. coli produced 
human and mouse IL-10, hence non-glycosylated, had the same molecular mass of 18 kDa 
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when compared to plant-produced hIL-10 and mIL-10N29S. The molecular weight of mIL-10 
and hIL-10S29N was, as expected upon single N-glycosylation, approximately 1.5 kDa higher. 
Both mIL-10 and hIL-10S29N samples also showed a small proportion of non-glycosylated IL-
10.  
The effect of glycosylation on human and mouse IL-10 yield was compared. ELISA 
indicated that removal of the glycosylation of mouse IL-10 decreased yield on average 4-fold, 
however, this was found not to be significant (Figure 3c). Introducing a glycosylation site in 
human IL-10 did not lead to a yield increase (Figure 3f), however, for hIL-10 the band 
intensities on Western blot (Figure 3b) showed that an increased amount of glycosylated hIL-
10 was extracted. This discrepancy might be explained by interference of the glycan on Asn-
29 of hIL-10S29N with the binding of the monoclonal antibodies used in ELISA.  
 
Figure 3 !  Analysis of the effect of N-glycosylation at Asn29 on granulation. Glycosylation of IL-10 plays 
a role in preventing granulation. A/D Whole mount confocal microscopy output of leaves expressing GFP 
fused C-terminally to human (h) and mouse (m) IL-10 including native signal peptide (SP) and with 
introduced (S29N) or removed (N29S) glycosylation site, respectively. B/E Western blot analysis under 
reducing conditions of plant produced (p) hIL-10 and mIL-10 with and without glycosylation site. As 
controls, empty vector (EV) and 50 ng recombinant (r) E. coli produced hL-10 and mIL-10 were used. A 
molecular weight marker is indicated in kDa. C/F Yield of hIL-10 and mIL-10 with and without 
glycosylation site in crude extracts 2 to 5 days post infiltration (dpi) as determined by ELISA (n=4, error 
bars indicate standard error).  
A B C 
SP-mIL-10N29S-GFP 
SP-hIL-10S29N-GFP 
D E F 
250
150 
100 
75 
 
50 
37 
 
 
25 
20 
 
15 
rh
IL
-1
0 
  E
V
 
 ph
IL
-1
0 
 
 ph
IL
-1
0S
29
N
 
 
250 
150 
100 
75 
 
 
50 
 
37 
 
 
 
 
 
 
 
25 
20 
 
15 
 
 
rm
IL
-1
0 
  E
V
 
 pm
IL
-1
0 
 
 pm
IL
-1
0N
29
S
 
0,00!
0,05!
0,10!
0,15!
0,20!
0,25!
2! 3! 4! 5!
μg
 IL
-1
0/
m
g 
TS
P"
dpi"
  hIL-10!
  hIL-10!
0,00!
1,00!
2,00!
3,00!
4,00!
2! 3! 4! 5!
μg
 IL
-1
0/
m
g 
TS
P"
dpi"
  mIL-10!
  mIL-10!
!
 !
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 !
S29N 
N29S 
IL-10 multimerises extensively in planta 
 
 
! 31 
Glycosylation does not influence biological activity 
The possible effects of glycosylation on the biological activity of plant-produced human and 
mouse IL-10 was next assessed. The capacity of the different IL-10 variants to reduce Tumor 
Necrosis Factor-alpha (TNF-α) expression by human (THP-1) and mouse (RAW264.7) 
macrophages upon stimulation by lipopolysaccharide from E. coli was determined. Figure 4 
shows the percentage inhibition of TNF-α secretion by macrophages when compared to the 
empty vector control. As expected, glycosylated as well as non-glycosylated mouse IL-10 
suppressed the secretion of pro-inflammatory TNF-α from mouse macrophages, confirming that 
glycosylation is not necessary for mouse IL-10 activity [3]. Strikingly, our data show that 
glycosylated human IL-10 is as active as its native non-glycosylated form on both human and 
mouse cells. Apparently, the structure of human IL-10 is not negatively influenced by the 
glycosylation event. Neither non-glycosylated nor glycosylated mouse IL-10 was active on 
human cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 !  Biological activity of human and mouse IL-10 variants on human and mouse macrophages. 
Plant produced (p) and recombinant (r) E. coli produced human (h) or mouse (m) IL-10 were calibrated to 
contain the same amount of IL-10 as well as total soluble protein by using the empty vector control. 
Human (THP-1) and mouse (RAW264.7) macrophages were then pretreated with 10 ng/ml hIL-10 or mIL-
10 for 20 min and subsequently stimulated with 1 µg/ml E. coli lipopolysaccharide. Tumor Necrosis 
Factor-alpha (TNF-α) expression was determined by ELISA and IL-10 activity is indicated as the percentage 
of inhibition of TNF-α expression as compared to the empty vector control (n=3, error bars indicate 
standard error).  
 
 
Granulation of human IL-10 is caused by extensive multimerisation 
Literature describes IL-10 to be a 3D domain swapping protein, a term used to describe a 
process wherein two or more protein chains exchange identical structural elements or 
“domains” [9, 17]. Two IL-10 monomers dimerise by exchanging their E-F helices. However, 
when the concentration of a potentially 3D domain swapping protein is high, swapping of 
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domains does not have to be limited to two partners [18]. For example, IL-10 can provide its 
A-D helices to one partner, while giving its E-F helices to another partner. This can create a 
chain reaction that can, in theory, continue until a stable form is reached. To determine if 
human IL-10 granulation was triggered by extensive multimerisation, a flexible linker was 
introduced between α-helices D and E of human IL-10. This allows helices E-F of one human 
IL-10 molecule to fold into its own A-D α-helices, creating a stable monomer (hIL-10mono) as 
designed by Josephson and co-workers [15]. Figure 5a shows three cartoons of the expected 
human IL-10 (I) dimer, (II) monomer and (III) stable monomer conformations. When the 
monomeric form of hIL-10 was fused to GFP no signs of granulation was observed (Figure 5b). 
hIL-10mono-GFP was detected in the ER and, putatively, the apoplast. Unlike hIL-10-GFP and 
mIL-10-GFP, fluorescence was also observed in the cytoplasm and nucleoplasm. This may be 
indicative of partial failure of the protein to be taken up into the secretory pathway. However, 
on Western blot a band of 21 kDa, the expected size for hIL-10mono with signal peptide, was 
never observed. Therefore, hIL-10mono-GFP must be expelled from the secretory pathway and 
enter the nucleoplasm by either diffusion or active transport. Active transport into the nucleus 
after expulsion from the ER was demonstrated with a secretory GFP fusion with the P-domain 
of the chaperone calreticulin [19].  
Western blot analysis demonstrated that hIL-10mono was indeed present as a monomer, 
whereas plant and E. coli produced hIL-10 also revealed bands corresponding to dimeric (36 
kDa) and multimeric hIL-10 (Figure 5c). In repetitive experiments a small proportion of dimeric 
hIL-10mono was observed occasionally, but never larger multimers. 
Analysing average yields of hIL-10 and hIL-10mono by ELISA revealed that the hIL-10mono 
protein level was significantly higher (P=0.048) resulting in 16-fold more protein. Maximum 
yield obtained with hIL-10mono was 3,2 µg IL-10/mg (0.32%) TSP at 3 dpi (Figure 5d). 
However, when hIL-10mono was tested for biological activity by assessing its ability to suppress 
TNF-α expression by LPS stimulated macrophages, it appeared not to be functional (Figure 6a), 
which was expected as IL-10 receptor binding studies suggest that the dimeric form of IL-10 
confers biological activity [20]. This experiment was repeated several times and on some 
occasions slight activity of the hIL-10mono was observed, however, always less than E. coli 
produced hIL-10. It appeared that the biological activity coincided with the proportion of 
dimeric hIL-10mono seen on Western blot. It is likely that the extent of dimerisation and 
multimerisation of IL-10 is dependent on sample treatment such as freeze-thaw cycles, 
temperature and pH of the solution after extraction.  
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Figure 5 !  Analysis of expression of a stable monomeric form of human IL-10. A stable monomeric form 
of human IL-10 (hIL-10mono) does not granulate and yield increases 30-fold. A Three cartoons illustrating 
the human IL-10 (I) dimer, (II) monomer and (III) stable monomer structure, as well as a schematic 
representation of the human (h) IL-10 alpha helices A-F. Helices are represented by ovals, whereby a 
fragment of the amino acid sequence and the location of insertion of the small GS-linker is indicated. B 
Whole mount confocal microscopy output of GFP fused C-terminally to hIL-10mono including native signal 
peptide (SP). C Western blot analysis under non-reducing conditions of plant produced hIL-10 and hIL-
10mono. As controls, empty vector (EV) and 50 ng recombinant (r) E. coli produced hL-10 were used. A 
molecular weight marker is indicated in kDa. D Yield of hIL-10 and hIL-10mono in crude extracts 2 to 5 
days post infiltration as determined by ELISA (n=3, error bars indicate standard error). Average yield of hIL-
10mono was significantly higher compared to hIL-10.  
 
 
Biological activity of hIL-10mono was restored by fusion to Fcα  
To re-establish biological activity, dimerisation of hIL-10mono was forced by fusion to the C-
terminus of constant domains 2 and 3 of human immunoglobulin A2m1 (Fcα). As a reference, 
a construct with unmodified hIL-10 fused to Fcα was also made. Figure 6a shows the 
percentage inhibition of TNF-α secretion by macrophages when compared to the empty vector 
control. As mentioned before, hIL-10mono was found to have reduced biologically activity, but 
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by fusion to Fcα we were able to restore its biological activity (P=0.0230). Also, fusion of 
native hIL-10 to Fcα slightly increased biological activity, but not significant. While the activity 
of the monomeric IL-10 Fcα fusion had no significant difference with E. coli or plant produced 
native hIL-10, a significant difference was found with the native IL-10 Fcα fusion (P=0.0375).  
Both fusion proteins showed similar accumulation patterns as observed for the unfused 
variants of IL-10. However, yield of Fcα-hIL-10mono was slightly lower compared to the unfused 
variant on dpi 3, but was found not to be significant (Figure 6b). This indicates that fusion with 
a stable fusion partner does not ensure increase in yield of IL-10, as was the case with fusion to 
elastin-like polypeptides [14, 21].  
Western blot analysis using antibodies raised against hIL-10 showed that the largest 
proportion had the expected size of dimeric Fcα-hIL-10 (95 kDa) for both hIL-10 and hIL-
10mono fusions, but also bands at 200 kDa and 300 kDa were observed, which could again 
indicate the presence of multimers of these fusion proteins (Figure 6c). Using antibodies raised 
against IgA revealed, in addition to all bands corresponding with the IL-10 blot, an extra band 
around 50 kDa (Figure 6d). Because this band does not appear on the IL-10 blot, it is probably 
a cleavage product whereby IL-10 is removed. Specifically, a dimeric Fcα protein without hIL-
10 would have an expected size of 50 kDa. Yet, no separated IL-10, expected at 18 or 36 kDa 
for monomeric and dimeric IL-10 respectively, was seen and must therefore be completely 
degraded.  
 
 
Discussion  
 
Here we show that extensive multimerisation of human IL-10 is the most important factor 
limiting yield and not protein instability. Human IL-10 has previously been expressed in plants 
[12, 14, 21-23]. The highest yield of 0.55% of TSP was obtained by transient expression of 
human IL-10 fused to an elastin-like polypeptide while retained in the ER. It was suggested that 
retention in the protein friendly environment of the ER protects the protein against degradation 
and that elastin-like polypeptides might prevent aspecific aggregation by association with 
chaperones [12, 14]. These data suggested a role for protein instability or inefficient post-
translational processing as a limiting factor for production of human IL-10. Protein instability 
as a bottleneck for production of IL-10 would not be surprising, as cytokines are known for 
their short half-life in vivo.  
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Figure 6 !  Analysis of biological activity and expression of human IL-10 and human IL-10mono fused to 
Fcα. Forced dimerization of human IL-10mono restores biological activity. A Bioactivity assay of hIL-10mono 
and Fcα-hIL-10 fusion proteins on mouse macrophages (RAW267.4). Plant produced (p) and recombinant 
(r) E. coli produced hIL-10 were calibrated to contain the same amount of IL-10 as well as total soluble 
protein by using the empty vector control. Cells were then pretreated with 50 ng/ml hIL-10 for 20 min and 
subsequently stimulated with 1 µg/ml E. coli lipopolysaccharide. Tumor Necrosis Factor-alpha (TNF-α) 
expression was determined by ELISA and IL-10 activity is indicated as the percentage of inhibition of TNF-
α expression as compared to the empty vector control (n=4, error bars indicate standard error). Significant 
difference (P<0.05) between samples is indicated with an asterisk, where biological activity of hIL-10mono 
was significantly different to all other samples. B Yield of human (h) IL-10 in crude extracts 2 to 5 days 
post infiltration as determined by ELISA (n=3, error bars indicate standard error). C/D Western blot analysis 
under non-reducing conditions of plant produced (p) Fcα-hIL10 and Fcα-hIL-10mono using an antibody 
raised against human IL-10 and human IgA for visualization, respectively. As controls, empty vector (EV), 
50 ng recombinant (r) E. coli produced hIL-10 and 10 ng purified hIgA were used. A molecular weight 
marker is indicated in kDa.  
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When we studied the cellular fate of human and mouse IL-10 in planta using GFP 
fusions, we revealed that human IL-10 accumulates in granules, while mouse IL-10 does not. 
The most evident difference between human and mouse IL-10 is the N-glycosylation of mouse 
IL-10. Both proteins have one potential N-glycosylation site (Asn134) that is not glycosylated, 
while mouse IL-10 has yet another site that is glycosylated (Asn29). Removal of the Asn29 
glycosylation site resulted in increased granulation of mouse IL-10, whereas introduction of 
this glycosylation site in human IL-10 prevented granulation to a large extent. As glycosylation 
can aid in protein folding and stabilization, we hypothesized that the granules were in fact 
very large aggregates, potentially compartmentalised as a cell protective mechanism.  
Aggregation can be due to protein instability and/or misfolding resulting in random 
hydrophobic patch interaction or, in the case of IL-10, due to extensive multimerisation. 
Literature describes IL-10 to be a 3D domain swapping protein, a term used to describe a 
process wherein two or more protein chains exchange identical structural elements or 
“domains” [9, 17]. IL-10 monomers form biologically active dimers by exchanging their E-F 
helices. However, at high concentrations of IL-10 it would be possible that the domain 
swapping of IL-10 is not limited to two partners and causes a chain reaction that, in theory, 
could go on unlimited until a stable form is reached. To determine whether human IL-10 
granulation was due to protein instability or due to 3D domain swapping, the behaviour of a 
previously developed stable monomeric form of human IL-10 [15] was studied in planta. This 
stable monomeric form of human IL-10 has a short glycine-serine (GS)-linker between helices 
D and E allowing the helices E-F to fold back into its own hydrophobic core created by the A-
D helices (human IL-10mono). No granulation was observed when human IL-10mono was fused 
with GFP. Multimeric or high molecular weight bands of human IL-10mono were also not 
detected by Western blot. Furthermore, yield was increased on average 16-fold by this minor 
modification of the human IL-10 protein. This expression level was comparable to the highest 
yield obtained for human IL-10 so far, however, without retention in the ER or fusion with a 
stable protein partner. Taken together, we show that not protein instability, but extensive 
multimerisation of human IL-10, due to its intrinsic 3D domain swapping characteristic, is the 
major limiting factor for yield.  
Bennett and colleagues introduced the term 3D domain swapping [17] and up to date 
almost 300 proteins have been reported with 3D domain swapping ability [24]. Besides IL-10, 
the cytokines Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-5 (IL-
5) and Interferon-beta (IFN-β) are also described as 3D domain swapping proteins [9] and have 
been heterologously expressed in several platforms. Upon expression in E. coli the formation 
of inclusion bodies were described for these four cytokines [25-28]. Although formation of 
inclusion bodies could be indicative of multimerisation, they are a relatively common feature 
when expressing eukaryotic proteins in E. coli due to aggregation of folding intermediates. 
However, in the case of IFN-β and IL-5, experiments also demonstrated the need for slow 
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removal of denaturing agents to prevent aggregation to reoccur after solubilisation of inclusion 
bodies [25, 27]. To our knowledge, IL-5 has not been produced in plants before and 
expression of human IFN-β in lettuce leaves resulted in poor yields [29]. On the other hand, 
many research groups have produced human GM-CSF in planta. Interestingly, human GM-CSF 
secreted by a tobacco cell culture could be stabilized in the growth medium by addition of 
bovine serum albumin, gelatin or salt, all methods that could inhibit protein aggregation [30, 
31]. Next to that, when produced in rice seeds a morphological change in both plant protein 
body type I and the ER were observed together with high molecular weight variants of human 
GM-CSF from 50 to 120 kDa [32, 33]. Menassa and colleagues also described a 200 kDa 
weight variant of human IL-10 when expressed stably in a tobacco species [12]. For both 
human IL-10 and human GM-CSF yield from rice seeds was relatively high compared to the 
leaf-based and cell culture systems, however, extraction from rice seeds was only efficient 
using reducing agents [23, 34]. Unfortunately, use of reducing agents during extraction would 
increase production costs again, as the protein would need to be chemically refolded. There 
are many indications that extensive multimerisation has also hampered the production of other 
3D domain swapping cytokines, and may represent a more common mechanism affecting 
yield than thus far anticipated. In addition, it is unclear how 3D domain swapping influences 
biopharmaceutical proteins during formulation, storage and administration. 
Although we could increase the yield of human IL-10 significantly by expression of a 
stable monomeric form of IL-10, this form was not biologically active, as determined by its 
ability to reduce TNF-α secretion by lipopolysaccharide-stimulated macrophages. Even though 
human IL-10mono has all the receptor binding sites, the affinity may be reduced. Josephson and 
co-workers did show biological activity of human IL-10mono based on its ability to induce 
proliferation of a B cell line, however, a 10-fold higher amount of human IL-10mono was 
needed to obtain the same effect as recombinant human IL-10 [15]. Stable monomeric forms 
of IL-5 were also created and shown to have reduced receptor affinity. Nevertheless, they did 
show biological activity with concentration dependence close to that of the wild type [35]. 
Such stabilized biologically active forms of 3D domain swapping cytokines will ensure that the 
protein stays in its biologically active conformation, which may have great benefit for 
formulation and administration to patients.  
To mimic the natural dimerization of IL-10 while still preventing multimerisation, 
human IL-10mono was fused to the naturally dimerising Fc portion of IgA2m1 (Fcα), which 
restored the ability to suppress TNF-α in stimulated macrophages. As well as ensuring dimeric 
conformation, it is likely that fusion with Fcα increases in vivo half-live of IL-10, which could 
be beneficial for efficacy. Our construct is comparable to that of mouse IL-10 fused to the N-
terminus of a non-cytolytic version of the Fc portion of mouse IgG2a, which was shown to be 
functional in vivo with a prolonged efficacy due to its increased circulating half-life [36]. 
However, an increased half-life of IL-10 could also lead to unwanted systemic side effects, 
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such as a compromised immune system. By using complete antibodies it may be possible to 
circumvent these side effects. Through the antigen binding capacity of an antibody with IL-10 
fused C-terminally, specific cells or tissues can be targeted enabling IL-10 therapy for a variety 
of diseases, as was already demonstrated by Schwager and co-workers [37]. In disease 
therapy, use of a human fusion protein is desired to limit the chance of an immune response 
against the therapeutic agent. Also, in inflammatory disease therapy the use of IgA may be 
preferred over other antibody isotypes, as it does not activate the classical complement 
pathway. Thus, a stable molecule that ensures a biologically active conformation and 
targeting, such as Fcα-IL-10, may be a more suitable format for medical applications and may 
prove effective in therapy of inflammatory diseases.  
 
 
Experimental procedures  
 
Construction of expression cassettes and vector 
The complete native open reading frames (ORF) of human and mouse IL-10 were amplified 
from the MegaMan Human Transcriptome cDNA library (Stratagene) and FirstChoice PCR-
Ready Mouse Spleen cDNA library (Ambion), respectively, using oligonucleotides indicated in 
Table 1. Sense and antisense oligonucleotides included NcoI and KpnI restriction sequences, 
respectively, for subsequent cloning steps. Introduction of the NcoI restriction site resulted in 
the addition of two extra amino acids to the signal peptide at the N-terminus. All 
oligonucleotides used for subsequent reamplification, mutagenesis and insertion can be found 
in Table 1.  
To create hIL-10thk and mIL-10thk, both hIL-10 and mIL-10 ORFs were reamplified, 
resulting in the removal of the stop codon and replacement of the KpnI by a NotI restrictrion 
site. The thk coding DNA fragment could be added in frame. To remove and introduce the 
glycosylation site of mouse and human IL-10 respectively, the QuickChange XL kit (Stratagene) 
was used. For insertion of the 6 amino acid glycine-serine spacer overlap extension PCR was 
performed in combination with original hIL-10 oligonucleotides.  
The DNA fragment encoding the enhanced green fluorescent protein (eGFP) was 
reamplified from gateway vector pK7FWG2 [38]. Constructs with eGFP fused C-terminally to 
IL-10 were composed of the IL-10 fragments ending with NotI (as described for the h/mIL-
10thk constructs) the “NotI-NcoI” oligo and the eGFP fragment.  
The constant domains 2 and 3 of human immunoglobulin A2m1 heavy chain including 
a N-terminal IgA signal peptide and a C-terminal linker sequence was synthetically 
constructed by GeneArt and fused N-terminally to reamplified SpeI-hIL-10 and SpeI-hIL-
10mono fragments. All constructs were placed under the control of the 35S promoter of the 
Cauliflower mosaic virus with duplicated enhancer (d35S) and the Agrobacterium tumefaciens 
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nopaline synthase transcription terminator (Tnos). A 5’ leader sequence of the Alfalfa mosaic 
virus RNA 4 (AlMV) was included between the promoter and construct to boost translation. All 
elements were present in pRAP35 (or pUCAP35S [39]) from which expression cassettes were 
digested with AscI and PacI and ligated into a modified version of the expression vector 
pMDC32 [40], renamed pHYG. The pHYG vector resulted upon removal of the Gateway 
recombination sequences by digestion with EcoRI and HindIII and replacement with a DNA 
fragment (oligos “pHYG adaptor”) including AscI and PacI restriction sites for insertion of the 
expression cassettes. All construct sequences were confirmed by sequencing (BaseClear) at the 
expression vector stage. The expression vectors were subsequently transformed to 
Agrobacterium tumefaciens strain MOG101 for plant expression. 
 
 
Table 1 !  Oligonucleotides for construct re-amplification, mutagenesis and insertion. 
 
Gene 
fragment  
Function 5'->3' Sense oligonucleotides 5'->3' Antisense oligonucleotides 
hIL-10 Isolation hIL-10 
NcoI/KpnI 
ccatgggcATGCACAGCTCAGCAC
TGCTCT 
cggtaccTCAGTTTCGTATCTTCAT
TGTCA 
mIL-10 Isolation mIL-10 
NcoI/KpnI 
ccatggccATGCCTGGCTCAGCAC
TGCTAT 
ccggtaccTTAGCTTTTCATTTTGA
TCATC 
pHYG 
adaptor 
MCS including 
AscI/PacI 
aattcggcgcgcctacgcgtaaggacgagct
ctgaggtacctctagattaattaaa 
agcttttaattaatctagaggtacctcagagctc
gtccttacgcgtaggcgcgccg 
hIL-10-
NotI 
Removal stop 
codon, addition 
NotI 
ccatgggcATGCACAGCTCAGCAC
TGCTCT 
ggcggccgcGTTTCGTATCTTCATT
GTCATG 
mIL-10-
NotI 
Removal stop 
codon, addition 
NotI 
ccatggccATGCCTGGCTCAGCAC
TGCTAT 
ggcggccgcGCTTTTCATTTTGATC
ATCATG 
thk Thrombin, 
6xHIS, KDEL 
ggccgcattagttcctcgtggttctgctagccat
caccatcaccatcacaaagatgagctatgac
gtacgggtac 
ccgtacgtcatagctcatctttgtgatggtgatg
gtgatggctagcagaaccacgaggaactaat
gc 
eGFP Isolation GFP 
NcoI/KpnI 
gtcgacggatccATGGTGAGCAAG
GGCGAGGAGCTGTTC 
aggtaccTTAGCTCATGACTGACT
TGTAGAGCTCGTCCATGCCGA
GAG 
NotI-NcoI Linker C-terminal 
GFP fusion 
ggccgctgcagtcgacggatc catggatccgtcgactgcagc 
mIL-10N29S Removal 
glycosylation site 
GCCGGGAAGACAATAgCTGCA
CCCACTTCCC 
GGGAAGTGGGTGCAGcTATTG
TCTTCCCGGC 
hIL-10S29N Introduction 
glycosylation site 
CCCAGTCTGAGAACAaCTGCA
CCCACTTCCCAG 
CTGGGAAGTGGGTGCAGtTGT
TCTCAGACTGGG 
hIL-10mono Insertion 
GGGSGG-linker 
AAACggtggcggatctgggggtAAGAG
CAAGGCCGTGGAGCAGGTGA
A 
CTTacccccagatccgccaccGTTTTC
ACAGGGAAGAAATCGATGA 
SpeI-hIL-10 Removal SP, 
addition SpeI 
accatggactagtAGCCCAGGCCAG
GGCAC 
cggtaccTCAGTTTCGTATCTTCAT
TGTCA 
h/m IL-10 Q-PCR analysis ATGATCCAGTTTTACCTGG AGAAATCGATGACAGCG 
Nb β-actin Q-PCR analysis CCAGGTATTGCCGATAGAATG GAGGGAAGCCAAGATAGAGC 
 
 
Native sequences in capitals, added/mutated sequences in small and restriction sites are underlined. h; 
human, IL-10; interleukin-10, MCS; multiple cloning site, m; mouse, Nb; Nicotiana benthamiana, SP; 
signal peptide for secretion, thk; thrombin-6xHIS-KDEL tag. 
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Agrobacterium tumefaciens transient transformation assay  
Agrobacterium tumefaciens clones were cultured overnight (o/n) at 28°C in LB medium (10g/l 
pepton140, 5g/l yeast extract, 10g/l NaCl with pH7.0) containing 50 µg/ml kanamycin and 20 
µg/ml rifampicin. The optical density (OD) of the o/n cultures was measured at 600 nm and 
used to inoculate 50 ml of LB medium containing 200 µM acetosyringone and 50 µg/ml 
kanamycin with x µl of culture using the following formula: x = 80000/(1028*OD). OD was 
measured again after 16 hours and the bacterial cultures were centrifuged for 15 min at 2800 
xg. The bacteria were resuspended in MMA infiltration medium (20g/l sucrose, 5g/l MS-salts, 
1.95g/l MES, pH5.6) containing 200 µM acetosyringone till an OD of 1 was reached. After 1-2 
hours incubation at room temperature, the two youngest fully expanded leaves of 5-6 weeks 
old Nicotiana benthamiana plants were infiltrated completely. Infiltration was performed by 
injecting the Agrobacterium suspension into a Nicotiana benthamiana leaf at the abaxial side 
using a 1 ml syringe. Infiltrated plants were maintained in a controlled greenhouse 
compartment (UNIFARM, Wageningen) and infiltrated leaves were harvested at selected time 
points. 
 
Total soluble protein extraction  
Leaves were immediately snap-frozen upon harvesting, homogenized in liquid nitrogen and 
stored at -20C until use. Homogenized plant material was ground in ice-cold extraction buffer 
(50mM phosphate-buffered saline (PBS) pH=7.4, 100 mM NaCl, 10 mM 
ethylenediaminetetraacetic acid (EDTA), 0.1% v/v Tween-20, 2% w/v immobilized 
polyvinylpolypyrrolidone (PVPP)) using 2 ml/g fresh weight. Crude extract was clarified by 
centrifugation at 16.000 xg for 5min at 4C and supernatant was directly used in an ELISA and 
BCA protein assay. For western blotting and biological activity assays, above-mentioned 
protein extraction would be followed by desalting using a G25 Sephadex column and filter 
sterilization (0.22 µm; Millipore Corporation).  
 
Quantification of human and mouse IL-10 mRNA levels  
mRNA was isolated from homogenized plant material using the RNAeasy Plant Mini Kit 
(Qiagen) according to suppliers protocol. A Turbo DNaseI (Ambion) treatment was included to 
remove any residual DNA. cDNA was synthesised using the SuperScript®III First-Strand 
Synthesis System (invitrogen) according to suppliers protocol. Samples were analysed by 
quantitative PCR in triplo using ABsolute SYBR Green Fluorescein mix (Thermo Scientific). 
Nicotiana benthamiana β-actin was used as a reference gene. Oligonucleotides used can be 
found in Table 1. Relative transcript levels of IL-10 versus actin were determined by the Pfaffl 
method [41]. 
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Quantification of human and mouse IL-10 protein levels  
IL-10 protein concentration in crude plant extract was determined by ELISA. Human and 
mouse IL-10 ELISA Ready-SET-Go!® kits (eBioscience) were used according to suppliers 
protocol using the model 680 plate reader (BioRad) to measure the OD at 450 nm with 
correction filter of 690 nm. For sample comparison the total soluble protein (TSP) 
concentration was determined by the BCA method (Pierce) according to supplier’s protocol 
using bovine serum albumin (BSA) as a standard. 
 
Protein analysis by western blot  
Soluble plant proteins were separated under reducing or non-reducing conditions by SDS-
PAGE on a NuPAGE® 12% Bis-Tris gel (Invitrogen). Recombinant E. coli produced human or 
mouse IL-10 (R&D Systems) or IgA1 (Invivogen) was used as a control. Proteins were 
transferred to an InvitrolonTM PVDF membrane (Invitrogen) by semi-dry blotting procedure. 
Thereafter the membrane was blocked in PBST-BL (PBS containing 0.1% v/v Tween-20 and 
5% w/v non-fat dry milk powder) for 1 hour at room temperature, followed by overnight 
incubation with hIL-10 specific goat polyclonal antibody (R&D systems), mIL-10 specific rat 
monoclonal antibody (BioLegend) or IgA specific HRP conjugated goat polyclonal antibody 
(Sigma) in PBST at 4°C. The membrane was washed 5 times with 5 min intervals in PBST. For 
h/mIL-10 specific western blots the procedure was continued with a 1 hour incubation at room 
temperature with HRP conjugated secondary antibodies (Jackson ImmunoResearch) in PBST 
and washed again as described before. Finally, the SuperSignal West Femto substrate (Pierce) 
was used to detect HRP-conjugated antibodies.  
 
Confocal microscopy  
Plants were agro-infiltrated with expression cassettes encoding C-terminal fusions of GFP to 
human and mouse IL-10 as described previously. Leaves were taken from the plant and small 
sections were examined from the abaxial side using a Zeiss LSM510 confocal laser-scanning 
microscope in combination with an argon ion laser supplying a 488 nm wavelength.  
 
Biological activity assay 
The monocyte THP-1 and monocyte/macrophage RAW264.7 cell lines were purchased from 
the American Type Culture Collection and cells were maintained at 37°C with 5% CO2. THP-1 
cells were cultured in RPMI-1640 medium containing containing 4 mM L-glutamine, 25 mM 
HEPES and supplemented with 10% fetal calf serum, 50 U/ml penicillin and 50 µg/ml 
streptomycin. THP-1 monocytes were differentiated into macrophages for 4 days using 30 
ng/ml PMA at a density of 3x105 cells/ml in 96 well plates. Cells were allowed to rest for 2-3 
days in medium without PMA prior to bioassays. RAW264.7 cells were cultured in DMEM 
containing 4 mM L-glutamine, 25 mM HEPES and supplemented with 10% newborn calf 
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serum, 50 U/ml penicillin and 50 µg/ml streptomycin. Cells were sub-cultured every 2-3 days, 
whereby the cells were harvested by gently disrupting the monolayer with a cell scraper. For 
cell-based assays cells were seeded in 96 well plates at a density of 5x104 cells/well and 
allowed to rest overnight. For bioassays cells were pre-treated with 10-50 ng/ml plant 
produced or recombinant E. coli produced human or mouse IL-10 (R&D Systems) in plant 
extract for 20 min, and subsequently stimulated with 1 µg/ml of lipopolysaccharide (Sigma). 
After overnight incubation supernatants were analysed with the mouse TNF-α ELISA Ready-Set-
Go! Kit (eBioscience) according to the supplier’s protocol.  
 
Data analysis 
All data shown in the figures indicate the average of at least three biological replicates (n) that 
were determined by at least three technical replicates. In the figure legends n is indicated and 
error bars indicate the standard error. Significant differences between samples were calculated 
using the student’s t-test and regarded as significant when P<0.05. Significant differences in 
expression levels between constructs were calculated by using the whole data set from dpi 2 to 
5 and are indicated in the main text as well as the figure legends. When comparing biological 
activity between proteins significant differences are indicated in the figure by asterisks. 
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Abstract 
 
The unique features of IgA, such as the ability to recruit neutrophils and suppress the 
inflammatory responses mediated by IgG and IgE, make it a promising antibody isotype for 
several therapeutic applications. However, in contrast to IgG, reports on plant-production of 
IgA are scarce. We produced IgA1κ and IgG1κ versions of three therapeutic antibodies 
directed against pro-inflammatory cytokines in Nicotiana benthamiana: Infliximab and 
Adalimumab, directed against TNF-α, and Ustekinumab, directed against the interleukin-
12p40 subunit. We evaluated antibody yield, quality and N-glycosylation. All six antibodies 
had comparable levels of expression between 3,5 and 9% of total soluble protein content and 
were shown to have neutralizing activity in a cell-based assay. However, IgA1κ-based 
Adalimumab and Ustekinumab were poorly secreted compared to their IgG counterparts. 
Infliximab was poorly secreted regardless of isotype backbone. This corresponded with the 
observation that both IgA1κ and IgG1κ-based Infliximab were enriched in oligomannose-type 
N-glycan structures. For IgG1κ-based Ustekinumab and Adalimumab the major N-glycan type 
was the typical plant complex N-glycan; biantennary with terminal N-acetylglucosamine, 
β1,2-xylose and core α1,3-fucose. In contrast, the major N-glycan on the IgA-based antibodies 
was xylosylated, but lacked core α1,3-fucose and one terminal N-acetylglucosamine. This type 
of N-glycan occurs usually in marginal percentages in plants and was never shown to be the 
main fraction of a plant-produced recombinant protein. Our data demonstrate that the 
antibody isotype may have a profound influence on the type of N-glycan an antibody receives.   
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Introduction 
 
The use of monoclonal antibodies for the treatment of cancer, autoimmune diseases and 
inflammatory disorders is rapidly growing. Antibodies of the IgG isotype are most common, 
but other isotypes such as IgA may offer important advantages. IgA is best known as secretory 
IgA, a dimeric IgA complex enveloped by the secretory component, that helps protect mucosal 
surfaces against pathogens and control commensal bacteria. IgA is also the second most 
predominant isotype in the blood [1]. In primates serum IgA is monomeric, in contrast to other 
animals where serum IgA is dimeric. The immunotherapeutic potential of serum IgA has only 
been recognized recently, because the biology of serum IgA was poorly understood [2, 3]. 
Due to differences in IgA functioning between primates and other animals, a proper animal 
model was lacking. Most important in this regard is that rodents lack a homolog of the human 
Fc receptor for IgA (FcαRI or CD89) [3]. This already indicated that rodents lack an important 
effector function that is mediated by FcαRI in primates.  
The creation of a transgenic mouse expressing human FcαRI helped reveal IgA’s unique 
ability to recruit neutrophils, the largest population of white blood cells in the body [4]. This 
capacity may be a valuable feature in cancer therapy, because IgA induced tumour cell killing 
was shown to be mediated by neutrophils. IgG does not efficiently recruit neutrophils, but 
mediates cell lysis predominantly via the complement system and peripheral blood 
mononucleated cells [5]. In addition, serum IgA has immunosuppressive properties that may 
be of therapeutic interest. When free IgA associates with FcαRI on immune cells, inhibitory 
signals are triggered that block pro-inflammatory responses initiated by association of IgG and 
IgE with their Fc receptors. Thus, IgA may be used as an overall immune suppressor of 
inflammatory disorders [2]. The ability of IgA to suppress the immune response could be 
combined with the antigen binding capacity. Many autoimmune and inflammatory disorders 
are nowadays treated by neutralization of pro-inflammatory cytokines using antibodies. 
Neutralization of the pro-inflammatory cytokine TNF-α is the most common therapy. Because 
TNF-α also occurs as a membrane bound variant, use of an antibody directed against TNF-α 
not only results in neutralization of free TNF-α, but also result in neutrophil-mediated killing of 
immune cells harbouring TNF-α on their membrane [6, 7]. Use of IgA may enhance killing of 
these immune cells through its previously mentioned unique ability to recruit neutrophils. As a 
consequence this will result in better suppression of the immune response required for 
autoimmune and inflammatory disease treatment.  
Most, if not all, therapeutic antibodies are made using mammalian cell lines. However, 
plants have been shown to be an excellent alternative production platform. Like animal cell 
lines plants are capable of producing high levels of complex proteins, but are easier to 
manipulate and more economic in use [8, 9]. Next to that, plant-produced proteins often 
appear more homogeneously glycosylated compared to proteins produced by mammalian cell 
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lines [10]. Engineering of the N-glycosylation machinery has been successful in plants and 
research on humanizing N-glycosylation in plants has advanced over the last decade, allowing 
production of antibodies and other proteins with human N-glycan types [11-13]. However, 
most of this work has been based on the plant expression of IgG antibodies and few reports on 
the plant expression of IgA exist [14]. The few IgA antibodies that have been produced in 
plants were based on a variety of IgA backbones (murine, chicken and human), were 
expressed in different plant species (tobacco, maize, rice, tomato and Arabidopsis) and 
demonstrated a great variability in yield [15-20]. 
To obtain insight in the effect of isotype on the yield, quality and N-glycosylation of 
antibodies when expressed in plants we compared the expression of monomeric IgA and IgG 
in Nicotiana benthamiana. Thereto we expressed the therapeutic antibodies Infliximab, 
Adalimumab and Ustekinumab in their original form as IgG1κ antibodies as well as the IgA1κ 
variants of these three antibodies. Both Infliximab and Adalimumab are directed against TNF-
α. Infliximab is a chimeric antibody with mouse variable regions on a human backbone [21] 
and Adalimumab is a fully human antibody [22]. Ustekinumab is a human antibody directed 
against the interleukin-12 p40 subunit (IL-12p40) shared by the pro-inflammatory cytokines IL-
12 and IL-23 [23]. All three antibodies are used to treat several inflammatory disorders such as 
rheumatoid arthritis, psoriasis and inflammatory bowel disease. Upon plant expression we 
observed a similar high yield and quality of the IgA1κ-based antibodies compared to the 
original IgG1κ variants. The N-glycosylation pattern, however, was different. While IgG-based 
antibodies predominantly carried the typical plant complex N-glycan for secreted proteins; a 
biantennary N-glycan with terminal N-acetylglucosamine (GlcNAc) with β1,2-xylose and core 
α1,3-fucose (GnGnXF3), IgA-based antibodies lacked core α1,3-fucose and one terminal 
GlcNAc (GnMX or MGnX). 
 
 
Results 
 
Antibody isotype and idiotype have little effect on yield  
To establish the production potential of human IgA in plants we investigated the expression of 
the variable regions of the three therapeutic antibodies Infliximab (I), Adalimumab (A) and 
Ustekinumab (U) on both a human IgA1κ and human IgG1κ backbone in planta (Figure 1a). 
Light chain (κ) and either the alpha (α)-1 or gamma (γ)-1 heavy chain were combined in one 
expression vector and transiently expressed in Nicotiana benthamiana. Yield was determined 
up to 15 days post infiltration (dpi) with 3-day intervals. Figure 1b shows the average 
recombinant protein levels of three biological replicates. IgG yields peaked at dpi 6 with 82, 
90 and 68 µg of antibody (Ab) per mg of total soluble protein (TSP) for IgG-I, IgG-A and IgG-U, 
respectively. IgA yields peaked on later time points at dpi 9 for IgA-I and IgA-U and dpi 12 for 
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IgA-A. Although prolonged accumulation can be indicative of greater protein stability, the 
overall yield of the IgA’s is lower, 35, 70 and 46 µg Ab/mg TSP for IgA-I, IgA-A and IgA-U, 
respectively. Thus, antibody yield most likely depends more on the expression system than 
idiotype or isotype.  
 
 
 
 
Figure 1 ! Plant production of IgA1κ and IgG1κ antibodies. A Cartoon representing the expressed 
antibodies. B Yield of Infliximab (I), Adalimumab (A) or Ustekinumab (U) on an IgA1κ or IgG1κ backbone 
when transiently expressed in Nicotiana benthamiana up to 15 days post infiltration (dpi). Bars indicate 
average yield and error bars indicate standard error (n=3). 
 
 
Plants produce high quality IgA antibodies 
To investigate protein quality the antibodies were analysed by western blot. Figure 2 shows the 
visualization of the κ, γ and α chains when samples were run under reduced conditions. For all 
antibodies the predominant band of the heavy chain migrated at the expected size (~49 and 
~51 kDa for the γ and α chain, respectively). For α-A, α-U and the recombinant control a 
doublet (two bands migrating very close to each other) was observed. As the constant region of 
α-1 has two N-glycosylation sites these bands can represent α chains with none, one or two N-
glycans. Surprisingly, α-I shows only the higher of the two bands observed for α-A, α-U and the 
recombinant control. This suggests that the α-I chain lacks either the unglycosylated or the one 
time glycosylated variant of α-I. The κ-A and κ-U chains also had the expected size (~23,5 
kDa), while κ-I had a slightly higher molecular weight. Because no N-glycosylation sites are 
present in the κ chains this difference cannot be explained by differences in N-glycosylation. 
Comparison of plant-produced κ-I to the murine myeloma cell line produced κ-I showed equal 
electrophoretic mobility. This suggests that intrinsic properties of the variable domain lead to 
aberrant running behaviour and does not indicate an actual increase in molecular weight (data 
not shown).  
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For the α chains several additional bands were observed that migrated faster than the 
expected size. These additional bands most likely represent proteolytic degradation products. 
A different pattern can be seen for α-I compared to α-A and α-U. It is possible α-I is sensitive to 
other proteases than the other two chains or that IgA-I is exposed to different proteases, which 
would suggest a different intracellular location of this antibody. Alternatively, the bands of α-I 
represent different N-glycan variants of the same degradation products. For κ-I it was striking to 
observe that an additional band migrating around 20 kDa was only seen when co-expressed 
with the γ heavy chain, but not α heavy chain. It most likely also represents a degradation 
product that may be the consequence of a different conformation of IgA-I and IgG-I whereby 
κ-I is more susceptible to proteases when it is associated with the γ-I chain than the α-I chain. 
Alternatively, IgG-I subcellular targeting may be different to IgA-I and therefore may encounter 
different proteases. Whatever the cause of the differences in degradation products between the 
antibody chains, the majority of each antibody chain appears to be intact.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 !  Evaluation of quality of plant-produced IgA1κ and IgG1κ antibodies. Western blots under 
reducing conditions of 50 ng Infliximab (I), Adalimumab (A) or Ustekinumab (U) on an IgA1κ or IgG1κ 
backbone in leaf extracts visualizing the kappa chain (κ), gamma chain (γ) or alpha chain (α), as indicated. 
Recombinant IgG (G) or IgA (A) and empty vector (ev) control were included.  
 
 
 
Efficiency of antibody secretion from plant cells depends on isotype and idiotype 
As antibodies are secretory proteins we developed a method to compare secretion efficiency of 
proteins as an indicator of aberrant subcellular targeting. The amount of secreted antibody was 
determined by ‘washing out’ the apoplast fluid from the transformed leaf followed by isolation 
of intracellular proteins and determination of antibody concentration in both fractions. Figure 
3a shows the secretion efficiency of all six antibodies as the means of three biological 
replicates. Independent of idiotype, IgG secretion was at least three times more efficient than 
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IgA secretion. Poor secretion of a murine IgA/IgG chimera from plant cells was demonstrated 
before [24]. This murine IgA/G chimera was targeted to the vacuole due to a cryptic sorting 
signal in the tailpiece of murine IgA [25]. Human IgA has a similar tailpiece, although the 
sequence differs from mouse IgA. To reveal whether or not poor secretion of human IgA is also 
caused by its tailpiece, a variant of IgA-U without tailpiece (IgA-UΔT) was expressed and its 
secretion efficiency was determined (Figure 3b). While the average yield of IgA-UΔT was 
similar, the secretion efficiency was enhanced more than two fold. Like the murine tailpiece, 
the human tailpiece may be responsible for the poor secretion as a consequence of vacuolar 
targeting.  
To evaluate if the degradation products described in the previous section were caused 
by protease activity inside the cell or in the apoplast, both intracellular and apoplast fractions 
were evaluated by western blot analysis (figure 3c). As all apoplast fractions were enriched 
with the degradation products we assume that most, if not all, proteolytic degradation takes 
place in the apoplast. This explains why the degradation product of κ-I that was only detected 
upon co-expression with the γ chain, but not the α-chain, as 10% of IgG-I compared to only 
1,8% of IgA-I was secreted.  
The secretion efficiency between idiotypes also differed. IgG-I secretion was two times 
less efficient compared to IgG-A and IgG-U secretion. The same result was obtained 
comparing the IgA antibodies. Apparently, both isotype and idiotype are important for 
secretion efficiency.  
 
 
 
 
Figure 3 ! Secretion and proteolytic degradation of plant-produced IgA1κ and IgG1κ antibodies. A/B 
Percentage of secretion of IgG1κ and IgA1κ by determining the amount of antibody in apoplast fluids (ap) 
versus crude extracts (ce) (n=3, error bars indicate standard error). C Western blot analysis under reducing 
conditions of 50 ng Infliximab (I), Adalimumab (A) and Ustekinumab (U) with and without tailpiece (ΔT) 
on an IgA1κ or IgG1κ backbone visualizing the kappa chain (κ) or alpha heavy chain (α), as indicated. 
Recombinant IgG (G) or IgA (A) and empty vector (ev) control were included.  
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Differential N-glycosylation of IgA compared to IgG  
Because differences in subcellular localization can influence N-glycosylation, we evaluated N-
glycan maturity of all antibodies. Thereto the antibodies were treated with the enzymes 
peptide:N-glycosidase F (PNGase F) or endoglycosidase H (Endo H) followed by western blot 
analysis. PNGase F only cleaves N-glycans which lack the plant-specific α1,3-fucose, while 
Endo H only cleaves oligomannose-type N-glycans. Treatment of the IgG antibodies with 
either enzyme did not reduce heavy chain size, except the recombinant control (G), which 
became smaller upon PNGase F treatment (Figure 4, top panel). This indicates that the plant-
produced IgG antibodies do not carry oligomannose-type N-glycans and confirms the 
presence of the plant-specific α1,3-fucose. In contrast, when the IgA-A and IgA-U antibodies 
were treated with PNGase F a major fraction of the α heavy chains was reduced in size (Figure 
4, second panel). EndoH did not affect IgA-A and IgA-U. This suggests that a major fraction of 
IgA-A and IgA-U carry complex type N-glycans that are devoid of core α1,3-fucose. Treatment 
of IgA-I with Endo H or PNGaseF caused a reduction in size of the α-I chain suggesting that 
IgA-I carries oligomannose-type N-glycans.  
To determine if the atypical N-glycosylation of IgA-A and IgA-U is the result of poor 
secretion of IgA, both IgA-U and IgA-UΔT from the apoplast or crude leaf extract were 
evaluated by treatment with PNGase F (Figure 4, third panel). Treatment with PNGase F 
reduced the major fraction of the α heavy chains in size of both intracellular and secreted IgA-
U and IgA-UΔT. This suggests that the absence of a core α1,3-fucose on N-glycans of IgA does 
not depend on its subcellular targeting. Furthermore, the fact that IgA-UΔT shows only one 
band that is sensitive to PNGase F suggests that this band represents a glycosylated α chain. 
Because one of the N-glycan sites of human IgA resides in the tailpiece IgA-UΔT cannot carry 
more than one N-glycan. The absence of a second band for non-glycosylated IgA-UΔT 
therefore indicates that the N-glycan site in constant domain 2 must always receive an N-
glycan. The doublet in IgA-A and IgA-U must therefore be the result of partial N-glycosylation 
of the tailpiece. 
To assess the presence of β1,2-xylose on the IgA antibodies a western blot was done 
using a polyclonal rabbit anti-horseradish peroxidase antibody specific for plant α1,3-fucose 
and β1,2-xylose (Figure 4, bottom panel). For both IgA-A and IgA-U two bands appeared 
confirming the presence of β1,2-xylose on both N-glycan variants. For IgA-UΔT only one band 
appeared due to the absence of the N-glycosylation site present in the tailpiece.  
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Figure 4 !  Evaluation of N-glycan maturity of plant-produced IgA1κ and IgG1κ antibodies. Western blots 
under reducing conditions of 50 ng purified Infliximab (I), Adalimumab (A) or Ustekinumab (U) on an 
IgG1κ or IgA1κ backbone with or without tailpiece (ΔT) visualizing the gamma heavy chain (γ), the alpha 
heavy chain (α) or β1,2xylose/α1,3-fucose (HRP), as indicated. Ustekinumab (U/UΔT) was isolated from 
apoplast (ap) or crude extract (ce) and were analysed separately by visualizing the alpha heavy chain (α). 
Recombinant IgG (G) or IgA (A) and an empty vector (ev) were included. Samples were treated with Endo 
H (H) or PNGase F (P) to screen for the presence of oligomannose type N-glycans or α1,3-fucose, 
respectively. 
 
 
To obtain a more detailed picture we analysed the composition of the N-glycans on the 
plant-produced antibodies using matrix assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF-MS) (Table 1). For IgG, tryptic glycopeptides were prepared prior to 
MALDI-TOF-MS analysis. As predicted, the major N-glycan type present on IgG glycopeptides 
was identified as the typical plant complex N-glycan for secreted proteins; a biantennary N-
glycan with terminal GlcNAc with β1,2-xylose and core α1,3-fucose (GnGnXF3) (Supplement 
1). Surprisingly, IgG-I carried a small fraction of oligomannose-type N-glycans, which may be 
indicative of ER-retention. This is in line with the fact that IgG-I was less efficiently secreted 
compared to IgG-A and IgG-U (Figure 3).   
Analysis of IgA N-glycans based on tryptic glycopeptides was not successful. Tryptic 
digestion of IgA results in relatively large glycopeptides compared to IgG and might therefore 
not be suitable for this approach. Alternatively, IgA was digested with either trypsin, pepsin or 
thermolysin, followed by PNGase A release of N-glycans. Unfortunately, this approach did 
also not result in clear N-glycan profiles. Because we already confirmed that the majority of 
the N-glycans on plant-produced IgA do not carry α1,3-fucose, we used PNGase F to release 
N-glycans from IgA and this did result in clear N-glycan profiles (Supplement 2). The N-glycan 
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profiles for IgA revealed that IgA-I carries mainly oligomannose-type N-glycans. The 
predominant N-glycan type found on IgA-A, IgA-U and IgA-UΔT was similar to IgG, but 
lacked one terminal GlcNAc. Although we cannot exclude that N-glycans on plant-produced 
IgA may occasionally carry a core α1,3-fucose, we can assume that the predominant N-glycan 
on plant-produced IgA-A, IgA-U and IgA-UΔT is GnMX or MGnX. In conclusion, it seems that 
the N-glycan type that an antibody receives upon expression in planta is mainly determined by 
the antibody isotype.  
 
 
Table 1 !  Major N-glycan types carried by the 
plant-produced IgA1κ or IgG1κ variants of 
Infliximab (I), Adalimumab (A) and Ustekinu-
mab (U) as determined using MALDI-TOF-MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table'1'
Antibody!        Major glycan types!
IgG-I!                      ,                           & !
IgG-A!
IgG-U!
IgA-I!                        &!
IgA-A!                        &!
IgA-U!                        &!
IgA-UΔT!                        &!
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Antigen binding capacity  
To determine the antigen binding capacity of the plant-produced antibodies cell-based assays 
were performed. For Infliximab and Adalimumab, which are directed against TNF-α, we 
assessed the capacity of these antibodies to abrogate TNF-α induced apoptosis of L929 cells. 
For Ustekinumab, which is directed against the p40 subunit of IL-12 and IL-23, its capacity to 
block IL-23 induced production of IL-17 by murine splenocytes was assessed. 
Cell viability of L929 cells increased in a dose dependent manner upon increasing 
concentration of plant-produced IgG-I, IgA-I, IgG-A and IgA-A, but not plant-produced IgG-U 
and IgA-U, which were used as negative controls (Figure 5a). No significant difference was 
observed between the murine myeloma cell (SP2/0) produced Infliximab and plant-produced 
IgG-I, IgA-I, IgG-A and IgA-A. It is surprising that IgG-I and IgA-I perform equally well when 
compared to the control in this assay as both antibodies were enriched in oligomannose-type 
N-glycan structures that may indicate improper protein folding.  
IL-17 production reduced in a dose dependent manner upon increasing concentration 
of both plant-produced IgG-U and IgA-U, but not plant-produced IgG-I and IgA-I, which were 
used as negative controls (Figure 5b). No significant difference was observed between the 
murine myeloma cell (SP2/0) produced Ustekinumab and the plant-produced variants.  
Thus, regardless the antibody isotype plants produce functional Infliximab, 
Adalimumab and Ustekinumab. 
 
 
 
 
 
Figure 5 !  Biological activity of plant-produced IgA1κ and IgG1κ antibodies. A Cell viability of L929 
cells when exposed to TNFα in combination with different concentrations of plant-produced Infliximab (I), 
Adalimumab (A) and Ustekinumab (U) on an IgG1κ or IgA1κ backbone. Mammalian cell-produced 
Infliximab (IgG) and a commercially available anti-TNFα IgA were included. B IL-17 production by murine 
splenocytes exposed to IL-23 in combination with different concentrations of plant-produced Infliximab (I) 
and Ustekinumab (U) on an IgG1κ or IgA1κ backbone. Mammalian cell-produced Ustekinumab (IgG) was 
included. Bars indicate averages and error bars indicate standard error (n=3). 
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Discussion 
 
Currently, most therapeutic antibodies are of the IgG isotype. Yet IgA was suggested as a 
promising alternative isotype that may increase the therapeutic opportunities of several 
antibody-based therapies [2]. Therefore, we evaluated the plant production of IgA. We 
expressed IgA1κ variants of the three commercially available therapeutic antibodies, 
Infliximab, Adalimumab and Ustekinumab in Nicotiana benthamiana. The production of the 
IgA1κ variants was compared to the production of their original form as IgG1κ antibodies. 
Expression of all six antibodies was successful with high yields ranging from 3,5% to 9% of 
total soluble protein whereby IgG performed slightly better for all three antibodies. Although 
the majority of the antibodies remained intact, IgA was found to be somewhat more sensitive 
to proteolytic enzymes than IgG. Many reports on the plant expression of IgG exist, but these 
are often based on the expression of a single antibody. Comparing the results of these reports 
reveals a large heterogeneity in antibody quantity and quality, whereby antibody yield varies 
several orders of magnitude [14]. However, our data reveal only slight discrepancies in 
antibody quantity and quality between isotypes and idiotypes indicating that the previously 
reported heterogeneity may largely be attributed to e.g. differences in transformation method, 
subcellular targeting, and use of plant tissue and species.  
In line with previous reports on N-glycosylation of plant expressed IgG’s, all our IgG-
based antibodies predominantly carried the typical complex plant N-glycan for secreted 
proteins; biantennary with terminal GlcNAc and β1,2-xylose and core α1,3-fucose (GnGnXF3). 
However, our IgA-based Adalimumab and Ustekinumab predominantly carried a similar N-
glycan type as IgG, but lacked core α1,3-fucose and one terminal GlcNAc (GnMX or MGnX). 
Oligomannose-type N-glycans were found on both the IgG and IgA variants of our plant-
produced Infliximab. On IgG Infliximab oligomannose was found to a minor extent; however, 
on IgA Infliximab this was the predominant N-glycan type.  
Differences in N-glycosylation may be caused by differences in subcellular targeting. 
Infliximab was less efficiently secreted into the apoplast compared to Adalimumab and 
Ustekinumab, regardless of isotype backbone. This coincided with the presence of 
oligomannose-type N-glycans. Oligomannose-type N-glycans on heterologously expressed 
proteins are often indicative of retention in the endoplasmic reticulum (ER) and is associated 
with protein misfolding. Because only our IgG and IgA-based Infliximab showed enrichment of 
oligomannose-type N-glycans, improper processing of Infliximab chains in planta seems a 
logical explanation for the presence of these N-glycan types. As protein misfolding is coupled 
with protein degradation, the yield of a misfolded protein is expected to be low. However, we 
did not find significantly lower yields for both isotypes of Infliximab compared to the yields of 
Adalimumab and Ustekinumab. Also, both IgG and IgA-based Infliximab showed the same 
capacity to neutralize TNF-α when compared to murine myeloma cell (SP2/0) produced 
Chapter 3 
 
 
!60!
Infliximab. Still, oligomannose enrichment was only demonstrated for IgG and IgA infliximab 
and must therefore depend on idiotype. In conclusion, since folding of Infliximab leads to 
functional antibodies, the reason for oligomannose enrichment remains to be elucidated.  
Evaluation of the secretion efficiency of all antibodies revealed that the IgA variants 
were secreted less efficiently into the apoplast when compared to IgG. A previous study 
demonstrated that plant-based expression of a chimeric murine IgG/A antibody resulted in 
targeting of this antibody to the lytic vacuole. A cryptic targeting signal in the tailpiece of the 
antibody was responsible for vacuolar targeting [24, 25]. Upon arrival in the vacuole the 
murine G/A chimera underwent proteolytic degradation. We also found degradation products 
of our IgA-based antibodies, while no degradation was observed for the IgG-based variants. 
However, IgA isolated from the apoplast showed more prominent degradation than 
intracellular IgA. Thus, in contrast to the murine G/A chimeric antibody degradation of human 
IgA likely resulted from proteolysis in the apoplast. In the C-terminus of the vacuolar proteins 
tobacco β-glucanase and potato PT20 the dipeptides VS and SV are present [26, 27]. The 
murine tailpiece contains the sequence ‘VSVSV’, a repetition of VS and SV and was therefore 
suggested to be the cryptic vacuolar targeting. The human tailpiece contains the sequence 
‘VSV’ which may fulfil the same role. However, the human tailpiece also contains the 
dipeptides ‘AE’, which is a conserved motif in vacuolar targeting signals of several Graminea 
lectins [28], and ‘VD’, found in the vacuolar targeting signal of tobacco chitinase A [29]. These 
proteins are supposedly sorted to the protein storage vacuole [30], which may also be the 
destination of human IgA. Targeting to the protein storage vacuole instead of the lytic vacuole 
would explain the absence of proteolytic products of intracellular IgA as well as the fact that 
yield reduction in comparison to IgG was minor. 
Golgi dependent and independent vacuolar targeting pathways have been identified 
[31] and the route taken seems to depend on protein intrinsic properties. Because the 
attachment of β1,2-xylose occurs in the medial-Golgi [32, 33], our IgA-based antibodies must 
travel to the Golgi as the N-glycans on our IgA-based Adalimumab and Ustekinumab carried 
this sugar residue. After attachment of β1,2-xylose the core α1,3-fucose sugar residue is added 
in the trans-Golgi [32, 33]. The core α1,3-fucose sugar residue is absent from the majority of 
the N-glycans of our IgA-based Adalimumab and Ustekinumab. Thus, the lack of core α1,3-
fucose could be explained by vacuolar targeting if IgA is transported to the vacuole from the 
medial-Golgi. However, the core α1,3-fucose was also absent from the N-glycans of secreted 
IgA-based Ustekinumab, which must have travelled through the trans-Golgi to reach the 
apoplast. 
Another, more plausible, reason for the lack of core fucosylation may be found in the 
protein intrinsic properties. Petrescu and colleagues (2004) analysed the protein environment 
of N-glycosylation sites and demonstrated that many N-glycan sites are poorly accessible [34]. 
As a result N-glycans lacking one or more sugar residues are found, because the core of a N-
glycan cannot always be reached by core altering glycosyltransferases. On human serum IgA 
Plant-produced IgA carries aberrant N-glycans 
 
!
! 61!
less than half of the N-glycans carry the typical mammalian core α1,6-fucose [35, 36], whereas 
80-98% of the N-glycans on human serum IgG antibodies are core fucosylated [37]. IgG and 
IgA are both N-glycosylated in constant domain 2 (Cγ2 and Cα2, respectively) and structurally 
these domains are similar. The major differences between these domains are the positions of 
interdomain disulphide bridges and the N-glycans [38]. The N-glycans of Cγ2 of IgG stabilise 
the interaction between the γ heavy chains, whereas in IgA this is done by a disulphide bridge. 
Compared to IgG, the N-glycans of the Cα2 domain of IgA are overall more exposed and 
therefore more accessible for processing [39]. This may explain why these N-glycans have 
increased sialylation and galactosylation compared to N-glycans of IgG [35]. However, this 
does not rule out the possibility that the core of these N-glycans have lower accessibility for 
core altering enzymes compared to IgG. 
Alternatively, specific amino acids surrounding the N-glycosylation site may interfere 
with efficient core fucosylation. While evaluating the direct surroundings of the N-
glycosylation sites of human IgG1 and IgA1 (position -3 to +4 from the asparagine in the N-X-
S/T site), the only observed consistent difference was the presence of the hydrophobic amino 
acids leucine or valine on position X of the N-glycosylation sites of IgA1, whereas IgG1 
contains a hydrophilic serine. We found this striking as chicken ovalbumin also contains a 
leucine on position X of its N-glycosylation signal and when we expressed ovalbumin in 
plants, the core α1,3-fucose was absent from this N-glycan as well (unpublished data). Also 
plant-produced ovalbumin was insensitive towards PNGase A digestion. We therefore 
hypothesize that protein intrinsic properties that might interfere with core α1,3-fucosylation, 
could also interfere with PNGase A release of N-glycans for MALDI-TOF-MS analysis. How 
amino acids surrounding the N-glycan site can influence core fucosylation or in vitro N-glycan 
release may become apparent when more N-glycan profiles from plant-produced proteins 
become available in the future. 
Next to the core α1,3-fucose a terminal GlcNAc was lacking on IgA-based 
Adalimumab and Ustekinumab. Although GnM or MGn-type N-glycans occur in marginal 
percentages in plants, most proteins carry either MM (paucimannosidic) or GnGn-type N-
glycans. MM-type N-glycans are the result of the activity of enzymes that remove terminal 
GlcNAc’s. Three enzymes (HEXO1-3) capable of removing terminal GlcNAc residues were 
identified in Arabidopsis and shown to localize to the vacuole (HEXO1) and plasma 
membrane (HEXO2/3) [40, 41]. Therefore, N-glycans on secreted as well as vacuolar proteins 
can be modified in this manner. All three enzymes were demonstrated to remove the terminal 
GlcNAc residues from both α1,3- and α1,6-branched mannoses without strict preference. 
Thus, subcellular targeting cannot explain why only one terminal GlcNAc would be removed 
and not the other. The underlying mechanism controlling GlcNAc removal is unclear, but 
seems to depend on protein intrinsic properties. It is possible that the GlcNAc’s are 
inefficiently removed from the N-glycans of IgA resulting in a mix of GnMX and MGnX-type 
glycans. Alternatively, it is also possible that one of the terminal GlcNAc’s is not added. If this 
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is the case, the α1,6-branched mannose must not have received its GlcNAc, as β1,2-xylose 
was present and the terminal GlcNAc on the α1,3-branched mannose is required for β1,2-
xylosyltransferase activity [42]. N-acetylglucosaminyltransferase II (GnT-II) is the enzyme 
responsible for the addition of a GlcNAc to the α1,6-branched mannose. Thus, for unknown 
reasons it is possible that GnT-II does not act on N-glycans of IgA. This would, however, be a 
matter of efficiency, as we did find a proportion of N-glycans with terminal GlcNAc’s on both 
arms on our IgA-based Adalimumab and Ustekinumab. Galactosylation of IgA in planta could 
reveal if the GlcNAc residue is not added or removed. The presence of terminal galactose 
would prevent removal of GlcNAc’s. Humanising the N-glycans on IgA would be a necessary 
step in any case for future application of IgA as a biopharmaceutical.  
Monoclonal IgG antibodies are expressed in several other expression platforms, like 
yeast, insect cells and mammalian cells, however production of IgA based antibodies has also 
gained less attention in these platforms. In yeast for instance, only IgG-based antibodies have 
been expressed and were shown to carry high mannose-type N-glycans, which is typical for 
yeast [43]. Insect cells also add high mannose-type N-glycans to IgG or paucimannosidic type 
N-glycans carrying core α1,3-fucose and/or α1,6-fucose [43, 44]. Only one IgA based antibody 
has been expressed in insect cells and this antibody carried high-mannose type N-glycans [45]. 
Our Infliximab also carried high mannose-type N-glycans and like the insect cell produced IgA 
it is a chimeric antibody with mouse variable regions on a human backbone. In both yeast and 
insect cells attempts to humanise N-glycosylation of IgG have been successful [44, 46], 
however, have never been evaluated for IgA. Finally, expression of IgG and IgA in different 
types of mammalian cells (CHO and Sp2/0) have revealed differences in N-glycan 
composition, but main differences were found in the amount and type of sialylation or 
galactosylation [39]. As galactosylation would prevent the removal of GlcNAc's, we can only 
conclude that GlcNAc is efficiently added in these mammalian expression platforms. On the 
other hand, core α1,6-fucosylation of CHO cell produced IgA1 was less efficient compared to 
IgG, but was still comparable to that of serum IgA1 [39]. Due to large differences in N-
glycosylation pathways of these different expression hosts and the limited experience with N-
glycan analysis of IgA expressed in insect and mammalian cells, it is difficult to conclude 
whether or not the differences in N-glycosylation between plant-expressed IgG and IgA are 
plant specific. 
In conclusion, we have demonstrated that plants can be used equally well for the 
production of IgA as IgG in terms of yield and functionality. However, the N-glycan an 
antibody receives upon expression in Nicotiana benthamiana is determined by the isotype. 
Whether or not the N-glycans on plant produced human IgA can be humanized is a next step 
that will also yield insight in the protein intrinsic properties that influence N-glycosylation. 
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Experimental procedures 
 
Construct design 
All genes required for expression of the 3 different antibodies (Infliximab (I), Adalimumab (A) 
and Ustekinumab (U) on a human IgG1κ or IgA1κ backbone), were synthetically made by 
GeneArt (Bleiswijk, the Netherlands). The constant domains of human immunoglobulin alpha-
1 (ACC82528.1), gamma-1 (AJ294730.1) and kappa (AGH70219.1) chains were ordered in 
their native sequence. All variable regions and the signal peptide of the Arabidopsis thaliana 
chitinase gene (AAM10081.1) were recoded from the amino acid sequence using codons 
preferred by in-house codon optimisation. These gene fragments were flanked by the following 
restriction sites at the 5’ and 3’-end for subsequent cloning steps: NcoI-EagI, EagI-NheI, NheI-
KpnI, EagI-BsiWI, BsiWI-KpnI for the signal peptide, heavy chain variable regions, heavy chain 
constant domains, light chain variable regions and the light chain constant domain, 
respectively. None of the restriction sites introduced additional amino acids except NcoI, 
which introduced an alanine after the first methionine. Fragments were assembled using 
standard cloning procedures and ligated into the shuttle vector pRAPa, a pRAP (or 
pUCAP35S)[47] derivative modified to include an AsiSI restriction site by introduction of the 
self-annealed oligo 5’- AGCTGGCGATCGCC-3’ into a HindIII linearized pRAP. The kappa 
chain expression cassette was digested from pRAPa with AscI and PacI and ligated into the 
expression vector pHYG [48]. Subsequently, the heavy chain cassettes were combined with 
the kappa chain expression vector using the restriction sites AscI and AsiSI, of which the latter 
creates the same overhang as PacI. Vectors were transformed to Agrobacterium tumefaciens 
strain MOG101 for plant expression. 
 
Agrobacterium tumefaciens transient transformation assay  
Agrobacterium tumefaciens clones were cultured overnight (o/n) at 28°C in LB medium (10g/l 
pepton140, 5g/l yeast extract, 10g/l NaCl with pH7.0) containing 50 µg/ml kanamycin and 20 
µg/ml rifampicin. The optical density (OD) was measured at 600 nm and used to inoculate 50 
ml of LB medium containing 200 µM acetosyringone and 50 µg/ml kanamycin with x µl of 
culture using the following formula: x = 80000/(1028*OD). OD was measured again after 16 
hours and the bacterial cultures were centrifuged for 15 min at 2800 g. The bacteria were 
resuspended in MMA infiltration medium (20g/l sucrose, 5g/l MS-salts, 1.95g/l MES, pH5.6) 
containing 200 µM acetosyringone till an OD of 1 was reached. All constructs were co-
expressed with the tomato bushy stunt virus silencing inhibitor p19 by mixing Agrobacterium 
cultures 1:1. After 1-2 hours incubation at room temperature, the two youngest fully expanded 
leaves of 5-6 weeks old Nicotiana benthamiana plants were infiltrated at the abaxial side using 
a 1 ml syringe. Infiltrated plants were maintained in a controlled greenhouse compartment 
(UNIFARM, Wageningen) and infiltrated leaves were harvested at selected time points. 
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Apoplast soluble protein extraction 
Leaves were vacuum infiltrated with ice-cold extraction buffer (50mM phosphate-buffered 
saline (PBS) pH=7.4, 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.1% v/v 
Tween-20) for 10 min. Leaves were dried from the outside and placed in a 10-ml syringe 
hanging in a blue cap and centrifuged at 2000 x g for 15min at 4°C. The volume of apoplast 
fluid was determined and directly used in an ELISA and BCA protein assay. 
 
Total soluble protein extraction  
Leaves were snap-frozen, homogenized in liquid nitrogen (after apoplast extraction or 
immediately upon harvesting) and stored at -80°C until use. Homogenized plant material was 
ground in ice-cold extraction buffer (50mM phosphate-buffered saline (PBS) pH=7.4, 100 mM 
NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.1% v/v Tween-20, 2% w/v 
immobilized polyvinylpolypyrrolidone (PVPP)) using 2 ml/g fresh weight. Crude extract was 
clarified by centrifugation at 16.000 x g for 5min at 4°C and supernatant was directly used in 
an ELISA and BCA protein assay.  
 
IgA and IgG quantification  
IgA and IgG concentrations in apoplast fluids and crude extracts were determined by sandwich 
ELISA using goat polyclonal anti-human kappa antibody (Sigma-Aldrich; Zwijndrecht, the 
Netherlands) as capture antibody. HRP-conjugated goat polyclonal antibodies (Sigma-Aldrich) 
directed against the constant domains of IgG and IgA were used for detection. For sample 
comparison the total soluble protein (TSP) concentration was determined using the BCA 
Protein Assay (Pierce) according to supplier’s protocol using bovine serum albumin (BSA) as a 
standard. 
 
Protein analysis by western blot  
Fifty ng of antibody in crude extract was separated under reducing conditions by SDS-PAGE 
on a NuPAGE® 12% Bis-Tris gel (Life Technologies; Bleiswijk, the Netherlands) and 
transferred to an InvitrolonTM PVDF membrane (Life Technologies) by a wet blotting procedure. 
Recombinant IgG1κ (Sigma-Aldrich) or IgA1κ (InvivoGen) was used as a control. For 
visualization goat polyclonal antibodies  (Sigma-Aldrich) directed against human kappa or 
human IgA followed by incubation with a HRP-conjugated secondary antibody (Jackson 
ImmunoResearch; Suffolk, UK) or HRP-conjugated antibody directed against human IgG were 
used. SuperSignal West Femto substrate (Thermo Fisher Scientific; Etten-Leur, the Netherlands) 
was used to detect HRP-conjugated antibodies. Pictures were taken using a G:BOX Chemi 
System device (SynGene; Cambridge, UK).   
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Antibody purification 
For purification of plant-produced antibodies crude extracts were first desalted over G25 
Sephadex columns. Plant-produced IgG was then purified using Protein G affinity matrix 
(Thermo Fisher Scientific) and plant-produced IgA was purified using IgA CaptureSelect affinity 
matrix (Life Technologies).  
 
N-glycan analysis 
IgA or IgG (in apoplast fluids, crude extracts or purified) was deglycosylated with PNGase F or 
Endo H (both from Bioké; Leiden, the Netherlands) to screen for the presence of plant-specific 
α1,3-fucosylated or oligomannose-type N-glycans, respectively. A western blot using a rabbit 
polyclonal anti-horseradish peroxidase antibody (Jackson ImmunoResearch) was used to 
detected plant specific  α1,3-fucose and β1,2-xylose, followed by a HRP-conjugated donkey 
anti-rabbit IgG (Jackson ImmunResearch). 
For analysis of N-glycan composition, glycopeptides were prepared from 10 µg of 
antibody by in-gel trypsin digestion using the Trypsin Profile IGD kit (Sigma-Aldrich). Tryptic 
glycopeptides were purified over ZipTip
C18
 (Merck; Amsterdam, the Netherlands), eluted with 
18% v/v acetonitrile and analysed by MALDI-TOF-MS. For IgA N-glycan analysis proteolytic 
digestion with trypsin (Sigma-Aldrich), pepsin or thermolysin (both from Promega; Leiden, the 
Netherlands) was performed on 10-100 µg IgA prior to the release of N-glycans with 0.5 mU 
PNGase A (Roche; Woerden, The Netherlands). Released N-glycans were purified by C18 
BakerbondTM SPE cartridges (VWR; Amsterdam, The Netherlands) and subsequent Extract CleanTM 
Carbo SPE columns (Grace; Breda, the Netherlands). N-glycans were labelled with anthranilic 
acid (AA) (Sigma-Aldrich), desalted over Biogel P10 (BioRad) and analysed by MALDI-TOF-
MS. Alternatively, N-glycans were released from 20 µg IgA by PNGase F digestion (Bioké). 
Released N-glycans were purified on Extract-Clean™ Carbograph Columns (Grace), AA-
labelled and purified over ZipTipC18 (Merck) prior to MALDI-TOF-MS analysis. 
 
TNFα neutralization assay  
L929 cells (DSMZ; Braunschweig, Germany) were cultured in RPMI-1640 medium containing 
4 mM L-glutamine, 25 mM HEPES and supplemented with 10% fetal calf serum, 50 U/ml, 50 
µg/ml streptomycin and 50 µM β-mercaptoethanol at 37°C with 5% CO2. Cells were seeded in 
96 well plates at a density of 5x104 cells/well and allowed to rest overnight. The cells were 
then treated with a 10-fold serial dilution of purified plant-produced antibodies from 10 µg/ml 
to 0.01 µg/ml in combination with 1 ng/ml recombinant E. coli produced human TNF-α and 1 
µg/ml Actinomycin D (both from R&D Systems; Abingdon, UK). As positive controls 
mammalian cell produced infliximab and an anti-TNF-α-IgA (InvivoGen) were used. After 
overnight incubation cell viability was determined using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega) according to the supplier’s protocol.  
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IL-23 neutralization assay  
Splenocytes were isolated from spleens of C57BL/6 mice by passing them through a 70 µm 
nylon cell strainer (BD Biosciences; Breda, the Netherlands). Red blood cells were lysed using 
the Mouse Erythrocyte Lysing Kit (R&D Systems) and obtained splenocytes were seeded in 96 
well plates at a density of 5x105 cells/well in RPMI-1640 medium containing 4 mM L-
glutamine, 25 mM HEPES and supplemented with 10% fetal calf serum, 50 U/ml penicillin, 50 
µg/ml streptomycin and 50 µM β-mercaptoethanol. Splenocytes were treated with a 10-fold 
serial dilution of purified plant-produced antibodies from 10 µg/ml to 0.001 µg/ml in 
combination with 1 ng/ml recombinant E. coli produced human IL-23 and 10 ng/ml PMA. As 
positive control mammalian cell produced Ustekinumab was used. After 5 days supernatants 
were analysed for IL-17 expression with the mouse IL-17 Ready-Set-Go! ELISA Kit 
(eBioscience) according to the supplier’s protocol.  
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Supplementary Figures 
 
Supplementary Figure 1 
 
 
 
 
 
Supplementary Figure 1 !  N-glycan types carried by the plant-produced IgG1κ variants of Infliximab (I), 
Adalimumab (A) and Ustekinumab (U) as determined using MALDI-TOF-MS.  
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Supplementary Figure 2 
 
 
 
 
Supplementary Figure 2 !  N-glycan types carried by the plant-produced IgA1κ variants of Infliximab (I), 
Adalimumab (A) and Ustekinumab (U) as determined using MALDI-TOF-MS.  
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Abstract 
 
Secretory IgA (sIgA) is the most prominent antibody at mucosal surfaces playing a key role in 
the first line of defence. It is a promising antibody isotype for a variety of therapeutic settings 
such as passive vaccination or treatment of chronic inflammations by administering sIgA 
directed against pro-inflammatory cytokines. However, heterologous expression of sIgA is still 
suboptimal. The challenge for sIgA expression lies in the fact that it is a heteromultimeric 
protein complex for which assembly of four polypeptides; the alpha heavy chain, the light 
chain, the joining chain and part of the polymeric-Ig-receptor (called the secretory component) 
in a 4:4:1:1 ratio is required. We evaluated the transient expression in planta of sIgA variants of 
the clinical antibody Ustekinumab harbouring the heavy chain isotypes α1, α2m1 or α2m2. 
Ustekinumab is directed against the p40 subunit shared by the pro-inflammatory cytokines 
interleukin(IL)-12 and IL-23. Of the three different variants we obtained the highest yield with 
sIgA1. Combining all four required genes in one multi-gene expression vector increased yield 
three fold compared to co-infiltration of four separate expression vectors. However, not the 
expression strategy, but assembly turned out to be the limiting step for sIgA production, with 
the incorporation of the joining chain as the bottleneck. Our data demonstrate that different 
strategies of transient expression in planta are suitable for the production of heteromultimeric 
protein complexes such as sIgA, but can even be further enhanced by improving sIgA 
assembly. 
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Introduction 
 
Secretory (s)IgA is the most predominant antibody type in external secretions of the human 
body and plays a key role in the first line of defence against mucosal pathogens. While human 
serum IgA is primarily monomeric, B cells in mucosa-associated lymphoid tissue secrete IgA in 
a dimeric form through incorporation of the joining chain. Dimeric (d)IgA can bind the 
polymeric immunoglobulin receptor on the basolateral surface of epithelial cells and upon 
binding dIgA is transcytosed to the luminal side of the cell. Here, the receptor is cleaved and 
dIgA is released in association with a part of the receptor, called the secretory component (SC). 
This complex is referred to as secretory IgA. When dIgA binds antigen just before, during (e.g. 
intracellular viruses in the epithelial cells) or after secretion, the immune system is not 
stimulated due to the limited presence of FcαRI positive immune cells in the mucosal area and 
the reduced affinity of sIgA to FcαRI. On the luminal side of the mucosa the glycans on the SC 
facilitate binding of sIgA to bacteria as well as to the mucus followed by sIgA (and bacterial) 
clearance by mucus release. This concept of pathogen binding and clearing without immune 
stimulation is referred to as immune exclusion and is believed not only to play a role in 
combating mucosal pathogens, but also in controlling commensal bacteria. In order to fulfil 
this role the human body secretes 40-60 mg sIgA per kg body weight each day [1].  
IgA is found in two isotypes, IgA1 and IgA2 of which the latter occurs in two allotypes, 
IgA2m1 and IgA2m2. All three alpha heavy chains consist of one variable domain, three 
constant domains and an extended tailpiece allowing IgA to dimerise by incorporation of the 
joining chain. There are three major differences between these IgA variants. Firstly, IgA1 has 
an extended hinge region. This extension is heavily O-glycosylated, which is suspected to play 
a conformational role [2], allowing the binding of more distantly spaced antigens. Secondly, 
alpha heavy chains of isotypes 1 and 2m2 are covalently linked to their light chains via a 
disulphide bridge upon IgA assembly. No such linkage exists in IgA2m1, however, this allows 
the formation of a intermolecular disulphide bridge between the free cysteines within each of 
the two light chains. Finally, all variants differ from each other in the number of N-
glycosylation sites they carry (2, 4 and 5 for IgA1, IgA2m1 and IgA2m2, respectively). The ratio 
wherein sIgA isotypes are present depends on the mucosal area and is most likely the result of 
the presence of specific bacteria as the hinge of IgA1 is sensitive to bacterial proteases [3-6]. 
The use of recombinant sIgA in passive mucosal immunotherapy in humans and livestock 
has been suggested as a good alternative for antibiotics. Several in vivo studies demonstrated 
(s)IgA’s potential to locally control mucosal pathogens, such as Mycobacterium tuberculosis in 
the lungs [7], Streptococcus mutans in the mouth [8] and Salmonella typhimurium, Vibrio 
cholera, and Cryptosporidium parvum in the gastrointestinal tract [9]. When sIgA would be 
directed against pro-inflammatory cytokines and administered to the gut, it may relieve 
symptoms and induce remission in patients suffering from inflammatory bowel diseases (IBDs). 
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Currently treatment of IBD often includes anti-TNF-α therapy. However, systemic 
neutralization of this cytokine has been associated with the onset of tuberculosis [10]. Non-
systemic cytokine neutralization may reduce infection risks and other side effects. Because 
sIgA is stable in the gut, sIgA-based therapy could be localized. Luminal administration of an 
anti-TNF-α antibody has been demonstrated effective in mouse models of IBD [11] and local 
drug administration has been suggested to be important for efficacy of IBD therapies [12]. 
Plants are a great production platform for pharmaceutical proteins. As eukaryotes they are 
able to correctly fold complex proteins and assemble protein complexes such as virus like 
particles [13] and secretory IgA [14]. Compared to mammalian cells, plants are a more 
economic production platform, as they do not require expensive culture conditions. 
Furthermore, the N-glycosylation pathway has been engineered to facilitate expression of 
proteins with humanized N-glycans [15]. Also, the engineering of mammalian mucin-type O-
glycans has been achieved in plants [16, 17].  
Plant expression of a murine sIgA/G hybrid was achieved by stable transformation of the 
four individual genes required for sIgA assembly followed by crossing of the highest producers 
[14]. A drawback of this strategy is that it is a lengthy and laborious process. Transient 
expression is much faster and almost always results in higher yields, as there is no constraint 
on expression imposed by the site of insertion. To achieve transient expression of more than 
one gene simultaneously, Agrobacterium cultures harbouring vectors for the expression of the 
individual genes need to be co-infiltrated (co-expression) or a multi-cassette vector facilitating 
expression of all genes should be used. Transient expression of chicken sIgA was achieved by 
co-infiltration [18] and human sIgA was transiently expressed with a multi-cassette vector 
assembled using the GoldenBraid system [19]. The risk with co-infiltration is that cells may not 
be transformed with all genes, but use of a multi-cassette vector may be impractical if 
expression of the individual proteins needs to be adjusted to reflect the stoichiometry of the 
protein complex. While all studies achieved sIgA expression, they also showed the presence of 
a large proportion of monomeric IgA as well as other assembly intermediates. The presence of 
these assembly intermediates complicates down-stream processing.  
The objective of this study was to determine the factors that limit sIgA assembly. Thereto 
we studied the expression and assembly of a sIgA variant of the clinical antibody Ustekinumab 
(CNTO1275), which has specificity for the p40 subunit shared by interleukin-12 and 
interleukin-23. First, we evaluated the transient expression of all individual genes required for 
sIgA assembly whereby all three known alpha heavy chain types (1, 2m1 and 2m2) were 
included. Next we compared co-expression with the use of multi-cassette vectors. Although 
the use of a multi-cassette vector including all genes increased sIgA expression slightly 
compared to co-infiltration, the bottleneck for sIgA expression turned out not to be inefficient 
co-ordinate expression, but assembly of the complex. We conclude that the inefficient 
incorporation of the joining chain that limits sIgA assembly may be a consequence of 
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inefficient N-glycosylation of the IgA tailpiece and/or joining chain. Thus, improved N-
glycosylation may be the key to enhance sIgA assembly. 
 
 
 
Results  
 
Expression of individual components required for sIgA assembly 
In order to achieve in vivo assembly of a heteromultimeric protein complex all required genes 
should be expressed simultaneously in the same cell at the right level. The sIgA protein 
complex comprises four proteins and an overview of the individual proteins and the protein 
complexes IgA, dimeric (d)IgA and sIgA based on alpha heavy chain isotype 1 are given in 
figure 1a. Expression cassettes and the combinations thereof to achieve expression of these 
protein complexes are given in figure 1b.  
 
 
 
 
 
Figure 1 !  Overview of sIgA assembly and expression. A Individual proteins, alpha heavy chain 1 (α1), 
2m1 (α21) or 2m2 (α22), kappa chain (κ), joining chain (JC) and secretory component (SC), and protein 
complexes IgA1, dimeric (d)IgA1 and secretory (s)IgA1. B Expression cassettes with 35S promoter of the 
Cauliflower mosaic virus with duplicated enhancer (d35S), Agrobacterium tumefaciens nopaline synthase 
transcription terminator (Tnos), leader sequence of the Alfalfa mosaic virus RNA 4 (AlMV) and AscI, AsiSI 
and PacI restriction sites are indicated. Co-expression is required for IgA, dIgA and sIgA assembly as 
indicated by the accolades. 
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To evaluate the level and course of expression of the individual genes required for sIgA 
assembly we first expressed them individually and monitored expression over time using 
western blot analysis (Figure 2). All three known alpha heavy chain variants were evaluated. 
Upon expression of the alpha heavy chains and kappa chain bands were detected the 
expected size for these proteins and are assumed to represent the intact proteins. Furthermore, 
several bands >100 kDa were observed for the heavy chains and most likely represent 
multimers. A few faint bands below 50 kDa were detected, which most likely represent 
products of proteolytic degradation. Upon expression of the secretory component a band was 
detected that migrates ~10 kDa lower as compared to the secretory component of the sIgA 
control. This may be explained by differences in number and/or type of N-glycans received by 
the secretory component when expressed in plants. The secretory component has seven 
potential glycosylation sites, of which some may not be glycosylated in plants. Furthermore, 
the most common N-glycans of plant-secreted proteins are 0,7-1,1 kDa smaller than the most 
typical N-glycan found on human secretory component [20] which could account for the ~10 
kDa difference. Upon expression of the joining chain many bands were detected, but all 
migrate higher as expected for a single joining chain and most of them most likely represent 
multimers.  
 
 
 
Figure 2 !  Plant expression of individual genes required for sIgA assembly. Leafs were agro-infiltrated for 
the expression of alpha heavy chain 1 (α1), 2m1 (α21), 2m2 (α22), kappa chain (κ), joining chain (JC) or 
secretory component (SC) and harvested 3, 6 and 9 days post infiltration. Total soluble protein (TSP) was 
extracted and separated by SDS-PAGE under reducing conditions followed by visualization on a Western 
blot using protein specific antibodies as indicated. As controls 10 or 50 ng of recombinant IgA1κ (rI10/50), 
recombinant joining chain (rJ10/50) or 40 or 200 ng purified sIgA (rS40/200, containing ~10 or 50 ng SC) and 
an empty vector (EV) sample were used.  
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The course of expression of the individual proteins is similar and peaks at 6 days post 
infiltration (dpi), except for alpha heavy chain 2m2, which peaks at 9 dpi. However, yield of 
the individual proteins varies. By comparing the band intensity of each individual protein to 
the recombinant control we estimate yields between 1 and 5 µg/mg TSP for the alpha heavy 
chains, between 5 and 20 µg/mg TSP for the joining chain and between 50 and 200 µg/mg TSP 
for the kappa chain and the secretory component at dpi 6. Yield estimation of the heavy chains 
and joining chain is solely based on the intact monomeric proteins and is most likely 
underestimated due to the presence of multimers. Nonetheless, as the stoichiometric ratio 
between the heavy chain, the kappa chain, the joining chain and the secretory component is 
4:4:1:1, we assume heavy chain expression to be the limiting factor for sIgA assembly if 
stabilization of individual proteins upon co-expression does not occur.  
 
 
Co-infiltration and use of a multi-cassette vector yield similar amounts of sIgA 
Co-expression can be achieved by transient transformation in two ways, either by co-
infiltration of Agrobacterium cultures each harbouring a vector for individual gene expression 
or by using multi-cassette vectors facilitating expression of all genes. With co-infiltration it is 
possible that not all cells are transformed with all expression vectors. The use of a multi-
cassette vector would ensure that a transformed cell receives all genes, but transformation may 
be less efficient due to the larger size of the T-DNA. We successfully constructed several multi-
cassette vectors for expression of IgA1κ (alpha heavy chain 1 and kappa chain), dIgA1κ (alpha 
heavy chain 1, kappa chain and joining chain) and sIgA1κ (all four genes) whereby all genes 
are under control of the same promoter and terminator (Figure 1b). Subsequently, sIgA was 
expressed by co-infiltration of all genes individually (4-vector system), co-infiltration of the 
secretory component and the joining chain with the multi-cassette vector for IgA1κ expression 
(3-vector system), co-infiltration of the secretory component and the multi-cassette vector for 
dIgA1κ expression (2-vector system) and the infiltration of the multi-cassette vector for sIgA1κ 
expression (1-vector system) (Figure 3b). Figure 3a shows the average sIgA yield of three 
biological replicates. To correct for the lower OD of Agrobacterium in the final mix of the 3, 2 
and 1-vector system compared to the 4-vector system, an Agrobacterium culture carrying an 
empty vector was used to increase the OD (grey bars) or the OD of the Agrobacterium carrying 
a multi-cassette vector was increased (black bars). Combining all genes in the same vector 
results in only a slight increase in yield compared to the 2, 3 and 4-vector system. Apparently 
there is no clear optimal transient expression strategy for sIgA in terms of yield. Co-infiltration 
of different Agrobacterium cultures might still be preferred as the expression of individual 
genes can be adjusted to reflect the stoichiometric ratio of sIgA by adjusting the concentration 
of bacteria to be infiltrated. 
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Figure 3 !  sIgA yield upon plant transformation using co-infiltration and multi-cassette vectors. A 
Average sIgA yield 6 days post infiltration (n=3) in leaf extracts when co-infiltrating all genes individually, 
co-infiltrating the secretory component and joining chain with the multi-cassette vector for IgA1κ 
expression, co-infiltrating the secretory component and the multi-cassette vector for dIgA expression and 
the infiltration of the multi-cassette vector for sIgA expression as indicated as the 4, 3, 2 and 1-vector 
system, respectively, as depicted in B. The final OD of the Agrobacterium culture was set to 2,5 using 
either Agrobacterium carrying an empty vector (light grey bars) or the OD of the Agrobacterium carrying 
the multi-cassette vector (dark grey bars) was increased. Error bars indicate standard error. 
 
 
 
Stabilization of alpha heavy chains and kappa light chain upon co-expression 
To determine the limiting factor in sIgA assembly we first evaluated the efficiency of IgA 
assembly in the absence of the joining chain and secretory component. Thereto, we co-
expressed the alpha heavy chains and the kappa chain using the dual-cassette expression 
vectors for all three IgA variants and compared it with the individual expression of the alpha 
heavy chains and kappa chains. Leaf extracts were analysed by western blot under reducing 
and non-reducing conditions (Figure 4). Visualization of the alpha heavy chains and kappa 
chain under reducing conditions demonstrated that all proteins accumulate to a higher level 
upon co-expression. As the accumulation of the alpha heavy chains increases upon co-
expression with the light chain the presence of a degradation product just above 25 kDa also 
becomes clear. Considering the size of this degradation product it is most likely the result of 
cleavage in the hinge region. The hinge regions of alpha heavy chain 1 and alpha heavy 
chains 2m1 and 2m2 seem all sensitive to proteolysis.  
While analysing co-expression of alpha heavy chains with kappa light chain under non-
reducing conditions, a band around the expected size for IgA (~150 kDa) was detected on 
blots either treated with anti-alpha heavy chain or anti-kappa chain specific antibodies. We 
therefore assumed that this band represents the intact IgA complex. Next to the 150 kDa band, 
several bands migrating >250 kDa were detected. As these bands were also seen in the 
recombinant IgA control we assume they represent multimers of IgA. Also, several bands <150 
kDa were detected, which may represent assembly intermediates, degradation products and/or 
individual polypeptide chains. Proteolytic cleavage in the hinge region results in Fc and Fab 
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fragments of the same size as an intact alpha heavy chain (~50 kDa). A band of 50 kDa is 
clearly detected on both alpha heavy chain and the kappa chain specific blots and therefore 
most likely represents Fab fragments. Two bands only detected on the kappa chain specific 
blot just below 25 and 50 kDa most likely represent un-associated monomeric and dimeric 
kappa chains. Assuming only un-associated kappa chain is present, we conclude that 
accumulation of the alpha heavy chain is the limiting factor for IgA yield, despite the fact that 
the alpha heavy chains stabilize upon co-expression with the kappa chain.  
 
 
 
 
 
 
 
Figure 4 !  IgA assembly using multi-cassette expression vectors. Leafs were agro-infiltrated for the 
expression of alpha heavy chain 1 (α1), 2m1 (α21), 2m2 (α22) and kappa chain (κ) individually or co-
expressed (I) using a multi-cassette vector and harvested 6 days post infiltration. Total soluble proteins 
were extracted and 1 µg, unless stated otherwise, was separated by SDS-PAGE under reducing conditions 
followed by visualization using protein specific antibodies as indicated. As controls 50 ng of recombinant 
IgA1κ (rI50) and an empty vector (EV) sample were used.  
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IgA dimerization is the limiting step in sIgA assembly 
Next we evaluated the efficiency of sIgA assembly. We used the multi-cassette vectors to 
express IgA, dIgA and sIgA (Figure 3b) with all three alpha heavy chain variants. Leaf extracts 
were analysed on western blot under non-reducing conditions (Figure 5). Upon dIgA1, 
dIgA2m1 and dIgA2m2 expression two bands around 300 and >420 kDa were detected on the 
joining chain specific blot (third panel from the top). These bands can also be seen on the 
alpha heavy chain and kappa chain specific blots (first and second panel respectively). We 
assume that these bands represent dIgA and multimerized dIgA. The 150 kDa band 
representing monomeric IgA in the alpha heavy chain and kappa chain specific blots is still 
present upon co-expression of the joining chain. This could imply that dimerization of IgA is 
not 100% efficient or that the expression of the joining chain is limiting. The presence of free 
joining chains was, however, not detected.  
Upon sIgA1 expression monomeric IgA (~150 kDa) is still detected on the alpha heavy 
chain and kappa chain specific blots. Next to that, bands of <100 kDa, ~220 kDa, ~400 kDa 
and >420 kDa were detected on the secretory component specific blot (bottom panel). 
Because the band <100 kDa was only detected on the secretory component specific blot, this 
band most likely represents loose secretory component. The 220 kDa band was also detected 
on the alpha heavy chain and kappa chain specific blot, but not on the joining chain specific 
blot and therefore most likely represents secretory component associated with monomeric IgA. 
Both the ~400 kDa and >420 kDa bands were also detected on the alpha heavy chain, kappa 
chain and joining chain blot and therefore must represent sIgA and multimers of sIgA. Upon 
sIgA2m1 and sIgA2m2 expression only the band <100 kDa representing the loose secretory 
component and the band >420 kDa representing multimeric sIgA was clearly distinguished. It 
may be that alpha heavy chains 2m1 and 2m2 are more sensitive to multimerisation. No dIgA 
was detected upon expression of all four genes using any of the alpha heavy chains. 
Apparently sIgA assembly is equally efficient for all three alpha heavy chains and the 
expression of the secretory component is not limiting. The latter can also be concluded by the 
ample presence of loose secretory component in the sIgA samples.  
Both IgA and sIgA yield were determined using a sandwich ELISA. While yields of the IgA 
variants ranged between 10-40 µg/mg TSP, sIgA yield was at least 9 fold higher for all variants 
(Figure 6). The higher sIgA yield, compared to IgA yield, may be explained by the fact that sIgA 
assembly prevents proteolytic degradation of IgA. However, sIgA yield may also be 
overestimated due to the presence of monomeric IgA associated with the secretory component 
and/or the presence of multimers. Taken together our data show that dimerization of IgA is the 
limiting step for sIgA assembly. Improving dIgA assembly could further increase sIgA yield and 
simplify down-stream processing.  
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Figure 5 !  sIgA assembly using multi-cassette expression vectors. Leafs were agro-infiltrated for the 
expression of IgA1 (I1), 2m1 (I21) or 2m2 (I22) together with joining chain (dI) and secretory component (sI) 
using multi-cassette vectors (vector system 1 in figure 3b) and harvested 6 days post infiltration. Total 
soluble proteins were extracted and 1 µg was separated by SDS-PAGE under reducing conditions followed 
by visualization using protein specific antibodies as indicated. As controls 50 ng of recombinant IgA1κ 
(rI50) and 200 ng purified sIgA (rS200) and an empty vector (EV) sample were used. 
 
Figure 6 !  IgA and sIgA yield using multi-cassette expression vectors. A Average IgA yield (n=3) upon 
expression of IgA1, IgA2m1 and IgA2m2 using the multi-cassette vectors (vector system 1 in figure 3b) and 
harvested 6 days post infiltration. IgA yield in leaf extracts was determined by sandwich ELISA using a 
kappa chain specific capture and alpha heavy chain specific detection antibody. Error bars indicate 
standard error. B Average sIgA yield (n=3) upon expression of sIgA1, sIgA2m1 and sIgA2m2 using the 
multi-cassette vectors and harvested 6 days post infiltration. sIgA yield in leaf extracts was determined by 
sandwich ELISA using a kappa chain specific capture and secretory component specific detection 
antibody. Error bars indicate standard error. 
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Joining chain incorporation is the limiting factor for sIgA yield 
Next, we investigated whether joining chain expression is the limiting factor for sIgA 
assembly. Thereto, we attempted to increase the expression of the joining chain by increasing 
the OD of the Agrobacterium culture harbouring the vector for joining chain expression using 
the 3-vector system. sIgA yield was determined by sandwich ELISA and joining chain 
expression was evaluated using western blot analysis (Figure 7a and 7b). While the expression 
of the joining chain increased by using a higher OD of the Agrobacterium culture harbouring 
the vector for the joining chain expression, sIgA yield did not increase. We therefore assume 
that not joining chain expression, but its incorporation in the dIgA complex is the limiting 
factor for sIgA yield.  
On a side note, the band that most likely represents monomeric joining chain (~25 kDa) 
appears to be a doublet (two bands migrating very close to each other). A doublet may 
represent twice the same protein with a different number of N-glycans. Because the joining 
chain only harbours one N-glycosylation site, this doublet should represent a non-glycosylated 
and glycosylated joining chain.   
To evaluate if lowering IgA expression would influence the efficiency of dIgA assembly, 
we also attempted to decrease the amount of IgA by reducing the OD of the Agrobacterium 
culture harbouring the vector for IgA expression using the 3-vector system. Again sIgA yield 
was determined by sandwich ELISA and sIgA assembly was evaluated using western blot 
analysis (Figure 7c and 7d). Upon reduction of the OD of the Agrobacterium culture 
harbouring the vector for IgA expression the amount of monomeric and dimeric IgA reduced. 
However, also sIgA yield is reduced when the OD of the Agrobacterium culture that harbours 
the vector for IgA expression becomes lower than 0.2. At this OD, significant amounts of 
monomeric IgA with and without associated secretory component and dimeric IgA are still 
present. Thus, dIgA assembly cannot be improved by adjusting the expression of its individual 
components. It is therefore likely that not the capacity of the plant cell to assemble the protein 
complex, but intrinsic properties of the individual proteins determine dIgA assembly efficiency. 
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Figure 7 !  Incorporation of the joining chain is the limiting factor for sIgA yield. Leafs were agro-
infiltrated for the expression of IgA1, joining chain (JC) and secretory component (SC) by co-infiltration 
(vector system 3 in figure 3b) and harvested 6 days post infiltration. A Average sIgA yield (n=3, error bars 
indicate standard error) and B western blot analysis upon increasing the OD of the Agrobacterium culture 
facilitating joining chain expression. As controls recombinant joining chain (rJ50) and an empty vector (EV) 
sample were used. C Average sIgA yield (n=3, error bars indicate standard error) and D western blot 
analysis of sIgA assembly upon decreasing OD of the Agrobacterium culture facilitating IgA expression. As 
controls 50 ng of recombinant IgA1κ (rI50) and 200 ng purified sIgA (rS200) and an empty vector (EV) sample 
were used.  
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Discussion 
 
We have studied the limiting factors for sIgA production upon transient expression in N. 
benthamiana. Because sIgA is a heteromultimeric protein complex transient expression can be 
achieved in several ways. Agrobacterium cultures each harbouring expression vectors that 
facilitate expression of the individual components can be co-infiltrated or a multi-cassette 
expression vector facilitating expression of several or all components may be used. Also, a 
combination of these two strategies may be used. The risk with co-infiltration is that not all 
cells are transformed with all genes. This may result in the presence of un-associated 
components or assembly intermediates that may complicate downstream processing. Use of a 
multi-cassette vector would ensure that each transformed cell expresses each gene, however, 
the much larger T-DNA may be less efficiently transferred into the plant cells. We first 
evaluated the course of expression of all individual proteins followed by evaluation of four 
expression strategies to achieve sIgA production. We co-infiltrated all genes individually (4-
vector system), co-infiltrated the secretory component and joining chain with the multi-
cassette vector for IgA1κ expression (3-vector system), co-infiltrated the secretory component 
and the multi-cassette vector for dIgA1κ expression (2-vector system) and finally also used a 
single multi-cassette vector for sIgA1κ expression (1-vector system). Although the T-DNA of the 
single multi-cassette vector for sIgA1κ expression was ~10,3 kbp in size, it provided slightly 
higher sIgA yield compared to the 4, 3 and 2-vector systems. Thus, in our study increased size 
of the T-DNA does not reduce transformation efficiency. Furthermore, the 4, 3 and 2-vector 
systems all gave comparable sIgA yield. Therefore, most cells must have been transformed 
repeatedly, whereby most cells received all T-DNAs required to facilitate sIgA expression. 
Despite the fact that the same promoter and terminator sequences were used to facilitate 
expression of all genes, loss of vector parts during cloning or loss of sIgA expression upon 
repeated plant transformation was never observed. We therefore assume that our multi-cassette 
expression vectors are stable and recombination did not occur. 
Although the use of the single multi-cassette expression vector did result in accumulation 
of a significant amount of fully assembled sIgA, various assembly intermediates were also 
detected. Regardless of the expression strategy used a significant proportion of monomeric IgA 
was observed next to sIgA. In three other studies on expression of sIgA in plants a significant 
proportion of monomeric IgA was observed as well. Stable expression of a murine IgA/G 
hybrid with murine joining chain resulted in a 1:1 ratio of IgA and dIgA [14]. Upon transient 
co-expression of a chicken IgA and chicken joining chain just over half of the IgA dimerized 
[18]. In a study on transient expression of human sIgA, the use of a multi-cassette vector 
resulted in a mix of IgA, dIgA and sIgA of which 33% was confirmed to be sIgA [19]. Follow 
up studies on the expression of the murine IgA/G hybrid demonstrated that this antibody was 
targeted to the vacuole due to a cryptic targeting signal in the tailpiece of murine IgA [21, 22]. 
In our previous publication on expression of monomeric human IgA we demonstrate that 
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human IgA is also poorly secreted from plant cells [23]. The tailpieces of both human and 
chicken IgA contain similar sequences as the suggested cryptic targeting signal of murine IgA. 
Thus, it may well be that also chicken and human IgA are targeted to the vacuole. If IgA is 
targeted to the vacuole, it is possible that a proportion of IgA is transported to the vacuole 
before the joining chain can be incorporated. Unfortunately the tailpiece of IgA cannot be 
removed, as the penultimate cysteine residue forms a disulphide bond with a free cysteine of 
the joining chain [24]. An investigation if mutations in the cryptic vacuolar targeting signal can 
abolish the vacuolar targeting without influencing the complex assembly may provide a 
solution.  
Reports on the expression of sIgA in Chinese hamster ovary (CHO) cells also identify dIgA 
assembly as the yield-limiting step in sIgA expression [25, 26]. Because mammalian cells are 
devoid of vacuoles, vacuolar targeting cannot explain the lack of sIgA assembly. 
Unfortunately, both studies did not determine joining chain expression, thus it is unclear if 
sIgA assembly in CHO cells is caused by limited joining chain expression or inefficient 
incorporation of the joining chain. To evaluate if either joining chain expression or 
incorporation was the limiting step for the yield of our sIgA we increased the bacterial OD of 
the Agrobacterium culture facilitating joining chain expression and demonstrated that while 
joining chain expression was increased, sIgA yield was not, nor had the proportion of 
monomeric IgA diminished. We therefore assumed that joining chain incorporation was the 
limiting step for sIgA assembly. We also, observed that the band assumed to represent 
monomeric joining chain migrated as a doublet. Because the joining chain harbours only one 
N-glycosylation site it is possible that this doublet represents a non-glycosylated and a once 
glycosylated version of the joining chain. It was demonstrated that incorporation of the joining 
chain is reduced if the asparagine 48 of the joining chain or asparagine 549 of the alpha heavy 
chain is not glycosylated [24, 27]. In a previous study we already confirmed that the N-
glycosylation of the asparagine 549 of the alpha heavy chain is partial [23]. Partial N-
glycosylation as a reason for inefficient incorporation of the joining chain coincides with the 
fact that also reduced expression of IgA did not alter the IgA:sIgA ratio. We therefore assume 
that not the capacity of the plant cell to assemble dIgA is limiting, but that partial N-
glycosylation of IgA and/or joining chain is the reason for inefficient sIgA assembly both for 
plant as well as CHO cell produced sIgA.  
Because N-glycosylation is co-translational, limited access to the glycosylation site 
cannot explain inefficient N-glycosylation. However, in a large-scale analysis of glycoproteins 
it was demonstrated that the glycosylation signals N-X-T and N-X-S are N-glycosylated in 70% 
and 30% of the cases, respectively [28]. This suggests that the signal N-X-T is more efficiently 
glycosylated. Both the N-glycosylation site in the tailpiece of the alpha heavy chains and the 
joining chain are of the N-X-S type. Mutation of the serine to a threonine may enhance 
glycosylation and therefore also sIgA assembly. Despite the fact that sIgA yield was limited by 
the efficiency of joining chain incorporation, sIgA yield was already high, in the order of 
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hundreds of µg sIgA per mg TSP. If sIgA assembly can be improved by mutation of the N-
glycosylation signals of the alpha heavy chain and/or the joining chain, thereby reducing the 
presence of sIgA intermediates, plants could allow the economic production of sIgA for 
clinical use.  
 
 
Experimental procedures  
 
Construct design 
GeneArt (Bleiswijk, the Netherlands) synthesized all below-mentioned gene fragments except 
the constant domains of the human immunoglobulin alpha-2m1, which was amplified from 
the human transcriptome library MegaMan (Agilent Technologies, Middelburg, the 
Netherlands). First, undesired restriction sites were removed from the sequences of the 
constant domains of human immunoglobulin alpha-1 (ACC82528.1), alpha-2m1 (AL928742.3) 
and kappa (AGH70219.1) chains, joining chain (AK312014.1) and secretory component (1-
764 codons of the polymeric immunoglobulin receptor; AAB23176.1). To obtain the sequence 
for the constant domains of the human immunoglobulin alpha-2m2 the sequence of the 
human immunoglobulin alpha-2m1 was adapted (as indicated in P01877). The variable 
regions of the commercial antibody Ustekinumab (CNTO-1275) and the signal peptide of the 
Arabidopsis thaliana chitinase gene (AAM10081.1) were recoded from the amino acid 
sequence using codons preferred by Nicotiana benthamiana. For subsequent cloning and 
assembly of the full alpha heavy chain genes, the gene fragments were flanked by the 
following restriction sites at the 5’ and 3’-end: NcoI-EagI, EagI-NheI, NheI-KpnI, for the signal 
peptide, the heavy chain variable and alpha heavy chain constant regions, respectively. For 
subsequent cloning and assembly of the kappa chain, the gene fragments were flanked by the 
following restriction sites at the 5’ and 3’-end: NcoI-EagI, EagI-BsiWI, BsiWI-KpnI for the signal 
peptide the kappa chain variable and constant region, respectively. For subsequent cloning of 
the joining chain and secretory component the sequences were flanked by NcoI-KpnI at the 5’ 
and 3’-end, respectively. None of the restriction sites used introduced extra amino acids 
except NcoI, which in some cases introduced an extra alanine after the start methionine. 
Genes were ligated into the shuttle vector pRAPa, a pRAP (or pUCAP35S)[29] derivative 
modified to include an AsiSI restriction site by introduction of the self-annealed oligo 5’- 
AGCTGGCGATCGCC-3’ into a HindIII linearized pRAP. In pRAPa all open reading frames are 
placed under the control of the 35S promoter of the Cauliflower mosaic virus with duplicated 
enhancer (d35S) and the Agrobacterium tumefaciens nopaline synthase transcription 
terminator (Tnos). A 5’ leader sequence of the Alfalfa mosaic virus RNA 4 (AlMV) is also 
included between the promoter and gene to boost translation. From pRAPa the expression 
cassettes were digested with AscI and PacI, confirmed by sequencing, and ligated into the 
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expression vector pHYG [30]. Use of the restriction sites AscI and AsiSI allowed subsequent 
introduction of expression cassettes as AsiSI creates the same overhang as PacI (Figure 2a). 
Expression cassettes were transformed to Agrobacterium tumefaciens strain MOG101 for plant 
expression. 
 
Plant transformation 
Agrobacterium clones were cultured overnight (o/n) at 28°C in LB medium (10g/l pepton140, 
5g/l yeast extract, 10g/l NaCl with pH7.0) containing 50 µg/ml kanamycin and 20 µg/ml 
rifampicin. The optical density (OD) of the o/n cultures was measured at 600 nm and used to 
inoculate 50 ml of LB medium containing 200 µM acetosyringone and 50 µg/ml kanamycin. 
After 16 hours the bacterial cultures were centrifuged for 15 min at 2800 g and the bacteria 
were resuspended in MMA infiltration medium (20g/l sucrose, 5g/l MS-salts, 1.95g/l MES, 
pH5.6) containing 200 µM acetosyringone. For co-expression Agrobacterium cultures were 
either mixed or multi-cassette vectors were used. The final OD of each Argobacterium culture 
in an infiltration mix was 0.5 unless otherwise indicated. The total OD of the infiltration mix 
was kept the same within an experiment by use of an Agrobacterium culture harboring an 
empty vector if needed. The Tomato bushy stunt virus (TBSV) silencing inhibitor p19 was 
always co-expressed. After 1-2 hours incubation of the infiltration mix at room temperature, 
the two youngest fully expanded leaves of 5-6 weeks old Nicotiana benthamiana plants were 
infiltrated completely. Infiltration was performed by injecting the Agrobacterium suspension 
into a Nicotiana benthamiana leaf at the abaxial side using a needleless 1 ml syringe. 
Infiltrated plants were maintained in a controlled greenhouse compartment (UNIFARM, 
Wageningen) and infiltrated leaves were harvested at selected time points. 
 
Total soluble protein extraction  
Leaf disks were cut from infiltrated leafs and immediately snap-frozen upon harvesting and 
homogenized in liquid nitrogen using a TissueLyser II (Qiagen, Venlo, the Netherlands) and 
stored at -20°C until use. Homogenized plant material was mixed in ice-cold extraction buffer 
(50mM phosphate-buffered saline (PBS) pH=7.4, 100 mM NaCl, 10 mM EDTA, 0.1% v/v 
Tween-20, 2% w/v immobilized polyvinylpolypyrrolidone (PVPP)) using 2 ml/g fresh weight in 
the TissueLyser II. Crude extract was clarified by centrifugation at 16.000 xg for 5min at 4°C. 
 
IgA and sIgA quantification 
IgA and sIgA concentrations in crude extracts were determined by sandwich ELISA. ELISA 
plates (Greiner Bio One; Alphen aan den Rijn, the Netherlands) were coated with a goat 
polyclonal anti-human kappa antibody (Sigma-Aldrich-Aldrich; Zwijndrecht, the Netherlands) 
in coating buffer (eBioscience, Vienna, Austria) o/n at 4°C in a moist environment. After this 
and each following step the plate was washed 5 times with 30 sec intervals in PBST (1x PBS, 
0,05% Tween-20) using an automatic plate washer model 1575 (BioRad; Veenendaal, the 
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Netherlands). The plate was blocked with assay diluent (eBioscience) for 1 h at room 
temperature. Samples and a standard line were loaded in serial dilutions and incubated for 1 h 
at room temperature. For IgA determination recombinant human IgA1κ (InvivoGen; Toulouse, 
France) was used as a standard in a 2-fold dilution series from 100 to 0,31 ng/ml in assay 
diluent. For sIgA determination colostrum purified sIgA (Sigma-Aldrich) was used as a standard 
in a 2-fold dilution series from 1000 to 3,1 ng/ml in assay diluent. Hereafter a HRP-conjugated 
goat polyclonal antibody directed against the constant domains of human IgA (Sigma-Aldrich) 
or a biotinylated goat polyclonal antibody directed against the human secretory component 
(Sigma-Aldrich) was used for detection of IgA and sIgA, respectively. Avidin-HRP (eBioscience) 
conjugate was used to bind the biotin of the anti-secretory component antibody. 3,3’,5,5’-
Tetramethylbenzidine (TMB) substrate (eBioscience) was added and colouring reaction was 
stopped using 0.18M sulphuric acid after 1-30 min. OD read outs were performed using the 
model 680 microplate reader (BioRad) at 450 nm with correction filter of 690 nm. For sample 
comparison the total soluble protein (TSP) concentration was determined using the BCA 
Protein Assay Kit (Pierce) according to supplier’s protocol using bovine serum albumin (BSA) 
as a standard. 
 
Protein analysis by Western blot  
For western blot analysis clarified protein extracts were desalted using a Sephadex G25 (VWR 
International; Amsterdam, The Netherlands) column prior to BCA analysis. One µg (unless 
otherwise indicated) of total soluble protein was separated under reducing conditions by SDS-
PAGE on in house made 6 or 12% Bis-Tris gels. Recombinant IgA1κ (InvivoGen) and/or 
colostrum purified sIgA (Sigma-Aldrich) or recombinant joining chain (Sino Biological; 
Cologne, Germany) were used as controls. Proteins were transferred to an InvitrolonTM PVDF 
membrane (Invitrogen) by a wet blotting procedure (Life technologies; Bleiswijk, the 
Netherlands). Thereafter the membrane was blocked in PBST-BL (PBS containing 0.1% v/v 
Tween-20 and 5% w/v non-fat dry milk powder) for 1 hour at room temperature, followed by 
overnight incubation with an anti-human kappa (Sigma-Aldrich), anti-human immunoglobulin 
alpha (Sigma-Aldrich), anti-joining chain (Nordic Immunological Laboratories; Tilburg, the 
Netherlands) or HRP-conjugated anti-secretory component (Sigma-Aldrich) antibody. The 
membrane was washed 5 times in PBST (PBS containing 0.1% v/v Tween-20). For detection of 
human kappa, human immunoglobulin alpha and joining chain a HRP-conjugated anti-goat 
IgG antibody (Jackson ImmunoResearch; Suffolk, UK) was used where after washing steps 
were repeated. Finally, the SuperSignal West Dura substrate (Thermo Fisher Scientific; Etten-
Leur, the Netherlands) was used as HRP substrate. Pictures were taken using a G:BOX Chemi 
System device (SynGene; Cambridge, UK).   
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Abstract  
 
Schistosoma mansoni is a parasitic trematode that, like other helminths, secretes 
immunomodulatory proteins to sustain infection and to complete its life cycle. These secreted 
proteins are main topics of research as they are possible vaccine candidates or may have 
therapeutic potential to treat inflammatory disorders. Omega-1 is secreted by eggs of S. 
mansoni and is a key factor for the induction of Th2 cell polarisation via instruction of 
dendritic cells. In vitro induction of Th2 responses by omega-1 is dependent on its RNase 
activity as well as its N-glycans that are required for the internalisation by dendritic cells. 
However, the exact role(s) of N-glycans on the immunomodulatory properties of helminth 
secreted glycoproteins remains to be elucidated. As the purification of a single glycoprotein 
from S. mansoni egg extracts is inefficient and unsustainable, a platform is required that 
enables production of omega-1 with its native N-glycans. Here we show that S. mansoni-
derived omega-1 can be efficiently produced in Nicotiana benthamiana plants by means of 
agroinfiltration. Omega-1 was purified from the apoplast (intercellular space) of N. 
benthamiana leaves and was shown to have RNase activity. Omega-1 produced in wild-type 
plants carried paucimannosidic type N-glycans, which are typical for plant-secreted proteins. 
By the controlled co-expression of two glycosyltransferases in wild-type plants, omega-1 
received N-glycans that carried terminal Lewis X motifs, like S. mansoni-derived omega-1. Our 
results demonstrate that plants are an excellent platform for the expression of helminth 
glycoproteins carrying engineered N-glycans, which opens up a new field of research. 
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Introduction 
 
Over the last few decades the incidence of immune-mediated diseases, like inflammatory 
bowel disease, asthma, multiple sclerosis and autoimmune (type 1) diabetes, has strongly 
increased in industrialised countries. Interestingly, there is an inverse correlation between the 
occurrences of these immune-mediated diseases with parasitic helminth infections. Helminths 
are complex multicellular organisms that upon infection of their host are master regulators of 
their host's immune system. The trematode Schistosoma mansoni is one of the best-studied 
helminths and the ability of S. mansoni eggs to induce strong Th2 responses in humans and 
experimental animal models is well documented [1, 2]. The protective effect of infection with 
S. mansoni against immune-mediated disease was tested in several animal models for human 
diseases. For instance, S. mansoni was shown to protect mice against TNBS-induced colitis [3], 
allergen-induced airway hyperreactivity [4], autoimmune encephalitis [4, 5] and autoimmune 
diabetes [6, 7]. Protection against immune-mediated diseases was associated with the down-
regulation of Th1-type cytokines (IFN-γ and IL-12) and increased expression of regulatory and 
Th2-type cytokines (IL-4, IL-10 and/or IL-13). However, more information is required to 
understand exactly how helminths, like S. mansoni, modulate their host's immune system. 
Knowledge on helminth secreted proteins that play a key role in immune modulation could 
ultimately lead to the identification of new therapeutic targets for the treatment of several 
immune-mediated diseases. 
Immune modulation during helminth infection is mediated by a variety of proteins that 
are secreted by the cercariae (larvae), worms and/or their eggs [8]. The mix of soluble egg 
antigens from S. mansoni (SEA) is well known for its capacity to promote Th2 responses, 
however, S. mansoni eggs secrete several proteins and not all these proteins are functionally 
characterised [9, 10]. The purification and functional characterisation of a single protein from 
Schistosome egg extracts is difficult, because the amount of SEA that can be obtained is 
limited. Therefore, an expression platform is required that enables the production of helminth 
secreted proteins in large quantities.  
Recently omega-1 was identified as the major component in S. mansoni eggs that is 
responsible for conditioning dendritic cells (DC's) for Th2 polarisation [11-13]. Omega-1 is a 
glycoprotein secreted by the eggs of S. mansoni and has T2 ribonuclease activity. Site-directed 
mutagenesis of the catalytic domain or the two potential N-glycosylation sites of omega-1 
demonstrated that the priming of Th2 responses by omega-1 treated DC's was dependent on its 
RNase activity as well as its N-glycosylation [14]. The major N-glycans identified on S. 
mansoni-derived omega-1 are core-difucosylated diantennary N-glycans with one or two 
terminal Lewis X motifs [15]. Omega-1 was shown to bind to several C-type lectin receptors, 
but the mannose receptor (CD206) was shown to be crucial for internalisation into DC's and 
subsequent polarisation of Th2 cells [14]. Besides omega-1 several SEA components have been 
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shown to interact with antigen presenting cells via a range of C-type lectin receptors and in 
many cases this interaction is thought to be important for shaping immune responses during 
schistosomiasis [16]. As the interaction with distinct C-type lectin receptors can influence the 
outcome of the immune response that is initiated by a certain SEA protein, it is crucial that for 
the functional characterisation of such proteins that they carry appropriate N-glycan structures. 
Therefore, an expression platform is required that not only enables high expression of such 
helminth proteins, but it should also be capable of producing native helminth N-glycan 
structures.  
In the last two decades, plants have emerged as a promising expression platform for the 
production of recombinant proteins. Engineering of the N-glycosylation machinery has been 
successful in part because plants have demonstrated a high degree of tolerance towards 
changes in the glycosylation pathway, allowing the modification of recombinant glycoproteins 
in a specific and controlled manner [17]. Notably research on humanising N-glycans in plants 
has advanced over the last couple of years. Transgenic plants lacking non-human α1,3-fucose 
and β1,2-xylose sugar residues on their N-glycans have been generated (ΔXT/FT plants) and 
typical mammalian core α1,6-fucose can be engineered in plants as well [18, 19]. Lewis X 
motifs have been synthesised before in Nicotiana tabacum by stably expressing a hybrid β1,4-
galactosyltransferase and a hybrid α1,3-fucosyltransferase IXa that were targeted to the medial-
Golgi compartment [20]. However, these N-glycans were of a hybrid type as they only 
contained one antenna with a Lewis X motif and another antenna containing mannoses. The 
formation of hybrid N-glycans was attributed to the incorrect targeting of the 
glycosyltransferases. The efficiency of galactosylation in plants has proven to be a challenge. 
Expression of human β1,4-galactosyltransferase resulted in the formation of incompletely 
processed N-glycans, mainly lacking typical plant β1,2-xylose and/or α1,3-fucose or a single 
β1,4-galactose [21]. In contrast, targeting human β1,4-galactosyltransferase to the trans-Golgi 
compartment in ΔXT/FT plants allowed the generation of monoclonal antibodies with 
diantennary N-glycans containing two terminal galactose residues [22]. The authors postulated 
that the reason for inefficient galactosylation was that human β1,4-galactosyltransferase 
competes for the same acceptor substrate as the endogenous enzymes in the plant Golgi 
network.  
In this study we investigated the suitability of plants as expression platform for S. 
mansoni-derived omega-1 and we investigated the possibility to engineer the glycosylation 
machinery such that diantennary N-glycans carrying Lewis X motifs were synthesized. Thereto, 
we used co-expression of β1,4-galactosyltransferase from Danio rerio (zebrafish) and α1,3-
fucosyltransferase IXa from Tetraodon nigriviridus (pufferfish), which were targeted to the trans-
Golgi network with the cytoplasmic-transmembrane-stem (CTS) domain of rat α2,6-
sialyltransferase. Our work demonstrates that plants are an excellent expression platform for 
the production of omega-1 in large quantities and due to its efficient secretion is easily 
purified. Furthermore, we show that controlled expression of β1,4-galactosyltransferase is 
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required for efficient engineering of diantennary N-glycans that carry Lewis X motifs in wild-
type plants. 
 
 
Results  
 
Plants are an excellent expression host for S. mansoni-derived Omega-1 
To express biologically active omega-1 from Schistosoma mansoni we designed a codon-
optimised gene of omega-1. Codon optimisation was applied as the GC-content of the native 
omega-1 gene is only 40% and plants generally prefer a higher GC-content in their highly 
expressed genes [23]. The mature omega-1 protein sequence was preceded by the Arabidopsis 
thaliana chitinase signal peptide for secretion followed by a N-terminal 6x histidine-tag and 
FLAG-tag (H6F). Expression was achieved by agroinfiltration of 5-6 weeks-old Nicotiana 
benthamiana plants, while co-expressing the p19 silencing suppressor of tomato bushy stunt 
virus. Expression of omega-1 was analysed in crude plant extracts at 3, 5 and 7 days post 
infiltration using western blots probed with an anti-FLAG antibody (Fig. 1a). Omega-1 
migrated as two bands between 25 and 37 kDa, which were detected at all three time points 
with greatest band intensity at dpi 5. The calculated molecular weight of omega-1 is ~27 kDa, 
but omega-1 harbours two N-glycosylation sites. Thus, the two bands most likely represent 
intact omega-1, but with a different number of N-glycans. 
Next we tested whether omega-1 is efficiently secreted from plant cells into the 
apoplast. At 5 dpi we isolated apoplast fluids from empty vector and omega-1 infiltrated leaves 
and used the remaining leaf material to make crude extracts. Both samples were analysed by 
SDS-PAGE and Coomassie staining (Figure 1b). Strikingly, the majority of the plant-produced 
omega-1 (>90%) was recovered from the apoplast. This means that omega-1 is secreted with 
high efficiency. Only few endogenous proteins are present in apoplast fluids and upon 
expression of omega-1, it became the predominant protein constituting >50% of total soluble 
protein. Apoplast fluids would therefore be an excellent starting point for further purification of 
omega-1. 
Omega-1 was purified from the plant apoplast fluid using Ni-NTA affinity 
chromatography with a yield of approximately 150 µg omega-1 per ml of apoplast fluid. 
Purified omega-1 was analysed with SDS-PAGE followed by Coomassie staining and revealed 
two dominant bands that were previously detected with the anti-FLAG western blot (Figure 
1c). Coomassie staining also revealed a faint band of ~25 kDa, which likely represents non-
glycosylated omega-1.  
Since omega-1 was characterised as a T2 ribonuclease (RNase), purified omega-1 was 
analysed for its RNase activity. Purified omega-1 was used in a RNA break down assay using 
total RNA from mouse bone marrow-derived dendritic cells. A mutant of omega-1, which 
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should lack RNase activity (omega-1H58F) [14], was also expressed in plants, purified, and 
tested for activity. Figure 1d shows that purified omega-1 from plants is able to break down 
total RNA from mouse dendritic cells, whereas the omega-1H58F mutant did not. This indicates 
that plant produced omega-1 has RNase activity. 
Taken together our data show that plants offer an excellent expression platform for the 
production of large quantities of S. mansoni-derived omega-1. Furthermore, omega-1 is 
secreted into the apoplast with high efficiency, thereby enabling easy purification of active 
omega-1. 
 
 
 
 
Figure 1 !  Analysis of Omega-1 (ω1) expressed in N. benthamiana plants. (a) Anti-FLAG western blot 
analysis under reducing conditions of 1 μg total protein from crude plant extracts for omega-1 or empty 
vector (EV) infiltrated plants 3, 5 and 7 days post infiltration (dpi). (b). SDS-PAGE analysis under reducing 
conditions and Coomassie staining of 2.5 μl of crude extract (CE) or apoplast fluid (AF) from omega-1 or 
EV infiltrated plants. (c) SDS-PAGE analysis under reducing conditions and Coomassie staining of 2 μg 
purified omega-1. (d) RNase breakdown assay of total RNA from mouse bone marrow-derived dendritic 
cells using 500 ng purified omega-1 and omega-1H58F. RNase A was used a positive control. 
 
 
 
Glyco-engineering of omega-1 results in hybrid Lewis X-type N-glycans 
A major fraction of S. mansoni-derived omega-1 naturally harbours diantennary N-glycans that 
carry Lewis X motifs. We set out to engineer Lewis X type N-glycans in N. benthamiana. Lewis 
X carrying N-glycans were previously synthesised in N. tabacum, but resulted in the formation 
of hybrid Lewis X-type N-glycans due to targeting to the medial-Golgi [20]. In our study we 
used α1,3-fucosyltransferase IXa from Tetraodon nigriviridus (pufferfish) and β1,4-
galactosyltransferase 1 from Danio rerio (zebrafish). Both genes were genetically fused with the 
trans-Golgi targeting CTS domain of rat α2,6-sialyltransferase from here forward named 
sialFucT and sialGalT, respectively. We co-expressed both glycosyltransferases together with 
omega-1 and the p19 silencing suppressor in plants and purified omega-1 from the apoplast.  
For N-glycan analysis tryptic peptides were prepared from purified omega-1 and N-glycans 
were released by PNGase A digestion. The N-glycosylation profile was determined by matrix 
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assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS). 
Representative N-glycan profiles are shown in Figure 2 for omega-1 isolated from wild-type N. 
benthamiana plants with and without co-expression of sialFucT and sialGalT (Figure 2a and 
2b, respectively). Without co-expression of the glycosyltransferases the predominant N-glycan 
type found on omega-1 is a typical plant complex glycan for secreted proteins with β1,2-
xylose and core α1,3-fucose. The N-glycans lack terminal GlcNAc residues putatively due to 
β-hexosaminidase activity in the apoplast (paucimannosidic type N-glycan; MMXF3). 
 
 
Figure 2 !  N-glycan profiles for omega-1 expressed in N. benthamiana plants. N-glycans were analysed 
using MALDI-TOF-MS analysis upon tryptic digestion and PNGase A release of N-glycans. A N-glycan 
profile for omega-1 from wild-type N. benthamiana plants. B N-glycan profile for omega-1 from wild-type 
N. benthamiana plants upon co-expression of sialFucT and sialGalT to engineer Lewis X carrying N-
glycans. Optical densities of 0.5 were used for each construct. Each glycan profile is accompanied by an 
image of in vitro digestion of omega-1 with PNGase F (P) and Endo H (E) as analysed by anti-FLAG 
western blotting  
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The major N-glycan found on omega-1 upon co-expression of sialFucT and sialGalT 
consisted of one antenna carrying Lewis X, while the other antenna carried two additional 
mannoses (hybrid Lewis X). Furthermore, plant specific β1,2-xylose and core α1,3-fucose were 
absent. Besides the hybrid Lewis X-type N-glycan we also observed a smaller fraction of 
mannose-enriched N-glycans (Man5). To complement the N-glycan profiles, omega-1 was 
deglycosylated with PNGase F and Endo H to confirm the presence or absence of core α1,3-
fucose or oligomannose/hybrid type N-glycans, respectively. In the upper right corner of both 
N-glycan profiles, the deglycosylation of omega-1 is shown upon anti-FLAG western blotting. 
In both cases, deglycosylation with PNGase F or Endo H confirms the obtained N-glycan 
profile. N-glycans carrying Lewis X motifs are formed upon co-expression of sialFucT and 
sialGalT, but are still of the hybrid-type as reported by Rouwendal and co-workers (2009).  
 
Over-expression of sialGalT causes hybrid Lewis X-type N-glycans 
Over-expression of a glycosyltransferase might result in overflow of the glycosyltransferase into 
other Golgi sub-compartments. In our case, our glycosyltransferases might therefore not be 
restricted to the trans-Golgi only. Activity of β1,4-galactosyltransferase in the medial-Golgi 
may interfere with α-mannosidase II activity in this compartment resulting in the formation 
hybrid N-glycans [24]. As Endo H was capable of cleaving off hybrid Lewis X-type N-glycans, 
we employed Endo H digestion to investigate if over-expression of β1,4-galactosyltransferase 
causes the formation of these hybrid N-glycans. We co-expressed omega-1 with sialFucT and 
sialGalT, but used different ratio's for the Agrobacterium cultures of these two 
glycosyltransferases. By scaling down optical densities of Agrobacterium cultures (testing a 
range from 0.5 to 0.05) we assume the expression of either sialFucT or sialGalT can be 
reduced. Apoplast fluids were harvested at 5 dpi and were treated with Endo H. The cleavage 
of hybrid N-glycans by Endo H was then analysed using anti-FLAG western blots probed with 
an anti-FLAG antibody (Figure 3a). When using an optical density of 0.5 for both 
glycosyltransferases, omega-1 migrates slightly higher in the SDS-PAGE gel than omega-1 
expressed without co-expression of both glycosyltransferases, indicating a higher N-glycan 
mass. Upon treatment with Endo H the majority of omega-1 is deglycosylated, which confirms 
the presence of oligomannose- and/or hybrid-type N-glycans. When the optical density for 
sialGalT was lowered to 0.1 or 0.05, Endo H was only in part capable of cleaving the N-
glycans from omega-1. Lowering the expression of sialFucT on the other hand did not have 
this effect. This observation supports the hypothesis that the over-expression of sialGalT and 
not sialFucT is linked to the formation of hybrid Lewis X N-glycans.  
We also tested whether controlled expression of sialGalT by using a weaker promoter 
could prevent the formation of hybrid N-glycans completely. We chose the promoter region of 
the potato resistance gene Gpa2 to control the expression of sialGalT, because resistance 
genes are constitutively expressed at a low level. Co-expression of omega-1 with sialFucT and 
sialGalT, the latter being controlled by the Gpa2 promoter region, resulted in the production of 
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omega-1 that was hardly sensitive to Endo H (Figure 3b). Next, western blot analysis with a 
rabbit anti-HRP antibody, which specifically binds to plant β1,2-xylose and core α1,3-fucose, 
was performed as hybrid glycans do not carry these typical plant sugar residues (Figure 3c). As 
expected the anti-HRP antibody bound strongly to omega-1 from wild-type plants, but not to 
omega-1 co-expressed with the d35S:sialGalT construct. When the Gpa2:sialGalT construct 
was used, the N-glycans on omega-1 did carry typical plant sugars again. We therefore 
conclude that by co-expressing the Gpa2:sialGalT construct omega-1 does not receive hybrid-
type N-glycans. However, the question is whether sialGalT expression controlled by the Gpa2 
promoter is still high enough to facilitate efficient galactosylation. 
 
 
 
 
Figure 3 !  Screening for Lewis X type N-glycans. A Anti-FLAG western blot analysis of Endo H treated 
apoplast fluids for omega-1 expressed in wild-type plants while co-expressing 35S:sialFucT and 
35S:sialGalT at different ratio's of Agrobacterium cultures. Optical densities (OD) of 0.5-0.05 were used. B 
Anti-FLAG western blot analysis of Endo H treated apoplast fluids for omega-1 expressed in wild-type 
plants while co-expressing 35S:sialFucT and Gpa2:sialGalT (using an OD of 0.5-0.1) to lower sialGalT 
expression. C Anti-HRP western blot analysis of purified omega-1 expressed in wild-type plants or 
engineered omega-1 while co-expressing 35S:sialFucT (OD=0.1) with either d35S:sialGalT or 
Gpa2:sialGalT (using an OD of 0.5).  
 
 
 
Controlled expression of sialGalT enables Lewis X synthesis in wild-type N. benthamiana 
To investigate if omega-1 carries diantennary N-glycans with terminal Lewis X motifs upon co-
expression with 35S:sialFucT and Gpa2:sialGalT we analysed the N-glycan composition. N-
glycans were prepared as described above and a representative N-glycan profile is shown in 
Figure 4a. The predominant N-glycan type found on omega-1 upon Lewis X engineering is still 
the typical plant paucimannosidic N-glycan. However, by using this engineering strategy a 
significant proportion of diantennary N-glycans carrying Lewis X motifs was also found. On 
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top of that, several intermediate N-glycans containing antennae with a single Lewis X motif 
and/or a terminal galactose residue were found as well. Strikingly, all N-glycan structures 
contained typical plant β1,2-xylose. None of them were of the hybrid type carrying additional 
mannose residues on the α1,6-mannosyl branch. The presence of Lewis X was also confirmed 
by a binding assay with an agglutinin from Ricinus communis (RCA-I). As RCA-I does not bind 
to Lewis X motifs, omega-1 was first treated with α1,3/4-fucosidase from Xanthomonas 
manihotis. Figure 4b shows that RCA-I binds only to glyco-engineered omega-1 after removal 
of α1,3-linked fucose. Therefore, the N-glycans lacking a fucose residue must be missing this 
residue from the core, and not from the Lewis X motif. Altogether, we conclude that synthesis 
of diantennary N-glycans carrying Lewis X motifs can be achieved in wild-type N. 
benthamiana plants, but depends on the tightly controlled expression of sialGalT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 !  N-glycan profiles for omega-1 (ω1) 
carrying Lewis X motifs. N-glycans from purified 
omega-1 were analysed by MALDI-TOF-MS upon 
tryptic digestion and PNGase A release of N-
glycans. A N-glycan profile for omega-1 from 
wild-type N. benthamiana plants upon co-
expression of d35S:sialFucT (OD=0.1) and 
Gpa2:sialGalT (OD=0.5). B RCA-I binding assay 
of α1,3/4-fucosidase treated omega-1. Omega-1 
was coated at 1 μg/ml and then assayed for 
binding to RCA-I (5 μg/ml). 
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Discussion 
 
Schistosoma mansoni soluble egg antigens (SEA) play a crucial role in immune modulation 
during helminth infection and more detailed knowledge on the activity of its individual 
components can ultimately lead to the identification of new therapeutic targets for treatment of 
inflammatory disorders. Functional studies on individual components from this egg antigen 
mixture are challenged by the limited amount of SEA proteins that can be isolated. In our study 
we investigated the possibility to use Nicotiana benthamiana plants as a production platform 
for large quantities of the biologically active S. mansoni-derived egg antigen omega-1. 
Furthermore, we investigated whether the N-glycosylation machinery of plants could be 
engineered to synthesise diantennary N-glycans carrying terminal Lewis X motifs, which 
naturally occur on omega-1. Omega-1 was highly expressed and, most remarkable, >90% of 
omega-1 was secreted into the apoplast. The efficient secretion of omega-1 enabled easy 
purification as only few endogenous proteins reside in this extracellular compartment. In 
addition, purification from the apoplast fluid would ensure that all the proteins have passed 
through the entire secretory pathway and most likely results in a more homogeneous N-glycan 
composition. 
N-glycan analysis revealed that omega-1 expressed in wild-type N. benthamiana plants 
predominantly carries paucimannosidic N-glycans containing the plant specific sugar residues 
β1,2-xylose and core α1,3-fucose (MMXF3). The lack of terminal GlcNAc residues on the α1,3- 
and α1,6-mannosyl branches of N-glycans of plant proteins can be attributed to β-
hexosaminidase activity in the apoplast as postulated by Strasser and co-workers [25]. They 
identified three β-hexosaminidases (HEXO1-3) in Arabidopsis thaliana, which localised in 
either the vacuole (HEXO1) or the apoplast (HEXO2 and HEXO3) that were able to remove 
terminal GlcNAc residues from N-glycans. Especially HEXO3 seemed responsible for the 
formation of paucimannosidic N-glycans in leaves of A. thaliana [26]. Up to 7 genes with high 
similarity to β-hexosaminidases from Arabidopsis can be identified within the genome of N. 
benthamiana, but their function and localisation are unknown.  
In a first attempt to engineer terminal Lewis X motifs, a hybrid β1,4-
galactosyltransferase from Danio rerio (zebrafish) and a hybrid α1,3-fucosyltransferase IXa from 
Tetraodon nigriviridus (pufferfish) were co-expressed with omega-1. The CTS domain of rat 
α2,6-sialyltransferase was used for trans-Golgi targeting as it was previously shown to enable 
efficient galactosylation [22]. In contrast, medial-Golgi targeting of galactosyltransferase with 
the CTS domain of Arabidopsis β1,2-xylosyltransferase resulted in the formation of hybrid N-
glycans [20, 27]. These authors suggested that hybrid N-glycans are formed when early 
galactosylation in the medial-Golgi prevents trimming of mannose residues on the α1,6-
mannosyl branch of a N-glycan by α-mannosidase-II (Man-II). In our experiments, co-
expression of trans-Golgi targeted glycosyltransferases surprisingly resulted in the formation of 
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Lewis X hybrid N-glycans as well. Like previously observed, our hybrid Lewis X N-glycans are 
also devoid of plant specific β1,2-xylose and core α1,3-fucose. The lack of β1,2-xylose on 
Lewis X hybrid N-glycans would be in line with the suggestion that β1,2-xylosyltransferase 
only adds xylose after removal of the two mannoses on the α1,6-mannosyl branch, but before 
the addition of galactose to terminal GlcNAc residues [28]. This coincides with the fact that 
β1,2-xylosyltransferase from Arabidopsis thaliana is inhibited by mannoses on the α1,6-
mannosyl branch or terminal galactose on the α1,3-mannosyl branch [29]. Thus, early 
galactosylation in the medial-Golgi of plants blocks the addition of β1,2-xylose, but may also 
inhibit Man-II activity leading to hybrid N-glycans. This would infer that within our 
experiments the use of a trans-Golgi targeting CTS domain is not sufficient to retain zebrafish 
galactosyltransferase within the trans-Golgi compartment of plants. Perhaps, over-expression of 
zebrafish galactosyltransferase causes overflow of the trans-Golgi compartment, resulting in 
medial-Golgi localised galactosyltransferase. 
In order to lower the transient expression of sialGalT we used the Gpa2 promoter 
region. This controlled fashion of expressing sialGalT resulted in the complete lack of hybrid 
Lewis X N-glycans. Furthermore, this engineering strategy is the first report that describes the 
synthesis of diantennary N-glycans carrying Lewis X motifs. Besides complex N-glycans 
carrying two Lewis X motifs, several intermediate N-glycans containing antennae with a single 
Lewis X motif and/or terminal galactose residues were found. Still, a major fraction of 
paucimannosidic N-glycans is also found. This indicates that perhaps the efficiency of 
galactosylation is not yet optimal and it has to be investigated whether this efficiency can be 
increased by fine-tuning sialGalT expression. Still, our findings demonstrate another layer of 
complexity to glyco-engineering, as it is not sufficient to only choose a proper CTS domain for 
targeting of a glycosyltransferase. Controlled expression of the glycosyltransferase is also 
important to obtain correct Golgi-targeting. 
Alternatively, β-galactosidase activity may also interfere with obtaining a homogenous 
N-glycan composition. As the majority of the N-glycans, including some of the Lewis X 
intermediate N-glycans, lack terminal GlcNAc residues, we conclude that omega-1 is still 
sensitive to β-hexosaminidases in the leaf apoplast. This could be caused by inefficient 
galactosylation, as galactose would prevent GlcNAc removal by β-hexosaminidase. The 
presence of ungalactosylated N-glycan structures could also be due to the result of β-
galactosidase activity, also leading to sensitivity to β-hexosaminidase. However, Strasser and 
co-workers were able to stably express a trans-Golgi targeted human GalT (ST-GalT) in ΔXT/FT 
N. benthamiana plants, which enabled the transient expression of a monoclonal antibody with 
homogeneous galactosylation on both antennae [22]. If β-galactosidases would be able to 
remove galactose from N-glycans in plants, this efficiency of galactosylation would most likely 
not have been achieved. However, a difference in sensitivity towards β-galactosidases between 
proteins may exist. The N-glycans of IgG are not surface exposed and stabilise the interaction 
between the γ heavy chains [30] and might therefore be less accessible for β-galactosidases 
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compared to the N-glycans of omega-1. However, detailed structural information on omega-1 
does not exist and makes it hard to draw conclusions about differences in sensitivity to β-
galactosidases. 
In the case of Lewis X engineering, the addition of the α1,3-linked fucose to the Lewis X 
motif would protect the terminal galactose residues against β-galactosidases [20]. In our study, 
the sialFucT enzyme seems to be efficient as the predominant N-glycan found on omega-1 
upon co-expression with sialFucT and sialGalT (both controlled with the 35S promoter) carried 
complete Lewis X, although of the hybrid type.,Besides this hybrid Lewis X-type N-glycan we 
did observe a smaller fraction of mannose-enriched N-glycans (Man5), which could arise after 
inefficient fucosylation of the Lewis X motif and subsequent trimming down by β-
galactosidases and β-hexosaminidases. In subsequent experiments we reduced the optical 
density of the Agrobacterium culture that harbours the expression vector for sialFucT, which 
should result in reduced expression of this enzyme. Future experiment should therefore be 
performed where sialFucT expression is kept as high as possible to protect terminal galactose 
residues. Again this states that controlled and coordinate expression of glycosyltransferases is 
crucial for efficient glyco-engineering. The efficiency of fucosylation of the Lewis X motif 
could also be reduced by the presence of fucosidases in the plant apoplast. An α1,3/4-
fucosidase was cloned from A. thaliana and shown to be able to hydrolyse fucose in 3- and 4-
linkage to GlcNAc in Lewis determinants [31]. Within the genome of N. benthamiana several 
sequences with high similarity to this Arabidopsis α1,3/4-fucosidase can be found as well, but 
whether they have the same specificity and reside in the apoplast still has to be determined.  
From our study we can conclude that Lewis X glyco-engineering results in a 
heterogeneous mixture of N-glycans containing Lewis X motifs. However, the Lewis X 
containing N-glycans nicely resemble the heterogeneity of the N-glycans naturally found on S. 
mansoni-derived omega-1 [15]. Both N-glycans of S. mansoni-derived omega-1 are 
diantennary and display similar heterogeneity. The major motif found on the N-glycans of 
omega-1 is Lewis X, but Lewis X is not always found on both antennae. Antennae with 
terminal galactose and/or mannose are found as well as some tandem Lewis X motifs, N-
actylgalactosamine containing motifs (LDN-F), and difucosylated terminal motifs. In the future, 
efforts have to be made to shift the N-glycan composition on plant-produced omega-1 from 
paucimannosidic to Lewis X containing N-glycans. However, it is not necessary to obtain a 
homogenous N-glycan composition. Only when more detailed studies on the exact role of a 
specific N-glycan (like Lewis X) are planned, a more homogenous N-glycan composition is 
preferred. The use of ΔXT/FT or ST-GalT plants [22] may then be more suitable. 
Our study demonstrates that plants are an excellent platform for the production of S. 
mansoni-derived omega-1 carrying engineered N-glycans. This highlights the fact that plants 
are a promising research tool to produce helminth glycoproteins with immunomodulatory 
functions and study their function. The production of uncharacterised helminth glycoproteins 
could enable their functional characterisation and the role of their N-glycans in 
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immunomodulation. The use of plants as a production platform for helminth glycoproteins 
opens up a new field of research and might ultimately lead to the identification of new 
therapeutic targets for treatment of inflammatory disorders.  
 
 
Experimental procedures  
 
Construction of expression vectors 
The complete sequence encoding mature Schistosoma mansoni omega-1 protein was codon 
optimised according to an in-house optimisation procedure based on codons frequently used 
in highly expressed genes in plants. The mature protein sequence was preceded by a signal 
peptide from the Arabidopsis thaliana chitinase gene (cSP) and a N-terminal 6x histidine-FLAG 
tag (H6F). The amino acid sequence VEDAS was placed in-between the signal peptide and 
tags to ensure proper signal peptide cleavage and to prevent cleavage of the N-terminal 
histidine tag. The full cSP-H6F-omega-1 sequence was flanked by NcoI and KpnI restriction 
sequences at 5' and 3' ends respectively and synthetically constructed by GeneArt (Life 
Technologies; Bleiswijk, the Netherlands). The H58F mutation in the catalytic site of omega-1 
to remove RNase activity was introduced by means of overlap extension PCR. Both omega-1 
and omega-1H58F were cloned into the pHYG expression vector using NcoI/KpnI [32].  
Expression vectors for hybrid α1,3-fucosyltransferase IXa (Fut9a) from Tetraodon 
nigriviridus (pufferfish) and hybrid β1,4-galactosyltransferase (GalT) from Danio rerio 
(zebrafish) to engineer N-glycans carrying terminal Lewis X motifs were used [20, 33]. The N-
terminal domain of Arabidopsis thaliana β1,2-xylosyltransferase in the Fut9a hybrid gene was 
replaced by the CTS domain of rat α2,6-sialyltransferase enabling trans-Golgi targeting (from 
now on referred to as sialFucT). The GalT gene already contained this CTS domain for trans-
Golgi targeting (referred to as sialGalT). Expression cassettes for sialFucT and sialGalT were 
then transferred to the plant expression vector pBINPLUS [34]. For controlled expression of 
sialGalT the full gene was reamplified to introduce NcoI/KpnI restriction at the 5' and 3' ends 
respectively. sialGalT was then used to replace YFP in the pRAP-pGPAII::Gpa2-3'UTR-YFP 
vector, thereby placing the expression of sialGalT under the control of the promoter region of 
the Gpa2 gene [35]. The entire Gpa2:sialGalT expression cassette was then transferred to 
pBINPLUS with AscI/PacI. 
Expression of all constructs (unless stated differently) was driven by the 35S promoter of 
the Cauliflower mosaic virus with duplicated enhancer (d35S) and the Agrobacterium 
tumefaciens nopaline synthase transcription terminator (Tnos). A 5’ leader sequence of the 
Alfalfa mosaic virus RNA 4 (AlMV) was included between the promoter and construct to boost 
translation. In all experiments the silencing suppressor p19 from tomato bushy stunt virus in 
pBIN61 was co-infiltrated to enhance expression [36].  
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Agroinfiltration of Nicotiana benthamiana 
Agrobacterium tumefaciens clones were cultured overnight (o/n) at 28°C/250 rpm in LB 
medium (10g/l pepton140, 5g/l yeast extract, 10g/l NaCl with pH=7.0) containing 50 µg/ml 
kanamycin and 20 µg/ml rifampicin. The optical density (OD) of the o/n cultures was 
measured at 600 nm and used to inoculate 50 ml of LB medium containing 200µM 
acetosyringone and 50 µg/ml kanamycin with x µl of culture using the following formula: x = 
80000/(1028*OD). OD was measured again after 16 hours and the bacterial cultures were 
centrifuged for 15 min at 4000 rpm. The bacteria were suspended in MMA infiltration medium 
(20g/l sucrose, 5g/l MS-salts, 1.95g/l MES, pH5.6) containing 200 µM acetosyringone till a final 
OD of 0.5 was reached. For co-infiltration experiments with Agrobacterium harbouring the 
expression vectors for glycosyltransferases were used at a final OD of 0.05-0.5. After 1-2 hours 
incubation at room temperature, the two youngest fully expanded leaves of 5-6 weeks old 
Nicotiana benthamiana plants were infiltrated completely. Infiltration was performed by 
injecting the Agrobacterium suspension into a Nicotiana benthamiana leaf at the abaxial side 
using a 1 ml syringe. Nicotiana benthamiana plants were maintained in a controlled 
greenhouse compartment (UNIFARM, Wageningen) and infiltrated leaves were harvested at 
selected time points. 
 
Total soluble protein extraction  
Leaves were immediately snap-frozen upon harvesting, homogenized in liquid nitrogen and 
stored at -20°C until use. Homogenized plant material was ground in ice-cold extraction buffer 
(50mM phosphate-buffered saline (pH=7.4), 100 mM NaCl, 0.1% v/v Tween-20 and 2% w/v 
immobilized polyvinylpolypyrrolidone (PVPP)) using 2 ml/g fresh weight. Crude extracts were 
clarified by centrifugation at 16.000 rpm for 5 min at 4°C and supernatants were directly 
analysed for total protein content by a BCA protein assay (Life Technologies).  
 
Apoplast wash 
Leaves were submerged in ice-cold extraction buffer (50mM phosphate-buffered saline 
(pH=7.4), 100 mM NaCl and 0.1% v/v Tween-20) after which vacuum was applied for 10min. 
Vacuum was released slowly to ensure infiltration of the apoplastic space. Leaves were placed 
in 10-ml syringes and centrifuged for 20 min. at 2000xg. Apoplast washes were clarified by 
centrifugation at 16.000 rpm for 5 min at 4°C and supernatants were stored at -80°C. 
 
Purification of omega-1 
Plant produced omega-1 was purified from apoplast fluids using Ni-NTA Sepharose (IBA 
GmbH; Goettingen, Germany). Apoplast fluid was transferred over G25 Sephadex columns to 
exchange for Ni-NTA binding buffer (50 mM phosphate buffered saline (pH 8) containing 100 
mM NaCl). Ni-NTA Sepharose was incubated with the apoplast fluid for 30 min. followed by 3 
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washing steps with binding buffer. Omega-1 was eluted from the Ni-NTA Sepharose with 
0.5M imidazole (in binding buffer). Finally, purified omega-1 was dialysed against PBS. 
 
Protein analysis by western blot  
Omega-1 was separated under reducing conditions by SDS-PAGE on a 12% Bis-Tris gel. To 
analyse purity of the proteins the gel was stained with Coomassie brilliant blue staining. For 
western blotting proteins were transferred to a PVDF membrane by a wet blotting procedure. 
Thereafter the membrane was blocked in PBST-BL (PBS containing 0.1% v/v Tween-20 and 
5% w/v non-fat dry milk powder) for 1 hour at room temperature, followed by overnight 
incubation with a HRP conjugated anti-FLAG M2 antibody (Sigma-Aldrich; Zwijndrecht, the 
Netherlands) in PBST at 4°C. The membrane was washed 5 times with 5 min intervals in PBST. 
Finally, the SuperSignal West Femto substrate (Thermo Fisher Scientific; Etten-Leur, the 
Netherlands) was used to detect HRP-conjugated antibodies in the G:BOX Chemi System 
(Syngene; Cambridge, UK).  
 
Characterisation of Omega-1 N-glycosylation 
Omega-1 (100 ng) was deglycosylated with PNGase F or Endo H (both from Bioké; Leiden, the 
Netherlands) to screen for the presence of plant-specific α1,3-fucose or oligomannose/hybrid-
type N-glycans respectively. Deglycosylated omega-1 was then analysed by anti-FLAG western 
blot. The synthesis of Lewis X structures on omega-1 was analysed by ELISA with biotinylated 
agglutinin from Ricinus communis (RCA-I) (Bio-Connect; Huissen, The Netherlands). For this 1 
µg/ml of purified omega-1 was treated overnight with 0.5 mU α1,3/4-fucosidase from 
Xanthomonas manihotis at 37°C. Omega-1 was then coated overnight at 4°C on ELISA plates. 
Plates were blocked for 1 hour at room temperature with PBST with 1% w/v BSA and all 
subsequent steps were performed in blocking buffer. Biotinylated lectins (5 µg/ml) were 
incubated for 1 hour at room temperature and after washing the plate with PBST, avidin-HRP 
(eBioscience; Vienna, Austria) was incubated for 30 min. at room temperature. TMB substrate 
(eBioscience) was used for detection.  
 
Analysis of N-glycan composition by MALDI-TOF-MS 
1-2 µg of purified omega-1 was reduced for 10 min at 95°C in PBS containing 1.3% w/v SDS 
and 0.1% v/v β-mercaptoethanol. SDS was neutralized with NP-40 prior to overnight digestion 
at 37°C with trypsin (Sigma-Aldrich) using trypsin that was immobilized to NHS-activated 
Sepharose (GE Healthcare; Zwolle, The Netherlands). Trypsin-beads were removed from the 
digestion mix by centrifugation and the pH of the mix was adjusted to 5 using 1M sodium 
acetate. 0.5 mU of PNGase A (Roche; Woerden, The Netherlands) was used to release N-
glycans from omega-1 while incubating overnight at 37°C. Released N-glycans were purified 
by C18 BakerbondTM SPE cartridges (VWR; Amsterdam, The Netherlands) and subsequent 
Extract CleanTM Carbo SPE columns (Grace; Breda, the Netherlands). N-glycans were labeled 
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with anthranilic acid (Sigma) and desalted over Biogel P10 (BioRad; Veenendaal, The 
Netherlands). Samples in 75% acetonitrile were mixed with 1 µl of matrix solution (20 mg/ml 
2,5-dihydroxybenzoic acid in 50% acetonitrile, 0.1% TFA) and were dried under a stream of 
warm air. Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectra 
(MS) were obtained using an Ultraflex II mass spectrometer (Bruker Daltonics; Wormer, The 
Netherlands).  
 
Bone marrow-derived dendritic cells 
Wild-type C57BL/6J mice were bred and maintained under specific pathogen-free conditions 
in the animal facilities at Wageningen University. Bone marrow was isolated from the femur 
and tibia of 8-12 week old mice. Bone marrow derived dendritic cells (BMDC's) were 
differentiated as described [37] using 10% spent medium from murine GM-CSF transfected 
X63 cells [38]. X63-GM-CSF cells were kindly provided by dr. M. Lutz (University of Erlangen-
Nuremberg) with approval of dr. B. Stockinger (MRC National Institute for Medical Research). 
Briefly, bone marrow cells were plated at 2×105 cells/ml in bacteriological petri dishes and 
incubated at 37°C/5% CO2. At day 3, 6 and 8 medium was refreshed and at day 10 both 
adherent and non-adherent cells were harvested.  
 
RNase activity assay 
Total RNA was isolated from 5.0x106 BMDC's using the RNeasy Mini Kit (Qiagen; Venlo, The 
Netherlands) as described by the supplier’s protocol. 1 µg of total RNA was incubated with 
500 ng purified omega-1 for 1 hour at 37°C using PBS as buffer. PBS only was used as negative 
control and 500 ng RNase A as positive control. RNA breakdown was then analysed on a 
1.5% agarose gel and visualised with UV light. 
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Abstract 
 
To boost heterologous protein production the codon use of a gene of interest is often adapted 
to reflect the expression host’s codon use in highly expressed genes (optimal codons). 
However, the results obtained with this strategy are variable. A comparison between the 
overall codon use and the codon use in highly expressed genes of several plant species 
revealed that optimal codons are not always the codons of which the use is increased most 
with expression. Although the codon composition of highly expressed genes differs between 
monocots and dicots, the same codons often rise in frequency with increasing expression 
levels (expression codons) and are in many cases C-ending. We used these conserved 
expression codons to optimise the codon composition of three genes, which enhanced protein 
yield significantly upon stable and transient expression in plants. Upon stable transformation 
both transcript levels and protein yield per transcript had increased. Next, we analysed 
whether this expression-linked codon bias found in plants also extends to other kingdoms of 
life. Thereto, expression-linked codon use was investigated in Escherichia coli (Bacteria), 
Saccharomyces cerevisiae (Fungi), Caenorhabditis elegans (Animalia) and Mus musculus 
(Animalia) using more than 250 microarrays per species. We found that in all species, except 
M. musculus, C-ending codons are most often positively correlated with expression. In 
addition, computational analyses of various mRNA characteristics revealed a similar selection 
pressure across kingdoms that increases both stability and translatability. Combining gene 
expression data with available protein abundance data showed that an increased number of 
stem-loop transitions together with a reduction of stem size increases translation efficiency. 
Further studies are required to develop a codon optimisation strategy that involves the design 
of an ideal mRNA structure that maximizes mRNA stability and translatability, and the role of 
expression codons herein to boost heterologous protein expression.  
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Introduction  
 
Most amino acids are encoded by multiple synonymous codons and the frequency wherein 
synonymous codons are used is not equal within a given species. Also, within species a bias in 
codon use in highly expressed genes can be observed, linking codon use to gene expression. 
The codons used most frequently in highly expressed genes (optimal codons) have been shown 
to correspond to genomic G+C content [1] and often match the most abundant tRNAs in many 
species [2-7]. It is assumed that codons that match more abundant tRNAs would be translated 
faster as tRNA availability for translation occurs via diffusion and the chance of encountering a 
more abundant tRNA is larger than encountering a rarer tRNA [8]. An increase in translation 
rate would allow ribosomes to finish translation sooner to restart translation. Also, the chance 
that a ribosome initially loads a non-matching tRNA is smaller when a codon matches a more 
abundant tRNA. This creates an energetic advantage as three-quarter of the energy to 
incorporate an amino acid is lost if a non-matching tRNA has to be rejected after proofreading 
[8]. Thus, the use of optimal codons in highly expressed genes was hypothesized to provide a 
fitness gain by increasing translational efficiency.  
As an increased translation efficiency may boost protein yield, codon optimisation of 
heterologously expressed genes using optimal codons of the production host has been a 
common strategy that has met varying success [9]. A study on heterologous expression of 154 
variants of GFP differing only in synonymous codon use in E. coli demonstrated that the use of 
optimal codons was positively correlated with bacterial growth, but not protein yield [10]. 
About half of the variation in GFP protein levels was explained by folding energy of the first 
third of the mRNA. Therefore the authors argued that while translation rate may have been 
increased by the use of optimal codons, protein yield was not influenced because translation 
initiation must have been the rate-limiting step for translation. This may be a general feature as 
suggested by ribosomal density studies. Most ribosomes are found at the beginning of mRNAs 
and the overall packing density of nearly all mRNAs is below maximum [11, 12].  
In this study we present an alternative codon optimisation strategy that led to a 
significant increase in both mRNA stability and mRNA translatability (i.e higher mRNA levels 
and more proteins per mRNA molecule). Because we used an identical sequence to code for 
the signal peptide that preceded our genes we assumed translation initiation to be identical. 
Hence, an increase in mRNA translatability can only be explained by an increase in the rate of 
translation of the remainder of the messenger. This indicates that free ribosomes may be 
limiting during heterologous protein expression [13].  If free ribosomes are limited, the rate-
limiting step for translation would no longer be the time it takes for translation to initiate, but 
the time it takes for a ribosome to become available for translation. Thus, while translation 
initiation may be the rate-limiting step, an increased translation rate of the remaining mRNA 
will increase protein yield by enabling ribosomes to become available sooner.  
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Our codon optimisation strategy involved the selection of codons of which the use is 
increased most with expression (expression codons) across plant species. Wang and Roossinck 
[14] compared the codon use of highly expressed genes to the overall codon use in several 
plant species. They found that optimal codons and expression codons are not always the same. 
Also, while monocots and dicots differ significantly in their G+C content and have different 
optimal codons, they often have the same expression codons, which are C-ending in most 
cases. These conserved expression codons were used to optimize the codon use of three genes 
and boosted protein yield significantly upon stable and transient expression in plants. We 
demonstrate that upon stable transformation both transcript levels and protein yield per 
transcript increases. Next, we analysed whether the occurrence of this expression-linked 
codon bias is also observed in other kingdoms of life. Thereto, expression data were collected 
of Escherichia coli (Bacteria), Saccharomyces cerevisiae (Fungi), Caenorhabditis elegans 
(Animalia) and Mus musculus (Animalia) and more than 250 microarrays per species were 
analysed covering a wide range of strains/ecotypes, treatments, culture conditions, tissues and 
developmental stages. We found that in all species, except M. musculus, C-ending codons are 
most often positively correlated with expression. 
Studying the correlation between expression level and mRNA characteristics including 
gene length, minimal folding energy, number of bound nucleotides, mean stem and loop sizes 
(stretches of bound and unbound nucleotides, respectively) and number of stem-loop 
transitions uncovered a general trend across kingdoms. The number of bound nucleotides and 
the number of stem-loop transitions were positively correlated with expression levels, while 
loop size was negatively correlated with expression. Combining the gene expression data with 
available protein abundance data demonstrated that protein:mRNA ratio (proxy for translation 
efficiency) is positively correlated with the number of stem-loop transitions and negatively 
correlated with stem and loop size. This general pattern across kingdoms reveals a selection 
pressure created by gene expression on both mRNA stability and translatability. An increase in 
the number of nucleotide bonds favours stability, while a more even distribution of these 
bonds enhances translatability. Altogether, our data indicate that a successful codon 
optimisation strategy should focus on computational models that calculate the ideal mRNA 
structure whereby both stability and translatability are enhanced.  
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Results and discussion 
 
Codon optimisation improves mRNA stability and translatability 
Wang and Roossinck determined of which codons the use was increased most comparing 
overall codon use to the codon use in highly expressed genes in 11 plant species [14]. 
Although the codons used most frequently in highly expressed genes (optimal codons) differed 
between monocots and dicots, the use of the same codons often increases with expression 
(expression codons). We selected one codon per amino acid that was most often identified as 
an expression codon across these 11 plant species. Strikingly, most of these codons were C-
ending, except for the amino acids Arg (CGT) and Gly (GGT). The codons of the amino acids 
Gln, Glu and Lys, that can only be encoded by A or G-ending codons, were G-ending. To 
investigate the effect of these codons on heterologous protein production in plants, we 
recoded the gene sequence of three genes with these codons. We chose the genes of Aequorea 
victoria green fluorescent protein (GFP), Gallus gallus ovalbumin (OVA) and Mus musculus 
interleukin-10 (IL-10) because of their variation in codon use (Figure 1a). To eliminate 
differences caused by translation initiation all genes were preceded by the signal peptide of 
Arabidopsis thaliana chitinase. GFP was also expressed without this signal peptide, as it is 
normally not secreted.  
The native and optimised variants of these four constructs were used to transform 
Arabidopsis thaliana using the floral dip method and their expression in seedlings was 
evaluated by determining mRNA transcript and protein levels (Figure 1b; Table 1). An 
increased protein yield found upon optimisation could be partly explained by an increase in 
mRNA transcript levels, i.e. increased mRNA stability (Table 1). Comparing protein:mRNA 
ratios of transformants within a similar mRNA expression range showed that codon 
optimisation resulted in more protein per mRNA transcript. Thus, codon optimisation also 
resulted in increased mRNA translatability.  
Upon transient transformation transcript levels are always much higher. An increase in 
mRNA stability and translatability may than no longer improve protein yield. Therefore, we 
also determined protein yield upon transient expression of the three genes in Nicotiana 
benthamiana with and without co-expression of the gene silencing inhibitor p19 of tomato 
bushy stunt virus (Figure 1c; Table 2). Also upon transient expression codon optimisation lead 
to higher protein yield on all days for all genes, except for OVA unless p19 was co-expressed. 
In most cases co-expression of p19 had a favourable effect on protein yield independent of 
optimisation. This is not surprising as, mRNA transcript levels are always high in transient 
expression, which increases the risk of gene silencing. Thus, the mRNA of the optimised 
variant of OVA must have been more sensitive to gene silencing compared to the native 
variant.  
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Figure 1 !  Codon optimisation boosts protein yield by increasing mRNA stability and translatability. A 
Nucleotide content of the third codon position in the constructs for Aequorea victoria green fluorescent 
protein (GFP), Gallus gallus ovalbumin (OVA) and Mus musculus interleukin-10 (IL-10) with additional 
chitinase signal peptide (SP) expression. GFP was also expressed without SP. B Expression in transformed 
Arabidopsis thaliana seedlings. For each plant analysed the protein yield in ng per mg total soluble protein 
(TSP) is plotted against the relative mRNA transcript concentration as compared to the A. thaliana 
household gene TIP-41. C Transient expression in Nicotiana benthamiana leaves (native and optimised in 
black and blue bars, respectively). Protein yield in µg per mg TSP at 2 to 5 days post infiltration (DPI), * 
indicates co-expression with the silencing inhibitor p19 of tomato bushy stunt virus. n=3, error bars 
indicate standard error.  
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Table 1 !  Codon optimisation of GFP, interleukin-10 and ovalbumin genes boosts expression in 
Arabidopsis thaliana. 
 
  
n= 
Relative 
mRNA 
conc. 
Fold 
change 
Protein 
yield  
Fold 
change 
Relative 
mRNA 
conc. range n= 
Protein: mRNA 
ratio 
Fold 
change 
GFP N 32 0.88 
11*** 
17.03 
75*** 
0.8-2.7 4 22.8±2.70 
7.1 
  O 23 9.25 1276 0.9-2.5 14 161±58.5 
SP-
GFP N 26 1.63 5.8* 33.28 12** 1.4-4.9 11 18.0±5.16 3.5* 
  O 24 9.53 399.5 1.2-4.8 12 63.9±14.5 
SP-
OVA N 26 2.37 2.4*** 717.3 5.5*** 2.0-5.3 12 356.2±142.5 2.8** 
  O 30 5.62 3937 2.2-5.5 23 1014±121.7 
SP- 
IL-10 N 17 1.37 3.1*** 3.30 5.5*** 1.7-4.2 8 1.26±0.43 5.3*** 
 
O 25 4.23 17.9 1.7-4.1 16 6.68±1.02 
 
 
Average relative mRNA transcript concentration as compared to the A. thaliana household gene TIP-41 
and protein yield in µg per mg total soluble protein (TSP) determined in A. thaliana seedlings upon stable 
transformation of native (N) and optimised (O) sequences of Aequorea victoria green fluorescent protein 
(GFP), Gallus gallus ovalbumin (OVA) and Mus musculus interleukin-10 (IL-10) with additional chitinase 
signal peptide (SP). GFP was also expressed without signal peptide. Protein:mRNA ratios were calculated. 
Because translatability may be lower with a higher mRNA concentration due to the limited number of free 
ribosomes, the protein:mRNA ratios were calculated of samples within the same mRNA concentration 
range, as indicated. The fold change when comparing the optimised to the native variant was calculated 
for the relative mRNA concentration, protein yield and protein:mRNA ratio. For each average the number 
of included seedlings is indicated (n). Significance of fold changes were calculated with a Welch’s t-test: * 
P<0.05, ** P<0.01, ***P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
dpi 2-5 
 
dpi 5 + p19 
 
 
  
Protein 
yield 
Fold 
change 
Protein 
yield 
Fold 
change 
GFP N 5.7 
4*** 
7.0 
4.8 
  O 23 34 
SP-GFP N 1.0 
3.2** 
4.4 
2.1 
  O 3.2 9.2 
SP-OVA N 17 
0.7 
30 
2.0* 
  O 12 61 
SP-IL-10 N 8.4 2.5** 17 1.4 
 
O 21 24 
Table 2 !  Codon optimisation boosts protein yield in transient expression in Nicotiana benthamiana. 
Average protein yield in µg per mg total 
soluble protein determined in N. 
benthamiana leaves upon transient 
transformation of native (N) and optimised 
(O) sequences of Aequorea victoria green 
fluorescent protein (GFP), Gallus gallus 
ovalbumin (OVA) and Mus musculus 
interleukin-10 (IL-10) with additional 
chitinase signal peptide (SP) (GFP was 
also expressed without SP) at 2 to 5 days 
post infiltration (dpi) (n=12) or 5 dpi 
whereby tested genes were co-expressed 
with the viral silencing inhibitor p19 of 
tomato bushy stunt virus. (n=3). 
Significance of fold change in protein 
yield were calculated with a Welch’s t-
test: * P<0.05, ** P<0.01, ***P<0.001. 
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Evaluating the average yield from dpi 2-5 or with co-expression of p19 on dpi 5 
revealed a lower yield increase upon codon optimisation compared to stable expression in A. 
thaliana. This is not surprising as at least some of the gain in mRNA stability due to the codon 
optimisation is compensated by the increased transcription in transient expression. Whether 
this gain in protein yield is predominantly the result of an increase in mRNA translatability or a 
combination of a gain in mRNA stability and translatability remains to be determined. 
To explain the differences found in mRNA stability we first calculated the 
thermodynamic stability of the predicted secondary mRNA structures. Upon codon 
optimisation the minimum free folding energy had decreased, indicative for a more stable 
mRNA, from -0.25 to -0.35 and -0.31 to -0.33 kcal/mol/nt for GFP and OVA, respectively. 
However, for IL-10, the minimum free folding energy increased from -0.31 to -0.28 kcal/mol/nt 
indicating a less stable mRNA. Thus, an overall increase in physical stability could not explain 
the increased mRNA transcript levels of IL-10. However, it is still possible that instable regions 
of IL-10 were removed upon codon optimisation, while the overall stability decreased. 
In vivo mRNA half-life is predominantly controlled by other factors than physical 
stability, namely; the occurrence of a splicing event, through AU-rich destabilizing elements in 
the UTRs, and the presence of sequences that are targets for microRNA [15-17]. In our 
experiments, all genes were expressed using the same expression controlling components, thus 
contained the same UTRs and did not contain introns. However, the sequences of the ORFs 
varied greatly between the native and optimised variants (78, 76 and 83% homology for GFP, 
OVA and IL-10, respectively). Therefore, there could be a difference in the presence of 
microRNA targets and also a difference in the occurrence of stretches of double stranded 
(ds)RNA between the native and optimised variants. The dsRNA stretches could be processed 
to small interfering RNAs and, like binding of microRNAs, can trigger gene silencing [18]. In 
stable expression, gene silencing can also be due to gene methylation, but this always results 
in the complete absence of transcripts, and therefore transformants without detectable 
expression were not considered. In our transient expression experiment co-expression of the 
silencing inhibitor p19 gave comparable results. Taken together, differences in mRNA decay 
based on above mentioned sequence features are unlikely to explain the differences in mRNA 
stability in our experiments. 
Translation has also been linked to mRNA decay. Ribosomes can shield nuclease target 
sites [19], however, in large-scale in vivo studies mRNA half-life could not be linked to the 
number of nuclease target sites [20, 21] or ribosomal density [12]. When translation initiation 
is equal, as is expected in our experiments, an increase in translatability should result in a 
lower density of ribosomes. Thus, there would have been less ribosomes on the optimised 
variants compared to their native counterparts, and the optimised variants would be less 
protected against nucleases.  
While translation per se may not influence mRNA half-life, errors in translation have 
been proven to lead to mRNA degradation by mRNA surveillance mechanisms. Three mRNA 
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surveillance mechanisms have been identified: I) nonsense mediated decay by the recognition 
of a premature stop codon, II) non-stop decay by the lack of a stop codon and III) no-go decay 
by stalled ribosomes [21]. Occurrence of a premature stop codon or the lack of a stop codon 
can be caused by a mutation or a ribosomal slip causing a frame-shift. Frame-shifts can be 
caused by a ‘slippery’ sequence that may be found in proximity of a strong mRNA structure 
[22, 23]. A ribosome may also stall at a strong stem-loop structure without slipping [24] and 
trigger degradation [25, 26]. It is possible that the native and optimised variants differ in the 
presence of ‘slippery’ sequences and/or strong mRNA structures. Thus, differences in level of 
translation-linked mRNA decay may explain the difference in mRNA transcript levels in our 
experiment. In addition, ribosomes have intrinsic helicase activity [27] and recently it was 
shown that strong mRNA structures such as pseudoknots and hairpins can stall translation only 
temporarily [28]. Therefore, Qu et al argue that the mRNA structure provides a mechanical 
basis for cellular regulation of translation rate [28]. Thus, increased mRNA translatability of the 
optimised genes may be explained by an increased translation rate caused by differences in 
the mRNA structure. 
 
General codon bias extends to other kingdoms of life 
To investigate if the general codon bias found by Wang and Roossinck [14] among plants 
transcends kingdoms of life we acquired expression data of Escherichia coli (Bacteria), 
Saccharomyces cerevisiae (Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana 
(Plantae) and Mus musculus (Animalia). Per species >250 microarrays originating from several 
studies covering a wide range of strains/ecotypes, culturing conditions, developmental stages 
and tissues were used (Supplementary Table 1A-F). First, the expression was ranked and the 
average rank was used as a measure of overall expression. Subsequently, the correlation 
between expression and nucleotide content was analysed per species. The relation between 
the species based on this correlation was visualized in a heat map (Figure 2).  
Across all kingdoms a strong positive correlation between expression and overall G 
content, in particular G on the first codon position was found and a negative correlation 
between expression and A and T on the first codon position. Next, the correlation between 
expression and codon use was evaluated (Figure 3). Across kingdoms the use of CGT (Arg/R), 
AAG (Lys/K), GGT (Gly/G), GTT (Val/V) and GCT (Ala/A) is positively correlated with 
expression. However, the fact that the nucleotide contents of the first and second codon 
position are correlated with expression indicates that there is a correlation between amino acid 
usage and expression. Unsurprisingly, highly expressed genes are relatively rich in the amino 
acids encoded by G-starting triplets: Ala, Gly, and Val (Figure 4).  
First, to uncouple the amino acid bias from the codon use bias, we calculated the 
relative synonymous codon use. Subsequently, we made a comparison between high- and 
low-expressed genes, as a correlation between codon use and expression may only be found 
in genes expressed above a certain threshold. We started grouping genes based on expression 
Selection on mRNA stability and translatability across kingdoms 
 
 
 125 
from the centre (50% highest versus 50% lowest) until, with 1% steps, the pools with 5% 
highest and 5% lowest expressed genes were reached. With each step the codon use 
frequencies in both high- and low-expressed gene pools were calculated together with the 
difference in codon use frequency between the high- versus the low-expressed gene pool. 
Finally, the difference in codon use frequency was correlated (Spearman) to the expression 
defining percentage. The relation between the species based on this correlation was visualized 
in a heat map (Figure 5; Supplementary Table 2A-E show codon use frequencies of all, the 
bottom 5% low- and top 5% high-expressed genes and fold codon use change (top/bottom) 
per species).  
Strikingly, when clustering the correlations between the 5 species, E. coli, S. cerevisiae, 
C. elegans and A. thaliana group together well. M. musculus seems to have an overall lower 
codon bias and in ~50% of the cases selects for other codons compared to the overall 
selection of the other species. Excluding M. musculus, 13 codons are positively correlated with 
expression for all species. These 13 codons encode 11 different amino acids and a termination 
of translation (twice a codon for Thr/T). Comparable to the general codon bias found in plants 
[14], 8 of these 13 codons are C-ending. Furthermore, 18 codons are consistently negatively 
correlated with expression in these four species. Of these codons most are A-ending (8), while 
none of them are C-ending.  
Taken together our data suggest that a conserved selection pressure influences 
expression across kingdoms of life. Our heterologous protein expression experiments 
suggested a role for the mRNA structure in translation rate. As the translational machinery does 
not vary greatly across kingdoms, the mRNA structure is a likely candidate to be the driving 
force behind this selection pressure.  
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Figure 2 !  Heat map displaying the relation between species of several kingdoms of life based on 
expression-linked nucleotide use. Expression data of Escherichia coli (Bacteria), Saccharomyces cerevisiae 
(Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) 
(>250 microarrays per species) originating from multiple studies covering a wide range of strains/ecotypes, 
culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) were rank-normalized 
and averaged. Subsequently, correlations (Spearman) between expression and nucleotide use (overall and 
for each codon position) were calculated per species and used to generate this heat map. Consistent 
positive and negative correlations across species are indicated with a red and blue star, respectively.   
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Figure 3 !  Heat map displaying the relation between species of several kingdoms of life based on 
expression-linked codon use. Expression data of Escherichia coli (Bacteria), Saccharomyces cerevisiae 
(Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) 
(>250 microarrays per species) originating from multiple studies covering a wide range of strains/ecotypes, 
culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) were rank-normalized 
and averaged. Subsequently, correlations (Spearman) between expression and codon use were calculated 
per species and used to generate this heat map. Consistent positive and negative correlations across 
species are indicated with a red and blue star, respectively.   
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Figure 4 !  Heat map displaying the relation between species of several kingdoms of life based on 
expression-linked nucleotide use. Expression data of Escherichia coli (Bacteria), Saccharomyces cerevisiae 
(Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) 
(>250 microarrays per species) originating from multiple studies covering a wide range of strains/ecotypes, 
culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) were rank-normalized 
and averaged. Subsequently, correlations (Spearman) between expression and amino acid use were 
calculated per species and used to generate this heat map. Consistent positive and negative correlations 
across species are indicated with a red and blue star, respectively.   
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Figure 5 !  Heat map displaying the relation between species of several kingdoms of life based on 
expression-linked codon bias. Expression data of Escherichia coli (Bacteria), Saccharomyces cerevisiae 
(Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) 
(>250 microarrays per species) originating from multiple studies covering a wide range of strains/ecotypes, 
culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) was rank-normalized 
and averaged. Subsequently, we started grouping genes based on expression from the centre (50% highest 
versus 50% lowest) until, with 1% steps, the extremes (5% highest versus 5% lowest) were reached. With 
each step the synonymous codon use frequencies in both high- and low-expressed gene pool were 
calculated together with the difference in codon use frequency between the high- versus the low-
expressed gene pool. Finally, the difference in codon use frequency was correlated to the expression 
defining percentage (Spearman). The relation between the species based on this correlation is visualized in 
this heat map.  
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Highly expressed genes prefer a stable, but ‘airy’ mRNA structure  
To evaluate if the mRNA structure could be the driver of selection that gives rise to the 
observed general codon bias, we evaluated if expression is linked to mRNA structure 
characteristics. Thereto, we predicted the mRNA structures of all genes and determined gene 
length, minimal free folding energy, number of bound nucleotides, mean stem and loop 
(stretches of bound and unbound nucleotides, respectively) size and number of the number of 
stem/loop transitions and plotted these against expression (Figure 6; Table 3). Also a heat map 
displaying the relation between the species based on the correlation (Spearman) between these 
structure characteristics and expression was generated (Figure 7; Supplementary Table 3). This 
heat map demonstrates that the number of bound nucleotides and the number of stem/loop 
transitions was consistently positively correlated and mean loop size consistently negatively 
correlated with expression across all species.  
The positive correlation with the number of bound nucleotides indicates a general 
adaptation towards a more stable mRNA molecule. Also, a low folding energy (more stable) is 
correlated with high expression in S. cerevisiae, C. elegans and A. thaliana, but not in E. coli 
and M. musculus. Still, in E. coli there seems to be a relation between expression and folding 
energy, as is demonstrated by the trend line that indicates an optimum (Figure 6). An optimum 
in mRNA stability may indicate a trade-off between stability and translatability in this species. 
A trade-off in stability and translatability may also explain why there is a correlation between 
mRNA folding energy and expression in S. cerevisiae, C. elegans and A. thaliana. These 
species have an overall lower G+C content resulting in on average weaker mRNAs (Table 3) 
and have therefore more to gain in terms of stability before translatability is affected.  
The number of stem-loop transitions and mean loop size are also correlated with 
expression (positive and negative, respectively) in all species, which suggests that there is a 
general adaptation towards dividing nucleotide bonds equally over the mRNA molecule. In 
other words, highly expressed genes prefer a stable, but ‘airy’ mRNA molecule. This again 
indicates a trade-off between mRNA stability and translatability. It is striking that while folding 
energy in S. cerevisiae, C. elegans and A. thaliana is on average much higher (less stable 
mRNA) (6-10%) compared to E. coli and M. musculus, the fraction of bound nucleotides, 
mean stem and loop size and number of transitions do not differ that much (Table 3). This 
means that while the mRNA folding energy may differ between species with different G+C 
content, the overall mRNA structure characteristics are more similar across species.   
Taken together our data suggest that there is a general selection towards an optimal 
folding energy across kingdoms of life whereby number and type of nucleotide bonds (e.g. A-
U and G-U bonds are weaker than G-C bonds) are balanced with short loops to facilitate 
efficient translation. This is in line with the observation that translation rate is greatly 
influenced by G+C content and strong mRNA structures [28].  
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Figure 6 !  mRNA structure features plotted against ranked expression with moving average (black line). 
The mRNA structures of all genes of Escherichia coli (Bacteria), Saccharomyces cerevisiae (Fungi), 
Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) were 
predicted and gene length, minimal free folding energy (kcal/mol/nucleotide), fraction of bound 
nucleotides, mean stem and loop (stretches of bound and unbound nucleotides, respectively) size and 
number of stem/loop transitions per nucleotide were determined. Previously mentioned mRNA 
characteristics plotted against expression.  
Chapter 6 
 
 
 132 
Table 3 !  mRNA characteristics of highly expressed genes per species.  
 
  E. coli  S. cerevisiae C. elegans A. thaliana M. musculus 
G+C content 0.52 0.40 0.43 0.45 0.52 
Gene length (nt) 1004 1490 1359 1097 1752 
Energy (kcal/mol/nt) -0.34 -0.24 -0.25 -0.28 -0.34 
Bound nt (fraction) 0.63 0.59 0.60 0.62 0.62 
Mean stem size 5.42 5.29 5.18 5.29 5.18 
Mean loop size 3.12 3.72 3.48 3.26 3.10 
Transitions / nt 0.117 0.111 0.116 0.117 0.121 
 
Averages of mRNA characteristics of the top 5% high-expressed genes of 
Escherichia coli (Bacteria), Saccharomyces cerevisiae (Fungi), Caenorhabdites 
elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 !  Across kingdoms highly expressed genes prefer a stable, but ‘airy’ mRNA structure. The 
mRNA structures of all genes of Escherichia coli (Bacteria), Saccharomyces cerevisiae (Fungi), 
Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) were 
predicted and gene length, minimal free folding energy (kcal/mol/nucleotide), fraction of bound 
nucleotides, mean stem and loop (stretches of bound and unbound nucleotides, respectively) size and 
number of stem/loop transitions per nucleotide were determined and correlated with expression 
(Spearman) (Supplementary Table 3). Consistent positive and negative correlations across species are 
indicated with a red and blue star, respectively.   
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A link between mRNA structure and expression, may explain the increase in mRNA 
stability and translatability in our heterologous protein expression experiments. Therefore we 
predicted and evaluated the mRNA structures of the native and optimised variants of the 
expressed genes (Supplementary Figure 1; Supplementary Table 4). Optimised variants of GFP 
and OVA had an increased folding energy indicative of a more stable mRNA. All optimised 
variants had an increased number of stem-loop transitions (except SP-GFP), which is in line 
with a more ‘airy’ mRNA molecule. Thus, although changes in the mRNA structure upon 
optimisation differ from gene to gene, an improved mRNA structure could be the basis of 
increased protein yield in our experiments. 
 
A more ‘airy’ mRNA increases translation rate 
On a cellular level translation efficiency was demonstrated to be the most important factor in 
controlling protein abundance whereas protein turnover plays only a minor role [29]. 
Therefore, protein:mRNA ratio is a good proxy of translation rate. To evaluate if the mRNA 
structure characteristics we found to be linked to expression are also linked to translation rate 
we combined our expression data with large-scale protein abundance data retrieved from 
PaxDB. To evaluate to what extent our expression data predict protein abundance we 
calculated the correlation (Spearman) between our expression data and the protein 
abundance: E. coli 0.59, S. cerevisiae 0.67, C. elegans 0.59, A. thaliana 0.62 and M. musculus 
0.36. When we evaluated the relation between the protein:mRNA ratio and the previously 
mentioned mRNA structure characteristics we obtained a similar picture as when using the 
expression data (Figure 8; Supplementary  Table 5; Supplementary Figure 2-4 heat maps 
demonstrate the relation between species based on correlations of protein:mRNA ratio and 
nucleotide content, codon use and amino acid use).  
As with expression, the number of stem-loop transitions is positively correlated with 
protein:mRNA ratio and mean loop size is negatively correlated across all species. Also, the 
folding energy is negatively correlated (more stable mRNA) for S. cerevisiae, C. elegans and A. 
thaliana, but not for E. coli and M. musculus. However, in contrast to the expression data, gene 
length is consistently negatively correlated with protein:mRNA ratio. This is in line with the 
fact that the packing density of ribosomes was shown to decrease with mRNA transcript length 
[12]. Also, a negative correlation with mean stem size is found for all species and the fraction 
of bound nucleotides is not correlated, except for S. cerevisiae. Thus, small stem size must be 
important for an increased translation rate. This again highlights the trade-off between mRNA 
stability and translatability.  
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Figure 8 !  Across kingdoms high translated transcripts are ‘airy’. Correlation (Spearman) between mRNA 
structure characteristics and protein:mRNA ratios per species (Supplementary Table 5). The mRNA 
structures of all genes of Escherichia coli (Eubacteria), Saccharomyces cerevisiae (Fungi), Caenorhabdites 
elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia) were predicted and gene 
length, minimal free folding energy, percentage of bound nucleotides, mean stem and loop (stretches of 
bound and unbound nucleotides, respectively) size and number of stem/loop transitions were determined 
and correlated (Spearman) with protein:mRNA ratios. Rank-normalized mRNA levels were divided by 
protein abundance (retrieved from PaxDB). Consistent positive and negative correlations across species are 
indicated with a red and blue star, respectively.   
 
Selection on mRNA stability and translatability across kingdoms 
 
 
 135 
Concluding paragraph  
 
Our data indicate that across kingdoms of life mRNA structures are exposed to a selection 
pressure that increases both stability and translatability. However, a trade-off between stability 
and translatability most likely exists. An increase in the number of nucleotide bonds favours 
stability, but reduces translatability. This trade-off may explain the more even distribution of 
stems and loops in mRNAs coding for genes with high translational efficiency. Translatability is 
enhanced by an increase in the number stem-loop transitions, while loop and stem sizes are 
negatively correlation with translation efficiency. In E. coli, S. cerevisiae, C. elegans and A. 
thaliana a general expression-linked codon bias was found towards C-ending codons. A codon 
optimisation strategy that employed predominantly C-ending codons boosted the protein yield 
of three genes upon expression in plants by increasing mRNA transcript levels and protein 
yield per transcript. It is therefore likely that mRNA stability and translatability are increased by 
the use of by C-ending codons in these species. Only M. musculus demonstrated a weaker and 
different codon bias, while the same mRNA structural features were linked to expression. In 
the case of M. musculus other codons must therefore facilitate an improvement of the mRNA 
structure in this species, perhaps because M. musculus already has a high C content in its 
coding sequences. To develop a codon optimisation strategy that is robustly successful, 
computational models should be developed that determine the effects of expression codons on 
mRNA structures. Further analyses are required to pinpoint the effects of expression codons on 
the number of stem-loop transitions and size of stems and loops. Ideally, large-scale 
heterologous gene expression experiments should be carried out to verify the effectiveness and 
robustness of this novel codon optimization strategy to increase protein yield.   
 Codon optimisation is worthwhile, as increased translation rate of a heterologously 
expressed gene boost protein yield, even when the transcript levels are already high. In an 
extensive ribosomal density study in yeast [11] and in a global analysis on translation in 
mammalian cells [29] a large variation in translation rate was found. Both studies also revealed 
that translation rate was the major contributor in controlling protein abundance. Although 
many studies have shown evidence that translation initiation is the rate-limiting step of 
translation [11, 12], an increase in translation rate may still influence protein abundance if the 
number of free ribosomes is limiting. If free ribosomes are limiting increased translation rate 
will make translating ribosomes faster available for other messengers. Especially in 
heterologous gene expression, whereby the gene of interest is significantly over-expressed 
(often several orders of magnitude above household genes) it is likely that free ribosomes are 
limited. Increased translational efficiency of the heterologous gene can therefore increase 
protein yield significantly.  
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Experimental procedures  
 
Construct design 
The native and optimised sequences coding for Aequorea victoria green-fluorescent protein 
(GFP) (L29345.1; nt 7-807) Gallus gallus ovalbumin (OVA) (NM_205152.2; nt 4-1161) and 
Mus musculus interleukin-10 (IL-10) (NM_010548.2; nt63-537) together with the optimised 
sequence for the Arabidopsis thaliana basic chitinase signal peptide (cSP) (BAA82810.1; nt15-
33) were synthetically made by GeneArt (Thermo Fisher Scientific, Breda, the Netherlands). 
Optimisation was performed by recoding the protein sequences using the C-ending codons for 
all amino acids (TCC in the case of Ser), except Arg and Gly, for which the T-ending codons 
were used, and Gln, Glu and Lys, for which the G-ending codons were used. Synonymous 
mutations to either native or optimised sequences were sometimes introduced to remove 
undesired restriction and the cryptic splice sites in native GFP[30]. Gene fragments were 
flanked with sequences including the restriction sites NcoI (5’) and EagI-BspHI (3’) for cSP, 
EagI (3’) and KnpI (5’) for IL-10 and OVA and NcoI (3’) and KpnI (5’) for GFP to allow fragment 
assembly and subsequent in frame cloning into the plant expression vector pHYG[31]. 
Fragment assembly was accomplished by the in frame ligation of cSP with IL-10 and OVA 
using the EagI site and cSP with GFP using the BspHI (cSP) and NcoI (GFP) sites. ORFs were 
confirmed by sequencing in expression vector stage. All vectors were transformed to 
Agrobacterium tumefaciens strain GV3101 for stable transformation of Arabidopsis thaliana or 
MOG101 for agroinfiltration in Nicotiana benthamiana. 
 
Stable transformation of Arabidopsis thaliana 
Agrobacterium tumefaciens clones were cultured overnight (o/n) at 28°C in LB medium (10g/l 
pepton140, 5g/l yeast extract, 10g/l NaCl with pH7.0) containing 50 µg/ml kanamycin. 
Bacterial cultures were centrifuged for 15 min at 2800 g and resuspended in MMA (20g/l 
sucrose, 5g/l MS-salts, 1.95g/l MES, pH5.6) containing 200 µM acetosyringone and 0.03% 
silwet-L77 till an OD of 0.5 was reached. Arabidopsis thaliana plants were submerged in the 
bacterial suspension for 1 min and kept in a moist environment for 2 days. Plants were 
maintained in a controlled greenhouse compartment (UNIFARM, Wageningen) until seeds 
could be collected. Seeds were sterilized by 4-hour exposure to chlorine gas and plated on 
basic agar plates (8g/l Bacto Agar, 0.101g/l KNO3) containing 30 µg/ml hygromycin and 100 
µg/ml cefotaxim. Plates were kept in the dark at 4°C for 2 days, then placed in artificial light 
for 7 hours at 24°C, again kept in the dark at rt for 5 days and finally placed in a climate 
chamber with 12 hour light regime at 24°C for 2 days. At this stage 10 to 40 seedlings per 
transformant plant were selected and placed in individual pots with Knop agar (1x Knop, 1% 
sucrose, 8g/l Plant Agar pH6.4) containing 30 µg/ml hygromycin and 100 µg/ml cefotaxim. 
Seedlings that showed good growth and root formation after 10 days were transferred to fresh 
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pots and allowed to grow for 2 more weeks. Thereafter plants were harvested and snap-frozen. 
Plant material was homogenized using a TissueLyser II (Qiagen) and stored at -80°C until 
further use. 
 
Transient transformation of Nicotiana benthamiana  
Agrobacterium tumefaciens clones were cultured overnight (o/n) at 28°C in LB medium (10g/l 
pepton140, 5g/l yeast extract, 10g/l NaCl with pH7.0) containing 50 µg/ml kanamycin and 20 
µg/ml rifampicin. The optical density (OD) of the o/n cultures was measured at 600 nm and 
used to inoculate 50 ml of LB medium containing 200 µM acetosyringone and 50 µg/ml 
kanamycin with x µl of culture using the following formula: x = 80000/(1028*OD). OD was 
measured again after 16 hours and the bacterial cultures were centrifuged for 15 min at 2800 
g. The bacteria were resuspended in MMA infiltration medium (20g/l sucrose, 5g/l MS-salts, 
1.95g/l MES, pH5.6) containing 200 µM acetosyringone till an OD of 1 was reached. All 
constructs were co-expressed with the tomato bushy stunt virus silencing inhibitor p19 by 
mixing Agrobacterium cultures 1:1. After 1-2 hours incubation at room temperature, the two 
youngest fully expanded leaves of 5-6 weeks old Nicotiana benthamiana plants were infiltrated 
completely. Infiltration was performed by injecting the Agrobacterium suspension into a 
Nicotiana benthamiana leaf at the abaxial side using a 1 ml syringe. Infiltrated plants were 
maintained in a controlled greenhouse compartment (UNIFARM, Wageningen) and infiltrated 
leaves were harvested at selected time points. 
 
Determination of heterologous gene expression 
Total RNA was isolated from homogenized plant material using the RNAeasy Plant Mini Kit 
(Qiagen) according to supplier’s protocol. A Turbo DNaseI (Ambion) treatment was included 
to remove any residual DNA. cDNA was synthesised using the SuperScript®III First-Strand 
Synthesis System (invitrogen) according to suppliers protocol using an oligo(dT) primer. 
Samples were analysed by quantitative PCR in triplo using ABsolute SYBR Green Fluorescein 
mix (Thermo Scientific). Arabidopsis thaliana TIP-41 (AY074349.1) was used as a reference 
gene. The oligonucleotides used for amplification of both native and optimised IL-10, OVA 
and GFP and TIP-41were 5’-AACCTCTTCCTCTTCCTC-3’ / 5’-GGAAGTGGGTGCAGTT-3’;  
5’-AACCTCTTCCTCTTCCTC-3’ / 5’-GGGCAGTAGAAGATGTTC-3’; 5’-GACGGTAACTACAA-
GACC-3’ / 5’-TTGTCGGCCATGATGTA-3’; and 5’-GCTCATCGGTACGCTCTTTT-3’ / 5’-
TCCATCAGTCAGAGGCTTCC-3’, respectively. Relative transcript levels of the genes versus 
TIP-41 were determined by the Pfaffl method[32]. 
 
Determination of heterologous protein expression 
Homogenized plant material was ground in ice-cold extraction buffer (50mM phosphate-
buffered saline (PBS) pH=7.4, 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 
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0.1% v/v Tween-20, 2% w/v immobilized polyvinylpolypyrrolidone (PVPP)) using 2 ml/g fresh 
weight. Crude extract was clarified by centrifugation at 16.000xg for 5 min at 4°C and 
supernatant was directly used in an ELISA and BCA protein assay. Mouse IL-10 expression 
levels were determined using the Mouse IL-10 ELISA Ready-SET-Go! kit (eBioscience) 
according to the supplier’s protocol. For the quantification of OVA and GFP, a rabbit anti-
ovalbumin or a chicken anti-GFP (both from Rockland Immunochemicals Inc.) was used to 
coat ELISA plates o/n at 4°C in a moist environment. After this and each following step the 
plate was washed 5 times with 30 sec intervals in PBST (1x PBS, 0,05% Tween-20) using an 
automatic plate washer (BioRad model 1575). The plate was blocked with assay diluent 
(eBioscience) for 1 h at room temperature. Samples and standard lines were loaded in serial 
dilutions and incubated for 1 h at room temperature. Standard lines were made from purified 
chicken ovalbumin (Sigma) or recombinant GFP (Roche). For detection of OVA and GFP a 
rabbit anti-ovalbumin:HRP antibody or a rabbit anti-GFP:HRP antibody (both from Rockland 
Immunochemicals Inc.) were used, respectively. A 3,3’,5,5’-Tetramethylbenzidine (TMB) 
substrate (eBioscience) was added and colouring reaction was stopped using stop solution 
(0.18M sulphuric acid) after 1-15 min. Read outs were performed using the model 680 
microplate reader (BioRad) to measure the OD at 450 nm with correction filter of 690 nm. For 
sample comparison total soluble protein (TSP) concentration was determined using the BCA 
Protein Assay Kit (Pierce) according to supplier’s protocol using bovine serum albumin (BSA) 
as a standard. 
 
Gene expression datasets 
Gene expression datasets of 5 species (Escherichia coli, Arabidopsis thaliana, Saccharomyces 
cerevisiae, Caenorhabditis elegans, and Mus musculus) were downloaded from Gene 
Expression Omnibus (GEO). Gene-expression sets were selected based on platform 
(Affimetrix), release date (not earlier than 2008), publication linked to the GEO set and number 
of samples in the study. In total 2067 gene-expression profiles were collected, representing 8 
or 9 different studies per organism. An overview can be found in Supplementary Table 1A-F. 
 
Protein abundance datasets 
Protein abundance datasets were retrieved from PaxDb [33], where the integrated datasets of 
Escherichia coli, Arabidopsis thaliana, Saccharomyces cerevisiae, Caenorhabditis elegans, and 
Mus musculus were downloaded. 
 
Gene expression normalization 
Gene expression was normalized based on rank. Per species one array platform was used and 
per species probes were ranked according to their intensities. The average rank per probe was 
used as a measure of overall gene expression to distinguish genes with overall low and high 
expression levels for each species. 
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mRNA Sequences 
The coding sequences (CDS) of all genes of 5 species were downloaded from 
sequence/genome repositories. For Escherichia coli, the CDS of strains CFT073, EDL933, 
MG1655 and Sakai were obtained from NCBI, accesscions NC_004431.1, NC_002655.1, 
NC_U00096.3 and NC_002695.1 respectively. For Arabidopsis thaliana, the CDS of the 
20101108 release were obtained from TAIR [34]. For Saccharomyces cerevisiae, the open 
reading frames (without UTR, introns, etc.) of the 20110203 release were obtained from the 
Saccharomyces genome database [35]. For Caenorhabditis elegans, the CDS of WS241 were 
obtained from WormBase [36]. For Mus musculus, the CDS of the 20130508 release 
(GRCm38.p1) were obtained from the NCBI CCDS database [37]. 
 
mRNA folding 
The mRNAs of all species were folded using Vienna RNA fold [38], at 20oC, using the 
parameters of Andronescu, 2007 [39]. The M. musculus mRNA was also folded at 37oC and 
the S. cerevisiae also at 30oC, but all the reported comparisons are based on 20oC.  
 
mRNA sequence and structure statistics 
Several statistics were taken from the mRNA sequence: gene length, codon usage, and 
nucleotide usage. Also from the predicted mRNA structure several statistics were taken: 
number of bound nucleotides, number of free nucleotides, average stem size, average loop 
size, variation in stem size, variation in loop size, and energy of the structure. 
 
Gene expression and mRNA folding statistics 
The correlations (Spearman) between gene expression and the various mRNA-based statistics 
were calculated by Spearman correlation (in R 3.0.2 x64). For some of the factors a correction 
was applied for gene-length, these were: number of bound nucleotides, number of unbound 
nucleotides, energy of the structure, number of stems, number of loops, triplet usage, 
nucleotide usage, and amino acid usage. 
 For expression codon analysis, the frequencies of use of synonymous codons was 
calculated. This was done over a receding window, from 50% highest versus 50% lowest until 
5% highest versus 5% lowest, in increments of 1%. 
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Supplementary figures 
 
Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1 !  mRNA structure predictions of the constructs used for heterologous protein 
expression. Sequences of the native and optimised variants of Aequorea victoria green fluorescent protein 
(GFP), Gallus gallus ovalbumin (OVA) and Mus musculus interleukin-10 (IL-10) with additional signal 
peptide (SP) and GFP without SP flanked by the 5’ and 3’-UTRs asexpected from our expression cassette 
were used to predict the mRNA secondary structure. 
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Supplementary Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2 !  Heat maps displaying the relation between species of several kingdoms of life 
based on translation rate-linked nucleotide use. Correlation (Spearman) between mRNA:protein ratios 
(proxy for translation rate) and nucleotide content (overall and for each codon position) for the species 
Escherichia coli (Bacteria), Saccharomyces cerevisiae (Fungi), Caenorhabdites elegans (Animalia), 
Arabidopsis thaliana (Plantae) and Mus musculus (Animalia). For each species >250 microarrays 
originating from multiple studies covering a wide range of strains/ecotypes, culturing conditions, 
developmental stages and tissues (Supplementary Table 1A-F) was rank-normalized, averaged and divided 
by protein abundance (retrieved from PaxDB) before correlations (Spearman) between protein:mRNA 
ratios and nucleotide use were calculated. 
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Supplementary Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3 !  Heat maps displaying the relation between species of several kingdoms of life 
based on translation rate-linked codon use. Correlation (Spearman) between mRNA:protein ratios (proxy 
for translation rate) and codon use for the species Escherichia coli (Bacteria), Saccharomyces cerevisiae 
(Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus (Animalia). 
For each species >250 microarrays originating from multiple studies covering a wide range of 
strains/ecotypes, culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) was 
rank-normalized, averaged and divided by protein abundance (retrieved from PaxDB) before correlations 
(Spearman) between protein:mRNA ratios and nucleotide use were calculated. 
C.
 e
leg
an
s
A.
 th
ali
an
a
M
. m
us
cu
lus
S.
 ce
re
vis
iae
E.
 co
li
ACG (T)
CTA (L)
CCC (P)
ACA (T)
AAT (N)
ATA (I)
GGA (G)
CTC (L)
TGG (W)
GGG (G)
TAT (Y)
AGG (R)
TCG (S)
CAT (H)
TCA (S)
CCT (P)
TGT (C)
TGC (C)
TTT (F)
CTT (L)
AGT (S)
TTA (L)
CGG (R)
CGA (R)
TTG (L)
AGA (R)
CAA (Q)
CCA (P)
GTC (V)
GCC (A)
GCG (A)
CAG (Q)
CCG (P)
CAC (H)
GTA (V)
GCA (A)
CTG (L)
TTC (F)
AGC (S)
CGC (R)
ATG (M)
GTG (V)
ATT (I)
TAG (*)
TGA (*)
GAT (D)
GAG (E)
AAA (K)
GAC (D)
GAA (E)
AAG (K)
TCT (S)
CGT (R)
GTT (V)
GCT (A)
GGT (G)
GGC (G)
ACT (T)
TCC (S)
TAC (Y)
TAA (*)
ATC (I)
ACC (T)
AAC (N)
−0.5 0 0.5
Correlation
2040
6080
100
Co
un
ts
C.
 e
leg
an
s
A.
 th
ali
an
a
M
. m
us
cu
lus
S.
 ce
re
vis
iae
E.
 co
li
ACG (T)
CTA (L)
CCC (P)
ACA (T)
AAT (N)
ATA (I)
GGA (G)
CTC (L)
TGG (W)
GGG (G)
TAT (Y)
AGG (R)
TCG (S)
CAT (H)
TCA (S)
CCT (P)
TGT (C)
TGC (C)
TTT (F)
CTT (L)
AGT (S)
TTA (L)
CGG (R)
CGA (R)
TTG (L)
AGA (R)
CAA (Q)
CCA (P)
GTC (V)
GCC (A)
GCG (A)
CAG (Q)
CCG (P)
CAC (H)
GTA (V)
GCA (A)
CTG (L)
TTC (F)
AGC (S)
CGC (R)
ATG (M)
GTG (V)
ATT (I)
TAG (*)
TGA (*)
GAT (D)
GAG (E)
AAA (K)
GAC (D)
GAA (E)
AAG (K)
TCT (S)
CGT (R)
GTT (V)
GCT (A)
GGT (G)
GGC (G)
ACT (T)
TCC (S)
TAC (Y)
TAA (*)
ATC (I)
ACC (T)
AAC (N)
−0.5 0 0.5
Correlation
2040
6080
100
Co
un
ts
 Selection on mRNA stability and translatability across kingdoms 
 
 
 145 
 
Supplementary Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4 !  Heat maps displaying the relation between species of several kingdoms of life 
based on translation rate-linked amino acid use. Correlation (Spearman) between mRNA:protein ratios 
(proxy for translation rate) and amino acid use for the species Escherichia coli (Bacteria), Saccharomyces 
cerevisiae (Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) and Mus musculus 
(Animalia). For each species >250 microarrays originating from multiple studies covering a wide range of 
strains/ecotypes, culturing conditions, developmental stages and tissues (Supplementary Table 1A-F) was 
rank-normalized, averaged and divided by protein abundance (retrieved from PaxDB) before correlations 
(Spearman) between protein:mRNA ratios and nucleotide use were calculated. 
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Supplementary tables 
 
Supplementary Table 1A-F !  Gathered expression data and references 
 
Supplementary Table 1A ! ! Overview of the gathered expression data per species.   
 
  E. coli S. cerevisiae C. elegans A. thaliana M. musculus 
Strains/ecotypes 7 13 14 8 9 
Samples 168 316 391 415 777 
Controls 105 211 109 101 565 
Papers 8 9 9 9 9 
Treatments 20 14 29 73 21 
Tissues 1 1 3 11 28 
Treatments: 
 
 
 
> Different strains/mutants and tissues receiving the same experimental  
treatment are counted as a single treatment, all measurements in a time  
series are counted as a single treatment 
      Additional remarks: 
 
> M. musculus data sets Thorrez et al., 2009 and Xue et al., 2013  
   do not include the control spot on the slide in their datasets      
 
 
> E. coli expression values from the Dong and Schellhorn 2009 dataset 
   off to a single decimal and from Ito et al., 2009 dataset  to two decimals 
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Supplementary Tables 2A-E !  Relative synonymous codon use frequency averages of all 
genes and gene subsets of Escherichia coli, Saccharomyces cerevisiae, Caenorhabdites 
elegans, Arabidopsis thaliana and Mus musculus.  
 
Supplementary Tables 2A !  Relative synonymous codon use frequency 
averages of all genes and gene subsets based on expression for E. coli. 
 
 
AA Triplet All Top 5% Bottom 5% Top/Bottom 
* TAA 0.648 0.871 0.643 1.355 
TAG 0.067 0.021 0.064 0.328 
TGA 0.285 0.107 0.293 0.365 
A GCT 0.160 0.332 0.154 2.156 
GCC 0.266 0.139 0.275 0.505 
GCA 0.209 0.258 0.216 1.194 
GCG 0.365 0.271 0.356 0.761 
C TGT 0.435 0.385 0.466 0.826 
TGC 0.565 0.615 0.534 1.152 
D GAT 0.617 0.429 0.649 0.661 
GAC 0.383 0.571 0.351 1.627 
E GAA 0.693 0.760 0.681 1.116 
GAG 0.307 0.240 0.319 0.752 
F TTT 0.562 0.290 0.615 0.472 
TTC 0.438 0.710 0.385 1.844 
G GGT 0.343 0.527 0.327 1.612 
GGC 0.413 0.406 0.395 1.028 
GGA 0.098 0.031 0.116 0.267 
GGG 0.146 0.036 0.162 0.222 
H CAT 0.557 0.295 0.591 0.499 
CAC 0.443 0.705 0.409 1.724 
I ATT 0.503 0.302 0.530 0.570 
ATC 0.434 0.688 0.380 1.811 
ATA 0.063 0.010 0.090 0.111 
K AAA 0.770 0.768 0.793 0.968 
AAG 0.230 0.232 0.207 1.121 
L TTA 0.124 0.042 0.155 0.271 
TTG 0.124 0.059 0.130 0.454 
CTT 0.100 0.065 0.112 0.580 
CTC 0.103 0.068 0.106 0.642 
CTA 0.035 0.008 0.041 0.195 
CTG 0.515 0.758 0.457 1.659 
M ATG 1.000 1.000 1.000 1.000 
N AAT 0.432 0.182 0.486 0.374 
AAC 0.568 0.818 0.514 1.591 
P CCT 0.152 0.140 0.165 0.848 
CCC 0.115 0.025 0.137 0.182 
CCA 0.185 0.134 0.199 0.673 
CCG 0.547 0.702 0.498 1.410 
Q CAA 0.337 0.213 0.369 0.577 
CAG 0.663 0.787 0.631 1.247 
R CGT 0.396 0.636 0.363 1.752 
CGC 0.410 0.332 0.410 0.810 
CGA 0.058 0.010 0.071 0.141 
CGG 0.089 0.011 0.094 0.117 
AGA 0.030 0.007 0.044 0.159 
AGG 0.016 0.004 0.019 0.211 
S TCT 0.150 0.323 0.132 2.447 
TCC 0.155 0.256 0.136 1.882 
TCA 0.117 0.058 0.123 0.472 
TCG 0.155 0.057 0.171 0.333 
AGT 0.143 0.060 0.158 0.380 
AGC 0.280 0.247 0.280 0.882 
T ACT 0.168 0.328 0.167 1.964 
ACC 0.449 0.508 0.409 1.242 
ACA 0.120 0.048 0.154 0.312 
ACG 0.263 0.116 0.270 0.430 
V GTT 0.257 0.436 0.258 1.690 
GTC 0.214 0.113 0.219 0.516 
GTA 0.152 0.225 0.153 1.471 
GTG 0.377 0.226 0.370 0.611 
W TGG 1.000 1.000 1.000 1.000 
Y TAT 0.555 0.331 0.582 0.569 
Gene subsets were defined by expression in terms of percentage; top 5% 
high-, bottom 5% low-expressed. The fold change in codon use comparing 
high to low expressed genes (Top/Bottom) was also calculated. 
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Supplementary Tables 2B !  Relative synonymous codon use frequency 
averages of all genes and gene subsets based on expression for S. cerevisiae.  
 
AA Triplet All Top 5% Bottom 5% Top/Bottom 
* TAA 0.480 0.731 0.403 1.814 
TAG 0.225 0.117 0.290 0.403 
TGA 0.295 0.152 0.307 0.495 
A GCT 0.367 0.593 0.339 1.749 
GCC 0.223 0.280 0.215 1.302 
GCA 0.296 0.105 0.319 0.329 
GCG 0.113 0.023 0.127 0.181 
C TGT 0.627 0.829 0.594 1.396 
TGC 0.373 0.171 0.406 0.421 
D GAT 0.656 0.526 0.642 0.819 
GAC 0.344 0.474 0.358 1.324 
E GAA 0.701 0.854 0.699 1.222 
GAG 0.299 0.146 0.301 0.485 
F TTT 0.593 0.353 0.616 0.573 
TTC 0.407 0.647 0.384 1.685 
G GGT 0.455 0.823 0.387 2.127 
GGC 0.197 0.093 0.197 0.472 
GGA 0.224 0.051 0.279 0.183 
GGG 0.124 0.033 0.138 0.239 
H CAT 0.643 0.440 0.617 0.713 
CAC 0.357 0.560 0.383 1.462 
I ATT 0.463 0.522 0.469 1.113 
ATC 0.258 0.430 0.236 1.822 
ATA 0.280 0.048 0.295 0.163 
K AAA 0.581 0.299 0.639 0.468 
AAG 0.419 0.701 0.361 1.942 
L TTA 0.279 0.216 0.244 0.885 
TTG 0.283 0.567 0.251 2.259 
CTT 0.127 0.057 0.163 0.350 
CTC 0.057 0.014 0.086 0.163 
CTA 0.142 0.103 0.143 0.720 
CTG 0.112 0.043 0.113 0.381 
M ATG 1.000 1.000 1.000 1.000 
N AAT 0.598 0.303 0.594 0.510 
AAC 0.402 0.697 0.406 1.717 
P CCT 0.310 0.227 0.305 0.744 
CCC 0.160 0.053 0.164 0.323 
CCA 0.407 0.701 0.401 1.748 
CCG 0.123 0.018 0.129 0.140 
Q CAA 0.686 0.893 0.663 1.347 
CAG 0.314 0.107 0.337 0.318 
R CGT 0.140 0.201 0.131 1.534 
CGC 0.058 0.017 0.078 0.218 
CGA 0.068 0.001 0.088 0.011 
CGG 0.040 0.002 0.064 0.031 
AGA 0.478 0.724 0.420 1.724 
AGG 0.217 0.055 0.218 0.252 
S TCT 0.261 0.452 0.246 1.837 
TCC 0.157 0.289 0.147 1.966 
TCA 0.211 0.108 0.218 0.495 
TCG 0.097 0.036 0.096 0.375 
AGT 0.163 0.063 0.172 0.366 
AGC 0.111 0.051 0.121 0.421 
T ACT 0.343 0.482 0.333 1.447 
ACC 0.210 0.352 0.213 1.653 
ACA 0.307 0.133 0.325 0.409 
ACG 0.140 0.034 0.129 0.264 
V GTT 0.389 0.511 0.368 1.389 
GTC 0.201 0.347 0.210 1.652 
GTA 0.216 0.060 0.226 0.265 
GTG 0.195 0.082 0.196 0.418 
W TGG 1.000 1.000 1.000 1.000 
Y TAT 0.568 0.302 0.558 0.541 
TAC 0.432 0.698 0.442 1.579 
 
Gene subsets were defined by expression in terms of percentage; top 5% 
high-, bottom 5% low-expressed. The fold change in codon use comparing 
high to low expressed genes (Top/Bottom) was also calculated. 
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Supplementary Tables 2C !  Relative synonymous codon use frequency 
averages of all genes and gene subsets based on expression for C. elegans.  
 
AA Triplet All Top 5% Bottom 5% Top/Bottom 
* TAA 0.496 0.694 0.439 1.581 
TAG 0.179 0.141 0.162 0.870 
TGA 0.325 0.165 0.399 0.414 
A GCT 0.354 0.423 0.325 1.302 
GCC 0.199 0.302 0.157 1.924 
GCA 0.314 0.198 0.385 0.514 
GCG 0.133 0.077 0.134 0.575 
C TGT 0.555 0.447 0.588 0.760 
TGC 0.445 0.553 0.412 1.342 
D GAT 0.679 0.631 0.693 0.911 
GAC 0.321 0.369 0.307 1.202 
E GAA 0.621 0.534 0.671 0.796 
GAG 0.379 0.466 0.329 1.416 
F TTT 0.481 0.261 0.605 0.431 
TTC 0.519 0.739 0.395 1.871 
G GGT 0.204 0.168 0.214 0.785 
GGC 0.124 0.086 0.134 0.642 
GGA 0.592 0.711 0.544 1.307 
GGG 0.080 0.035 0.109 0.321 
H CAT 0.611 0.513 0.649 0.790 
CAC 0.389 0.487 0.351 1.387 
I ATT 0.534 0.470 0.538 0.874 
ATC 0.314 0.478 0.226 2.115 
ATA 0.152 0.052 0.236 0.220 
K AAA 0.588 0.381 0.665 0.573 
AAG 0.412 0.619 0.335 1.848 
L TTA 0.110 0.049 0.169 0.290 
TTG 0.234 0.212 0.258 0.822 
CTT 0.249 0.306 0.214 1.430 
CTC 0.174 0.280 0.116 2.414 
CTA 0.091 0.042 0.112 0.375 
CTG 0.142 0.112 0.133 0.842 
M ATG 1.000 1.000 1.000 1.000 
N AAT 0.625 0.484 0.655 0.739 
AAC 0.375 0.516 0.345 1.496 
P CCT 0.178 0.126 0.220 0.573 
CCC 0.088 0.054 0.100 0.540 
CCA 0.532 0.691 0.494 1.399 
CCG 0.202 0.130 0.186 0.699 
Q CAA 0.651 0.650 0.679 0.957 
CAG 0.349 0.350 0.321 1.090 
R CGT 0.217 0.350 0.150 2.333 
CGC 0.096 0.175 0.067 2.612 
CGA 0.236 0.146 0.231 0.632 
CGG 0.091 0.046 0.098 0.469 
AGA 0.288 0.250 0.357 0.700 
AGG 0.071 0.032 0.097 0.330 
S TCT 0.206 0.235 0.214 1.098 
TCC 0.130 0.177 0.112 1.580 
TCA 0.257 0.205 0.273 0.751 
TCG 0.156 0.169 0.125 1.352 
AGT 0.149 0.104 0.173 0.601 
AGC 0.102 0.109 0.103 1.058 
T ACT 0.324 0.346 0.329 1.052 
ACC 0.175 0.297 0.144 2.062 
ACA 0.345 0.249 0.383 0.650 
ACG 0.156 0.108 0.143 0.755 
V GTT 0.388 0.413 0.407 1.015 
GTC 0.220 0.320 0.168 1.905 
GTA 0.158 0.097 0.191 0.508 
GTG 0.234 0.170 0.234 0.726 
W TGG 1.000 1.000 1.000 1.000 
Y TAT 0.559 0.414 0.631 0.656 
TAC 0.441 0.586 0.369 1.588 
 
Gene subsets were defined by expression in terms of percentage; top 5% 
high-, bottom 5% low-expressed. The fold change in codon use comparing 
high to low expressed genes (Top/Bottom) was also calculated. 
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Supplementary Tables 2D !  Relative synonymous codon use frequency 
averages of all genes and gene subsets based on expression for A. thaliana.  
 
AA Triplet All Top 5% Bottom 5% Top/Bottom 
* TAA 0.345 0.371 0.263 1.411 
TAG 0.204 0.194 0.194 1.000 
TGA 0.451 0.435 0.543 0.801 
A GCT 0.432 0.498 0.383 1.300 
GCC 0.161 0.171 0.174 0.983 
GCA 0.263 0.221 0.278 0.795 
GCG 0.144 0.110 0.164 0.671 
C TGT 0.593 0.561 0.591 0.949 
TGC 0.407 0.439 0.409 1.073 
D GAT 0.674 0.644 0.662 0.973 
GAC 0.326 0.356 0.338 1.053 
E GAA 0.511 0.442 0.523 0.845 
GAG 0.489 0.558 0.477 1.170 
F TTT 0.502 0.427 0.515 0.829 
TTC 0.498 0.573 0.485 1.181 
G GGT 0.334 0.398 0.316 1.259 
GGC 0.141 0.119 0.152 0.783 
GGA 0.371 0.367 0.387 0.948 
GGG 0.154 0.115 0.145 0.793 
H CAT 0.606 0.526 0.612 0.859 
CAC 0.394 0.474 0.388 1.222 
I ATT 0.400 0.429 0.375 1.144 
ATC 0.363 0.432 0.373 1.158 
ATA 0.236 0.139 0.252 0.552 
K AAA 0.490 0.385 0.517 0.745 
AAG 0.510 0.615 0.483 1.273 
L TTA 0.135 0.082 0.148 0.554 
TTG 0.220 0.233 0.229 1.017 
CTT 0.257 0.290 0.248 1.169 
CTC 0.181 0.207 0.172 1.203 
CTA 0.105 0.080 0.121 0.661 
CTG 0.102 0.108 0.082 1.317 
M ATG 1.000 1.000 1.000 1.000 
N AAT 0.502 0.430 0.489 0.879 
AAC 0.498 0.570 0.511 1.115 
P CCT 0.381 0.407 0.353 1.153 
CCC 0.106 0.112 0.109 1.028 
CCA 0.327 0.336 0.351 0.957 
CCG 0.186 0.146 0.186 0.785 
Q CAA 0.564 0.465 0.648 0.718 
CAG 0.436 0.535 0.352 1.520 
R CGT 0.168 0.241 0.161 1.497 
CGC 0.070 0.077 0.068 1.132 
CGA 0.118 0.087 0.120 0.725 
CGG 0.092 0.059 0.086 0.686 
AGA 0.352 0.301 0.363 0.829 
AGG 0.199 0.234 0.202 1.158 
S TCT 0.280 0.303 0.253 1.198 
TCC 0.129 0.147 0.127 1.157 
TCA 0.204 0.178 0.212 0.840 
TCG 0.108 0.100 0.114 0.877 
AGT 0.151 0.139 0.158 0.880 
AGC 0.127 0.134 0.135 0.993 
T ACT 0.334 0.374 0.300 1.247 
ACC 0.207 0.260 0.213 1.221 
ACA 0.302 0.253 0.313 0.808 
ACG 0.157 0.114 0.175 0.651 
V GTT 0.400 0.432 0.372 1.161 
GTC 0.193 0.219 0.199 1.101 
GTA 0.145 0.095 0.157 0.605 
GTG 0.262 0.253 0.271 0.934 
W TGG 1.000 1.000 1.000 1.000 
Y TAT 0.504 0.418 0.508 0.823 
TAC 0.496 0.582 0.492 1.183 
 
Gene subsets were defined by expression in terms of percentage; top 5% 
high-, bottom 5% low-expressed. The fold change in codon use comparing 
high to low expressed genes (Top/Bottom) was also calculated. 
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Supplementary Tables 2E !  Relative synonymous codon use frequency 
averages of all genes and gene subsets based on expression for M. musculus.  
 
AA Triplet All Top 5% Bottom 5% Top/Bottom 
* TAA 0.258 0.351 0.323 1.087 
TAG 0.235 0.222 0.253 0.877 
TGA 0.507 0.427 0.424 1.007 
A GCT 0.289 0.320 0.316 1.013 
GCC 0.377 0.331 0.340 0.974 
GCA 0.232 0.246 0.266 0.925 
GCG 0.101 0.103 0.078 1.321 
C TGT 0.476 0.516 0.507 1.018 
TGC 0.524 0.484 0.493 0.982 
D GAT 0.450 0.521 0.500 1.042 
GAC 0.550 0.479 0.500 0.958 
E GAA 0.412 0.466 0.495 0.941 
GAG 0.588 0.534 0.505 1.057 
F TTT 0.445 0.507 0.499 1.016 
TTC 0.555 0.493 0.501 0.984 
G GGT 0.175 0.208 0.197 1.056 
GGC 0.332 0.319 0.287 1.111 
GGA 0.257 0.272 0.313 0.869 
GGG 0.236 0.201 0.204 0.985 
H CAT 0.410 0.468 0.472 0.992 
CAC 0.590 0.532 0.528 1.008 
I ATT 0.343 0.404 0.362 1.116 
ATC 0.495 0.448 0.419 1.069 
ATA 0.162 0.148 0.219 0.676 
K AAA 0.398 0.407 0.471 0.864 
AAG 0.602 0.593 0.529 1.121 
L TTA 0.068 0.089 0.095 0.937 
TTG 0.132 0.152 0.152 1.000 
CTT 0.132 0.154 0.154 1.000 
CTC 0.194 0.169 0.176 0.960 
CTA 0.079 0.079 0.092 0.859 
CTG 0.396 0.357 0.331 1.079 
M ATG 1.000 1.000 1.000 1.000 
N AAT 0.436 0.481 0.501 0.960 
AAC 0.564 0.519 0.499 1.040 
P CCT 0.306 0.335 0.316 1.060 
CCC 0.298 0.250 0.275 0.909 
CCA 0.288 0.310 0.323 0.960 
CCG 0.108 0.105 0.086 1.221 
Q CAA 0.253 0.258 0.350 0.737 
CAG 0.747 0.742 0.650 1.142 
R CGT 0.084 0.105 0.080 1.312 
CGC 0.170 0.153 0.122 1.254 
CGA 0.123 0.145 0.104 1.394 
CGG 0.194 0.179 0.128 1.398 
AGA 0.213 0.232 0.318 0.730 
AGG 0.216 0.186 0.249 0.747 
S TCT 0.193 0.222 0.220 1.009 
TCC 0.211 0.195 0.188 1.037 
TCA 0.143 0.149 0.170 0.876 
TCG 0.054 0.057 0.039 1.462 
AGT 0.156 0.171 0.174 0.983 
AGC 0.243 0.206 0.209 0.986 
T ACT 0.249 0.273 0.275 0.993 
ACC 0.345 0.313 0.312 1.003 
ACA 0.295 0.314 0.328 0.957 
ACG 0.111 0.099 0.085 1.165 
V GTT 0.174 0.225 0.217 1.037 
GTC 0.245 0.215 0.241 0.892 
GTA 0.119 0.138 0.146 0.945 
GTG 0.461 0.423 0.395 1.071 
W TGG 1.000 1.000 1.000 1.000 
Y TAT 0.423 0.481 0.498 0.966 
TAC 0.577 0.519 0.502 1.034 
 
Gene subsets were defined by expression in terms of percentage; top 5% 
high-, bottom 5% low-expressed. The fold change in codon use comparing 
high to low expressed genes (Top/Bottom) was also calculated. 
 Selection on mRNA stability and translatability across kingdoms 
 
 
 157 
 
Supplementary Table 3 !  Correlation between mRNA structure characteristics and 
gene expression per species.  
 
  E. coli S. cereviciae C. elegans A. thaliana M. musculus 
Gene length -0.146 -0.041 0.093 0.030 -0.016 
Energy (kcal.mol/nt) -0.006 -0.319 -0.316 -0.229 0.006 
Bound nt (fraction) 0.038 0.236 0.061 0.172 0.015 
Mean stem size -0.111 0.054 -0.182 0.053 -0.055 
Mean loop size -0.115 -0.241 -0.179 -0.155 -0.046 
Transitions /nt 0.140 0.144 0.227 0.071 0.069 
 
The mRNA structures of all genes of Escherichia coli (Bacteria), Saccharomyces 
cerevisiae (Fungi), Caenorhabdites elegans (Animalia), Arabidopsis thaliana (Plantae) 
and Mus musculus (Animalia) were predicted and gene length, minimal free folding 
energy, percentage of bound nucleotides, mean stem and loop (stretches of bound 
and unbound nucleotides, respectively) size and number of stem/loop transitions were 
determined and correlated (Spearman) with expression. Basis of the heat map 
presented in Figure 7.  
 
 
 
Supplementary Table 4 !  Calculated mRNA structure characteristics of the constructs used for 
heterologous protein expression.  
 
    Energy kcal/mol/nt Bound nt’s (fraction) Mean stem size Mean loop size Transitions 
GFP N -0.21 0.56 5.74 4.48 0.097 
  O -0.33 0.57 5.15 3.85 0.111 
SP-GFP N -0.22 0.57 5.21 3.89 0.109 
  O -0.32 0.54 5.22 4.31 0.104 
SP-OVA N -0.29 0.61 5.28 3.34 0.116 
  O -0.31 0.55 4.38 3.56 0.126 
SP-IL-10 N -0.29 0.60 5.02 3.29 0.120 
 
O -0.27 0.54 4.08 3.47 0.131 
 
Analysis of the mRNA secondary structure predictions given in Supplementary Figure 1. Folding energy, 
bound nucleotides and number of transitions are corrected for gene length. Stem and loop sizes are mean 
values. 
 
 
 
Supplementary Tables 5 !  Correlation between mRNA structure characteristics and 
protein:mRNA ratios per species. 
 
 
E. coli S. cerevisiae C. elegans A. thaliana M. musculus 
Gene length -0.146 -0.116 -0.180 -0.139 -0.288 
Energy (kcal/mol/nt) 0.043 -0.237 -0.212 -0.138 0.087 
Bound (fraction) -0.009 0.148 -0.006 0.062 -0.058 
Mean stem size -0.193 -0.011 -0.216 -0.058 -0.121 
Mean loop size -0.121 -0.182 -0.139 -0.105 -0.015 
Transitions /nt 0.199 0.140 0.213 0.104 0.081 
 
Correlations (Spearman) between mRNA structure characteristics and mRNA:protein 
ratios per species. The mRNA structures of all genes of Escherichia coli (Bacteria), 
Saccharomyces cerevisiae (Fungi), Caenorhabdites elegans (Animalia), Arabidopsis 
thaliana (Plantae) and Mus musculus (Animalia) were predicted and gene length, 
minimal free folding energy, percentage of bound nucleotides, mean stem and loop 
(stretches of bound and unbound nucleotides, respectively) size and number of 
stem/loop transitions were determined and correlated (Spearman) with mRNA:protein 
ratios. Rank-normalized mRNA levels were divided by protein abundance (retrieved 
from PaxDB). Basis of the heat map presented in Figure 8. 
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The development and application of biopharmaceuticals has benefited from the revolution in 
life sciences that took place over the last three decades. Today many biopharmaceuticals have 
been approved for medical use. Most are produced in heterologous production systems that 
make use of the bacterium Escherichia coli, the yeast Saccharomyces cerevisiae or mammalian 
cell lines. All production systems have their advantages and disadvantages and the choice of 
system depends on requirements of the produced protein. As the cost of biopharmaceuticals is 
becoming increasingly important, plants may provide an alternative as they combine the 
advantage of E. coli being economic with the advantage of mammalian cells being able to 
fold, assemble and glycosylate complex proteins. This thesis describes the production of a 
variety of proteins in planta and focuses on increasing yield and biological activity. In this 
chapter parameters influencing yield and activity, i.e. transformation, transcription, translation 
and protein behaviour, will be discussed. 
 
 
Transformation efficiency and transcription 
 
The promoter of a gene predominantly determines the level of its transcription. However, in 
heterologous expression not only the choice of the promoter, but also the manner of 
transformation has a profound influence on the transcript level of the gene(s) of interest. The 
two aspects that are relevant in this matter are the number of gene copies available for 
transcription and whether or not the gene is integrated into the genome. 
Transient transformation often results in higher expression levels than stable 
transformation. Even when both transient and stable transformation are mediated by 
Agrobacterium and when a binary vector system is used [1]. Stable transformation results in 
the integration of one or a few copies of the gene into the plant genome. Subsequently, 
transcription depends on the type of promoter as well as its accessibility. The promoter will be 
readily accessible if the gene is integrated into a part of the genome that is actively used for 
transcription. This is more often the case with Agrobacterium-mediated transformation 
compared to indirect transformation methods. However, transcription does not depend on 
genomic integration. As long as the expression cassette is double stranded, transcription can 
occur. Although the T-DNA fragment that Agrobacterium transfers to the plant cell is single 
stranded a double strand is formed to allow genomic integration. From the moment that the T-
DNA is double stranded, transcription is possible [2-4]. Agrobacterium transfers many more T-
DNA copies to the plant cell than are eventually integrated. T-DNAs that are not integrated 
into the genome are eventually broken down, explaining the transient nature of initial 
expression [4]. Thus, in Agrobacterium-mediated transient expression many more copies of T-
DNA are transcriptionally active independent of integration. This results in higher transcript 
levels when compared to stable transformation.  
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High copy numbers also explain the success of transient expression using viral vectors. 
Upon using a viral vector, transcription of the gene of interest is also not limited by genomic 
integration. And as the virus replicates and spreads throughout the plant the copy number of 
the gene of interest increases. An example of a superior transient expression system using viral 
vectors is the magnICON® system [5]. This system is based on the use of two vectors each 
carrying (parts of) the genome of the noncompeting viruses tobacco mosaic virus and potato 
virus X. This system is suited for the expression of heterodimeric proteins, such as antibodies, 
and has frequently resulted in high yields. 
Before the research described in this thesis, heterologous gene expression in plants was 
mainly used in our laboratory to investigate the role of resistance genes and virulence factors. 
For these studies, high expression levels are usually not preferred. Agrobacterium-mediated 
transient transformation using a binary vector system with pBINPLUS [6] as the expression 
vector was always sufficient to facilitate gene expression in plants for this purpose. Upon our 
first effort to produce interleukin (IL)-10 in plants we achieved a very low yield. Initially, we 
attributed this to IL-10’s supposed inherent instability. However, when we needed another 
antibiotic resistance gene for stable transformation we obtained another expression vector 
known as pMDC32 [7]. To suit our cloning needs this vector was modified and re-named 
pHYG for its hygromycin resistance gene (Chapter 2). We noticed that pHYG has a higher 
copy number in E. coli. Because of this and the smaller size of pHYG (~3 kbp difference) it 
became easier to manipulate expression cassettes at this stage. Therefore we started to use this 
vector for our transient transformations. To our surprise protein yield also increased 
tremendously using pHYG in comparison to pBINPLUS. As we used identical expression 
cassettes, we concluded this must be due to a higher copy number of pHYG in Agrobacterium 
as well, resulting in more T-DNA copies being transferred to the plant cell. 
pBINPLUS carries two origins of replication (ori); one originated from the plasmid pRK2 
of Klebsiella aerogenes (RK2) and one from the plasmid pMB1 of Bifidobacterium longum 
(pMB1 is the parental plasmid of pBR322 and its ori is known as ColE1). ColE1 was added to 
boost replication in E. coli, however, this was not sufficient to facilitate easy cloning in this 
vector [6]. pHYG is a derivative of pCambia1300 and also carries ColE1 together with the ori 
isolated from the plasmid pVS1 of Pseudomonas aeruginosa (VS1). VS1 does not facilitate 
replication in E. coli. Thus, although pHYG uses ColE1 and pBINPLUS uses ColE1 and RK2 to 
facilitate replication in E. coli, pHYG has a higher copy number in E. coli than pBINPLUS. This 
may be due to the smaller size of pHYG and/or the replication facilitated by ColE1 is limited 
when combined with RK2 in pBINPLUS. As mentioned, we suspect that pHYG also has a 
higher copy number in Agrobacterium. Again, this may be due to the smaller size of pHYG 
and/or the possibility that VS1 leads to higher replication levels in Agrobacterium when 
compared to RK2.  
mRNA transcript levels of human and mouse interleukin (IL)-10 that were expressed 
using pHYG exceeded the mRNA transcript level of the household gene actin by ~1000-fold 
General discussion 
 
 
! 165 
(Chapter 2). When we expressed three IgG and three IgA antibodies average yield was ~50 µg 
antibody per milligram (or 5% of) total soluble protein (TSP) (Chapter 3). This translates to ~1 g 
of antibody per kg fresh weight. Similar expression levels were described by Giritch and co-
workers using the magnICON® system [8]. Thus, although we are still using an ‘old school’ 
binary vector system for expression, we concluded that transformation efficiency and 
subsequent transcription were not limiting with regard to protein yield using our plant 
expression system.  
 
 
Transcript half-life 
 
The use of the pHYG vector had improved yield of human and mouse IL-10. Next, we further 
improved yield of human IL-10 30-fold by preventing its extensive multimerization. Thereto 
we inserted a small glycine-serine linker between helices E and D of IL-10, which allowed IL-
10 to fold into itself abolishing the need to dimerise. As a result the yield of human IL-10 
increased to ~2 µg/mg TSP, which was comparable to the yield of mouse IL-10 (Chapter 2). 
Nevertheless, this was still ~25-fold less compared to the yield of IgG and IgA (Chapter 3). We 
concluded that the difference between IL-10 and antibody yield are most likely not caused by 
differences in transformation efficiency or level of transcription. Therefore differences in 
transcript half-life, translation efficiency and/or protein half-life must exist. First we will 
evaluate the impact of transcript half-life.  
Thanks to many studies on mRNA decay we now know that in vivo mRNA half-life is 
connected to gene function whereby transcripts of proteins that have to be tightly regulated 
have generally short half-lives and transcripts of household genes have generally longer half-
lives [9-11]. The features that predominantly determine mRNA half-life are an intron splicing 
event, sequence elements in the 3’ UTR and the presence of microRNA targets [9]. In 
heterologous expression most of these features are controlled. The expression cassette 
determines the UTRs a transcript receives and a choice can be made regarding the use of 
introns. Sequences that are targets for microRNAs can be present and vary from gene to gene. 
Binding of microRNAs and overexpression of a gene can trigger gene silencing. To prevent 
gene silencing the co-expression of a viral silencing inhibitor is often used in transient 
expression [12]. A less potent variant of the silencing inhibitor p19 of tomato bushy stunt virus 
can even be considered in stable transformation [13].  
Initially we did not use a viral silencing inhibitor when expressing IL-10, while we did 
when expressing antibodies. In chapter 6 we describe the expression of mouse IL-10 with p19, 
which boosted protein yield significantly at 5 dpi (~1 and ~17 µg IL-10 per mg TSP without 
and with p19, respectively). However, this was not significantly higher when compared to 
mouse IL-10 yield on dpi 3 without p19 (~15 µg IL-10 per mg TSP). Strikingly, mouse IL-10 
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yields were overall much higher in this experiment than previously reported in chapter 2 (~2 
µg IL-10 per mg TSP on dpi 3 without p19). The only difference was the use of a non-native 
signal peptide derived from the Arabidopsis thaliana chitinase gene in this mouse IL-10 
construct during the later experiments. Although, improper processing of the native signal 
peptide was not suspected [14], a different signal peptide may change the translation initiation 
efficiency, which will be discussed in the section ‘Translation efficiency’. Differences in yield 
may also be due to the fickle nature of transient expression. We found that protein yield in 
biological replicates of experiments performed in consecutive weeks is often similar when 
plants and leaves of the same age are used. However, protein yield can differ ~2 to 10-fold 
when performed at different times of the year as a consequence of seasonal effects 
(unpublished data). This illustrates the difficulty with drawing conclusions about protein yield 
upon heterologous expression. Biological replicates can best be done during the same season 
using as identical as possible experimental conditions. These findings also illustrate the 
difficulty of comparing results between different studies, as conditions will almost certainly 
differ. In any case, we could conclude that the transcript of mouse IL-10 was sensitive to 
silencing.  
The calculated minimal free folding energy of mRNA, which predicts physical stability, 
has not been linked to mRNA half-life in vivo. However, it may well be that mRNA stability 
plays a significant role in determining mRNA half-life in heterologous expression. In fact, a 
recent publication showed that removal of instable mRNA sequences reduced transcript 
degradation significantly upon stable heterologous expression of isomaltulose in sugarcane 
[15]. However, whether or not differences in mRNA stability result in differences in protein 
yield upon transient transformation, whereby mRNA transcript levels are generally much 
higher, remains to be investigated. In a study whereby 154 variants of GFP differing only in 
synonymous codon use were expressed in E. coli, overall mRNA folding energy was not 
significantly correlated to protein yield [16]. Yet, this does not prove that one or more regions 
of poor stability that reside in the transcript of an overall stable mRNA do not affect mRNA 
half-life. When we expressed native and codon optimised variants of GFP, chicken ovalbumin 
(OVA) and mouse IL-10 upon stable transformation in Arabidopsis thaliana and upon transient 
transformation in N. benthamiana co-expressed with p19, the optimised variants resulted in 
higher protein yields in all cases (Chapter 6). Transcript levels were also determined in the 
stable A. thaliana transformants and demonstrated that the increase in protein yield upon 
codon optimisation could be partly explained by an increased concentration of transcript. 
Because gene silencing in stable transformation leads to a complete absence of transcripts and 
recombinant protein, differences in gene silencing could not explain the differences in 
transcript levels. Thus, increased mRNA stability may result in increased transcript half-lives. 
Yet, while the mRNA transcripts of GFP and OVA had lower folding energies (more stable 
mRNA) upon codon optimisation, the mouse IL-10 mRNA transcript did not. As previously 
mentioned, it is still possible that unstable regions of IL-10 were removed upon codon 
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optimisation, while the overall stability decreased. Furthermore, not only transcript levels had 
increased. Also the amount of protein per mRNA transcript was higher for the optimised 
variants. This can only be explained by the fact that codons optimisation increased translation 
efficiency. An increase in translation efficiency may have also influenced transcript levels. It 
has been demonstrated that ribosomes can stall or slip causing a frame-shift and both can lead 
to the degradation of the mRNA transcript and its product. All in all, while mRNA stability is 
not linked to mRNA half-life in vivo, mRNA stability most likely has significant influence on 
mRNA half-life and thus protein yield in heterologous protein production.   
 
 
Translation efficiency 
 
A higher protein yield per mRNA molecule can only be explained by an increase in translation 
rate. The efficiency of translation initiation and the speed of translation itself both determine 
translation rate. Ribosomal density studies have shown that more ribosomes are found at the 
beginning of a transcript compared to the rest of the transcript [17, 18]. This observation has 
lead to the assumption that translation initiation is the rate-limiting step of translation. A high 
folding energy of the 5’ end of a mRNA is believed to facilitate efficient translation initiation as 
this is a general feature of mRNA structures [19]. 
As mentioned, when mouse IL-10 was expressed with a different signal peptide, yield 
was found to be ~7,5-fold higher, which may be due to an increase in translation initiation. 
When we calculated the folding energy of the first 75 nucleotides (positions -36 to +39) of 
both the mouse IL-10 transcript with the native or A. thaliana chitinase signal peptide, we 
found that the latter signal peptide increased the folding energy 7,7-fold (making it less stable). 
An increased translation initiation may therefore explain the yield increase of mouse IL-10. 
Even though translation initiation may be the rate-limiting step of translation, an 
increase in translation rate may still influence protein abundance in a situation where the 
number of free ribosomes is limiting. An increased translation rate will make translating 
ribosomes faster available for a next round of translation. Especially in heterologous 
expression, whereby the gene of interest is significantly over-expressed (with mRNA transcript 
levels often several orders of magnitude above household genes; Chapter 2), it is likely that 
free ribosomes are limiting. An increased translation rate of a heterologous gene can therefore 
also increase protein yield significantly through a faster ‘cycling’ of ribosomes.  
It is assumed that translation rate is predominantly controlled by tRNA availability and 
the mRNA structure. Availability of a cognate tRNA determines the speed with which a codon 
is translated because translation occurs via diffusion and arrival of the cognate tRNA is the 
rate-limiting step for elongation of the amino acid sequence [20]. In addition strong mRNA 
structures have been shown to hamper translation [21, 22], because ribosomes use their 
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intrinsic helicase activity [23] to dissociate the nucleotide bonds that occur during mRNA 
folding before translation can progress. Thus, a less stable mRNA structure can be translated 
faster. However, there must be a trade off between mRNA translatability and stability, because 
native mRNA sequences have a lower folding energy (more stable mRNA) than randomized 
mRNA sequences with the same base composition and length [24].  
Highly expressed genes are biased in their codon use and the codons they use most 
frequently (the so-called optimal codons) correspond with genomic G+C content [25] and 
have been matched to abundant tRNAs in many species [26-31]. In heterologous protein 
production codon optimisation of the gene of interest using optimal codons of their production 
host has shown great variability of success [15]. Optimal codons differ between species, which 
is in line with differences in G+C content and abundance of tRNA species between species. 
However, it was striking that a general codon bias was found across plant species, including 
monocots and dicots that differ significantly in their G+C content [32]. We designed a strategy 
making use of codons that are increased most with expression across plants (expression 
codons). Using the same coding sequence for the signal peptide that preceded all genes we 
ensured that translation initiation of genes is the same. This codon optimisation strategy 
resulted in higher transcript levels and higher protein yield, which we believe to be a result of 
an improved mRNA structure that balances mRNA stability with translatability. Because the 
translation machinery is quite conserved across kingdoms of life we evaluated whether this 
general codon bias found in plants could also be extended to other kingdoms. Using large-
scale gene expression and protein abundance data we observed that this general codon bias 
exists across kingdoms and conclude that codons in highly expressed genes are selected to 
facilitate a more stable mRNA structure (more and different type of nucleotide bonds) that is 
also sufficiently ‘airy’ (higher frequency of alternating bound (stems) and unbound nucleotides 
(loops)) to allow efficient translation. Because this codon use trend exists across kingdoms, the 
strategy of employing expression codons to optimise genes can be used to enhance protein 
yield in virtually any production platform. 
 
 
Protein half-life 
 
Transient expression of a codon optimised variant of mouse IL-10 without p19 resulted in a 
yield of 29 µg IL-10 per mg TSP on 2 dpi (Chapter 6). This has been the highest yield we have 
been able to obtain for mouse IL-10. Considering that mouse IL-10 is ~8 times smaller 
compared to an antibody, this level of expression in molar terms is even higher compared to 
what we obtained for antibodies (Chapter 3; ~50 µg IgG per mg TSP). Regardless of the 
expression strategy used, the peak of protein accumulation for interleukin-10 was always 
between 2 and 4 days post infiltration (dpi) (Chapter 2 and 6), whereas the peak of 
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accumulation of the antibodies was between 6 and 9 dpi (Chapter 3). This may be explained 
by the differences in protein half-life. It is expected that a less stable protein has its peak in 
expression earlier when compared to a more stable protein. Expression in a transient system is 
lost over time. Consequently, a more stable protein can accumulate for a longer period before 
the level of degradation becomes higher than the level of production as compared to an 
unstable protein. Thus, in planta interleukin-10 half-life is likely shorter than the half-life of 
antibodies. This is in line with their in vivo half-lives. Recombinant interleukin-10 is cleared 
from human blood within 2.5 hours after intravenous administration [33], while recombinant 
IgG1 could still be detected after 30 days [34]. IL-10 yield may be improved further by 
increasing protein stability. Fusion of inherently unstable proteins to more stable proteins has 
been reported to increase expression levels [35, 36]. The fusion of IL-10 to the Fc portion of 
IgG increased its in vivo half-life to 30 hours [37]. However, on dpi 2 or 3 we did not observe 
an increase in human IL-10 yield when we fused it to the Fc portion of IgA (Chapter 2). A 
fusion partner can aid in protein folding by increasing interaction with chaperones and protect 
against proteolytic degradation and ubiquitination. However, in our case the turnover of IL-10 
did not change. It is possible that IL-10 is not unstable in the sense that it is actively targeted 
for degradation, but merely quickly unfolds and is subsequently degraded. If this is the case, 
IL-10 yield could only be improved by modifying intramolecular interactions, disulphide 
bridges, hydrophobicity and/or charge of the protein. It would be a tremendous challenge to 
achieve this without disrupting biological activity or increasing immunogenicity.  
Another striking observation we made concerning antibody yield was that we found 
little variation in yield between idiotypes. This was unexpected as many reports on plant 
expression of antibodies exist and demonstrate a variation in yield of several orders of 
magnitude [38]. Although our experience is limited to two isotypes and three idiotypes, this 
suggests that the expression system determines yield to a greater extent than protein intrinsic 
properties. We used the same coding sequence for the signal peptide that preceded all genes 
and used expression codons to encode the variable regions. The native sequences of the 
constant domains of the human kappa chain, alpha and gamma heavy chains were used, as 
these already used expression codons at high frequency. Thus, in our case mRNA stability, 
translation initiation and translation rate between the antibodies should be comparable, 
leaving protein intrinsic properties as the main variables for yield.  
A unique opportunity to shed more light on variability in antibody yield lies in the 
hands of the company Icon Genetics that expresses antibodies for treatment of non-Hodgkin 
lymphoma. They will express a unique antibody idiotype for each patient and could establish 
a database with expression data of these antibodies. Comparing the expression of idiotypes 
could help determine the variation caused by the variable domains and link codon use of the 
variable regions or protein intrinsic properties, such as hydrophobicity, ubiquitination and 
amino acid content/sequences, to protein yield. Such findings may be translated to other 
proteins and may result in insight into possibilities to enhance protein stability and quality. 
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Protein secretion 
 
It has often been suggested that plants are poor protein secretors, likely based on the fact that 
plants do not secrete many endogenous proteins. We found that secretion efficiency varied 
between antibodies. Evaluation of the secretion efficiency of three idiotypes on both an IgG 
and IgA backbone revealed that secretion was reduced for one of the idiotypes and for IgA in 
general (Chapter 3). The reduction of secretion of IgA may be explained by the presence of a 
cryptic signal peptide in the tailpiece of the alpha heavy chain that leads to vacuolar targeting. 
The lack of secretion based on the idiotype can possibly be attributed to improper protein 
folding. This antibody was enriched in immature N-glycans (high mannose structures), an 
indication of protein misfolding. Misfolded proteins do not leave the ER and therefore do not 
undergo maturation of N-glycans in the Golgi. To our surprise the secretion of the Schistosoma 
mansoni egg antigen omega-1 was estimated to be over 90% (Chapter 5). This was in sharp 
contrast to the secretion of IgG, which was maximum 28%, while the A. thaliana chitinase 
signal peptide was used for expression of all antibody genes as well as omega-1. While cryptic 
subcellular targeting sequences or improper processing may explain some of the variation in 
secretion efficiency, one or more other intrinsic protein properties, such as hydrophobicity or 
charge, must also play a role.  
Judging by the efficiency of omega-1 secretion, plants are not per definition poor 
protein secretors. Increased knowledge on secretion efficiency may provide a solution for 
purification, which is one of the most important bottlenecks for plant-produced heterologous 
proteins. Upon extraction of the apoplastic proteins from N. benthamiana leaves expressing 
omega-1 more than 50% of the isolated proteins was omega-1 as revealed by SDS-PAGE. 
Apoplast extracts are therefore a great basis for purification, facilitating the use of robust 
traditional purification methods such as ion exchange chromatography that do not rely on the 
use of protein tags that may hinder protein activity. 
 
 
N-glycosylation 
 
Not only protein intrinsic properties that influence secretion are largely unknown, but also 
those properties underlying differences in N-glycosylation. Although it is a well-known fact 
that the N-glycan type a protein receives depends on species, tissue, environment and 
developmental stage, it can also differ from protein to protein under identical circumstances. 
The predominant N-glycan types on plant-produced IgG, IgA and omega-1 all differed from 
each other while they were all expressed in 5-6 weeks old N. benthamiana leaves. The typical 
N-glycan found on plant proteins is biantennary with terminal N-acetylglucosamine (GlcNAc 
or Gn) residues and the typical plant sugar residues β1,2-xylose (X) and core α1,3-fucose (F3), 
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abbreviated as GnGnXF3 [39]. This was found to be the predominant N-glycan type on IgG 
(Chapter 3). The second most common N-glycan in plants lacks the terminal GlcNAcs and is 
called paucimannosidic and is abbreviated to MMXF3 [39]. This was found to be the 
predominant N-glycan type on omega-1 (Chapter 5). The predominant N-glycan on IgA lacked 
one terminal GlcNAcs and the core α1,3-fucose (GnMX or MGnX) (Chapter 3), a glycan type 
that occurs in marginal percentages in plants [39], and was never found to be predominant on 
a particular protein. The absence of the α1,3-fucose may be explained by the fact that the core 
of the N-glycans on IgA may not be accessible for core altering glycosyltransferases. Petrescu 
and colleagues (2004) analysed the protein environment of N-glycosylation sites of a wide 
variety of glycoproteins and demonstrated that many N-glycan sites are poorly accessible [40]. 
This could explain why less than half of the N-glycans on human serum IgA carry a typical 
mammalian core α1,6-fucose [41, 42], whereas 80-98% of N-glycans on human serum IgG 
antibodies are core fucosylated [43].  
Thus, accessibility may explain variation in the presence of sugar residues that are 
attached to the N-glycan core. The cause of the variation in the presence of terminal GlcNAcs 
is more elusive. Three β-N-acetylhexosaminidases (HEXO1-3) were identified in Arabidopsis 
thaliana and their enzymatic activity explains the occurence of paucimannosidic N-glycan in 
this plant species [44]. In total 7 genomic sequences are present in N. benthamiana that have 
significant homology to HEXO1-3 [45]. It is therefore likely that also the paucimannosidic N-
glycan fraction in N. benthamiana is the result of β-N-acetylhexosaminidase activity and is not 
caused by a lack of GlcNAc attachment. Upon transient expression of A. thaliana HEXO-
fluorescent protein fusions in N. benthamiana HEXO1 localized to the vacuole and HEXO2/3 
to the plasma membrane [46]. This could imply that only vacuolar and secreted proteins are 
modified to bear paucimannosidic N-glycans. It could well be that the lack of one of the 
GlcNAc residues of the predominant N-glycan of IgA may be the result of β-N-
acetylhexosaminidase activity in either the vacuole or the apoplast. A. thaliana HEXO1-3 were 
all demonstrated to remove the terminal GlcNAc residues from both α1,3- and α1,6-branched 
mannoses without strict preference. However, N. benthamiana may harbour a β-N-
acetylhexosaminidase that does have branch specificity. Alternatively, attachment or removal 
of terminal GlcNAc residues of N-glycans on IgA is inefficient and the predominant N-glycan 
form found is an intermediate.  
The efficient secretion of omega-1 may explain the lack of both GlcNAc residues on 
the predominant N-glycan of omega-1. Nevertheless, another Schistosoma mansoni egg 
antigen expressed in N. benthamiana in our laboratory demonstrated similar secretion 
efficiency as omega-1 and carried N-glycans of the GnGnXF3 type (Wilbers, unpublished 
data). Thus, next to subcellular targeting other unknown protein intrinsic properties must 
influence GlcNAc removal.  
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Intrinsic protein properties may not only influence the type of N-glycan a protein 
receives, but may also influence N-glycosylation efficiency. N-glycosylation of a specific site is 
not always 100% efficient. We observed that the N-glycosylation site found in the joining 
chain and the tailpiece of the alpha heavy chain do not always receive a N-glycan when 
expressed in N. benthamiana (Chapter 3 and 4). Because N-glycosylation is co-translational, 
limited access to the N-glycosylation site cannot explain inefficient N-glycosylation. However, 
in a large-scale analysis of glycoproteins it was demonstrated that the glycosylation signals N-
X-T and N-X-S are N-glycosylated in 70% and 30% of the cases, respectively [40]. Also, the 
amino acid sequence requirements around the glycosylation sites were less biased around N-
X-T sites as compared to N-X-S sites [40]. This suggests that N-X-T sites are more efficiently 
glycosylated compared to N-X-S sites, perhaps through improved site recognition. Both the N-
glycosylation site in the tailpiece of the alpha heavy chains and the joining chain are of the N-
X-S type. Mutation of the serine to a threonine in N-glycosylation sites and/or mutations in the 
surrounding amino acids may increase N-glycosylation efficiency. Whether or not differences 
in N-glycosylation efficiency depend on production platform has not been extensively 
investigated. More knowledge on the protein intrinsic properties that influence N-glycosylation 
efficiency and the N-glycan type is valuable for the field of glyco-engineering, notably when 
combined with the production of biopharmaceuticals.  
 
 
Concluding remarks 
 
Protein intrinsic properties that hamper yield, secretion or N-glycosylation efficiency limit 
protein yield and quality in all platforms and deserve to be the main focus of research into 
heterologous protein production. Most production platforms, including plants, have most likely 
reached their limit in terms of transformation and transcription efficiency. However, an 
increase in translation efficiency may still increase protein yield in some cases. Transient 
expression in N. benthamiana is still unmatched in speed, ease of transformation and low 
costs. Nevertheless, it provides the same advantages as other eukaryotic production platforms. 
It is an excellent platform to study these properties and apply improvements to better produce 
interesting (glyco)proteins for research and possibly clinical purposes. When purification from 
plants is improved and when regulatory hurdles are taken it will be a matter of time before N. 
benthamiana and other plant species become an established production platform for 
biopharmaceutical proteins. 
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Summary 
 
 
 
Current treatments of inflammatory disorders are often based on therapeutic proteins. These 
proteins, so-called biopharmaceuticals, are isolated from a natural resource or, more often, 
made using cell based fermentation systems. The most common production platforms are 
based on the bacterium Escherichia coli, the yeast Saccharomyces cerevisiae or mammalian 
cell lines (mainly Chinese hamster ovarian (CHO) and murine myeloma (SP2/0) cells). Each 
platform has advantages and disadvantages and the protein to be produced largely dictates the 
choice of platform. Plants could provide a unique alternative production platform, as they 
combine the advantage of E. coli being economic with the advantages of mammalian cell lines 
being able to fold complex proteins, assemble heteromultimeric protein complex and, upon 
glyco-engineering, provide proteins with human type N-glycans. Furthermore, plant 
production is easily scaled up as the infrastructure is already in place due to our need for food 
and feed and plants have a limited risk of contamination with human pathogens. Transient 
transformation of N. benthamiana is a valuable plant production platform, as it is unmatched 
in terms of speed (matter of weeks). 
This thesis describes the production of a variety of proteins and protein complexes in 
planta that are or may be used as biopharmaceuticals. Since 1982, plants can be genetically 
manipulated, which has lead to the production of many proteins in a variety of plants. Initially, 
the plants greatest drawback was limited protein yield. However, significant increases in yield 
have been achieved in the last two decades, predominantly by increasing transformation 
efficiency and/or level of transcription. Nowadays several plant expression systems exist that 
facilitate high protein production levels. Most experience is based on the production of 
antibodies, mainly of the IgG isotype, as these are often used as biopharmaceuticals. In 
general, IgG antibodies are produced on a scale of several grams per kilogram fresh weight. 
However, production levels of antibodies have shown to be variable and production levels of 
particular proteins, such as cytokines, have lagged behind. Cytokines form a large group of 
immune-signalling molecules and several cytokines have promising therapeutic potential. 
Their short in vivo half-life suggests an inherent instability, which is regarded the major 
production bottleneck.  
In chapter 2 we describe the production of interleukin (IL)-10, a cytokine with 
immunosuppressive properties. We show that in contrast to mouse IL-10, human IL-10 
multimerises extensively in planta. Both human and mouse IL-10 form homodimeric protein 
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complexes through a mechanism referred to as 3D domain swapping. Only for human IL-10 
3D domain swapping results in extensive multimerisation. By fusing IL-10 to green fluorescent 
protein (GFP) multimerisation was visualised, demonstrating that human IL-10 forms granules 
of organelle size. We discovered that for mouse IL-10 granule formation was prevented by N-
glycosylation of the N-terminus. Introduction of this N-glycosylation site in human IL-10 partly 
prevented granule formation. The insertion of a glycine-serine linker between alpha helices D 
and E of human IL-10, allowing IL-10 to swap its own domains and form a stable monomer. 
This prevented granule formation completely and boosted protein yield 30-fold. However, the 
now comparable yields of human and mouse IL-10 were still low when compared to for 
instance IgG. 
In the next two chapters we shifted the focus to the production of antibodies. Thus far 
the IgA isotype received little attention as candidate biopharmaceutical. However, the unique 
features of IgA, such as the ability to recruit neutrophils and suppress the inflammatory 
responses mediated by IgG and IgE, make it a promising antibody isotype for several 
therapeutic applications. Therefore, we compared the plant-based expression of IgA to IgG 
(Chapter 3). The variable regions of three antibodies commonly used in the clinic to treat 
inflammatory disorders (Infliximab, Adalimumab and Ustekinumab) were grafted on either an 
IgG1κ or IgA1κ backbone. Surprisingly, we achieved comparable high expression levels for all 
antibodies. The large variation in antibody yield found in literature is therefore likely due to 
differences in expression systems and experimental conditions, but not to the antibody 
idiotype used.  
Evaluation of the secretion efficiency and N-glycosylation profiles revealed compelling 
differences between IgG and IgA antibodies when expressed in planta. Compared to IgG, IgA 
was poorly secreted. Poor secretion is most likely due to vacuolar targeting of IgA, as it was 
previously demonstrated that murine IgA contained a cryptic vacuolar targeting signal in the 
tailpiece. IgA also carried different N-glycans compared to IgG, which were never found to be 
a main fraction of a plant-produced protein. The predominant N-glycan on IgA lacked both the 
typical plant core α1,3-fucose and one terminal N-acetylglucosamine (GlcNAc). The core 
α1,3-fucose is most likely not added due to low accessibility of the core of the N-glycans. The 
lack of one GlcNAc may be due to inefficient addition of this sugar residue or (partial) β-
hexosaminidase activity that may occur in both the vacuole and the apoplast. Whether the 
vacuolar targeting plays a role in the lack of the GlcNAc and what protein intrinsic properties 
influence partial GlcNAc addition or removal is unclear. We also showed that the N-
glycosylation site in the IgA tailpiece does not always receive a N-glycan, which may be 
significant for secretory IgA formation as described in chapter 4. 
In chapter 4 we describe the expression of this large heteromultimeric protein complex. 
Secretory IgA consists of two IgA complexes that are connected via the joining chain and 
associate with a part of the polymeric-Ig-receptor (called the secretory component). The 
challenge for sIgA expression is that assembly of four polypeptides (the alpha heavy chain, the 
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light chain, the joining chain and the secretory component) in a 4:4:1:1 ratio is required. 
Previous studies on stable and transient expression of sIgA demonstrated that sIgA formation in 
plants is possible. However, sIgA was always accompanied by a large proportion of 
monomeric IgA as well as other assembly intermediates. The presence of assembly 
intermediates may be caused be unequal expression and/or stability of the individual 
components. However, we demonstrated that not the expression strategy, but protein complex 
assembly through impaired incorporation of the joining chain was the limiting step for sIgA 
production. Because joining chain incorporation depends on N-glycosylation of the IgA 
tailpiece we hypothesise that the partial N-glycosylation of the IgA tailpiece is the cause of 
inefficient joining chain incorporation. The efficiency of N-glycosylation may be improved by 
mutation of the glycosylation site N-X-S to an N-X-T site, as the latter glycosylation motif was 
shown to be more often occupied in a large-scale glycosylation site analysis. 
Successful engineering of the plant glycosylation pathway to provide 
biopharmaceuticals with human N-glycan types has been achieved. Glyco-engineering also 
provides the opportunity to generate potentially interesting N-glycan types with regard to 
immunogenicity for vaccination purposes or protein trafficking for in vivo targeting of 
biopharmaceuticals. In chapter 5 we describe the expression of the Schistosoma mansoni egg 
antigen omega-1, an immunomodulatory protein with therapeutic potential. Its biological 
activity depends on its RNAse activity and its N-glycans that enable internalisation by human 
dendritic cells. Omega-1 cannot be isolated from natural resources in sufficient quantities to 
study its in vivo biology i.e. which N-glycan types facilitate full activity of omega-1. Therefore, 
we set up the plant-based production of this protein. S. mansoni-derived omega-1 
predominantly carries diantennary N-glycans with a Lewis X motif on one or both antennae. 
Lewis X consists of a β1,4-linked galactose and α1,3-linked fucose residue attached to a 
terminal GlcNAc. This attachment is performed by β1,4-galactosyltransferase and α1,3-
fucosyltransferase IXa that naturally do not occur in plants. Co-expression of these two 
glycosyltransferases with omega-1 resulted in a N-glycan profile comparable to S. mansoni-
derived omega-1. However, it was necessary to control the expression of the β1,4-
galactosyltransferase to contain this enzyme in the trans-Golgi compartment. Overexpression 
most likely leads to overflow of β1,4-galactosyltransferase to the medial-Golgi and 
galactosylation at this stage disturbs the activity of other glycosyltransferases resulting in hybrid 
N-glycan types.  
We also observed that more than 90% of omega-1 was secreted to the apoplast, which 
facilitated efficient purification. This demonstrated that plants, as previously suggested, are not 
poor protein secretors. However, the underlying protein properties controlling secretion 
efficiency are currently unknown. Both omega-1 and IgG are very efficiently secreted under 
natural circumstances. Yet, despite the fact that we used the same signal peptide to facilitate 
secretion of IgG and omega-1, IgG was only secreted from plant cells to a maximum of 28%. 
More knowledge on protein secretion efficiency in plants may overcome cumbersome 
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purification, currently the greatest bottleneck in the downstream processing of plant produced 
proteins. 
Finally in chapter 6, we shifted focus from the expression of a particular protein to the 
effect of codon use on protein yield. We designed a codon optimisation strategy that, unlike 
other strategies, turned out to be surprisingly robust. This strategy is based on a general codon 
bias found in plants. Because this codon bias could be found among plant species, including 
monocots and dicots, and resulted in an increase in mRNA stability and translatability, we 
suspected that this codon bias arises from a selection pressure on the mRNA structure. We 
extended this general codon bias to representative species of other kingdoms of life and 
demonstrate that there is a selection pressure increasing mRNA stability and translatability 
(more protein per mRNA molecule). Stability was the result of an increase in the number of 
nucleotide bonds. However, there is a trade off between mRNA stability and translatability, 
and the nucleotide bonds in an mRNA should be well balanced over the entire molecule, 
making it ‘airy’, to ensure efficient translation.  
Altogether we conclude that transformation efficiency and level of transcription are no 
longer limiting factors for protein yield upon plant-based expression. However, an increase in 
translation initiation and translation rate dictated by codon use may still provide an increase in 
protein production. Furthermore, we show that many proteins demonstrated specific 
production bottlenecks. The yield of human IL-10 was hampered by its extensive 
multimerisation, sIgA assembly is most likely limited by inefficient N-glycosylation of the 
tailpiece of IgA, both IgG and IgA are inefficiently secreted compared to omega-1 and IgA 
displayed an aberrant N-glycosylation profile. Therefore, more knowledge on how protein 
intrinsic properties influence protein yield and/or quality of heterologous produced proteins in 
plants should now be generated. Transient expression in N. benthamiana is an ideal tool to 
study these protein intrinsic properties that limit protein yield in heterologous expression.!
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Samenvatting 
 
 
 
Farmaceutische eiwitten spelen een steeds grotere rol in de behandeling van auto-
immuunziekten en chronische ontstekingen. Deze eiwitten vallen onder de noemer 
‘biofarmaceutica’ en worden geïsoleerd uit menselijk of dierlijk bloed of weefsel, of, wat 
tegenwoordig vaker het geval is, gemaakt met behulp van levende cellen. Een bekend 
voorbeeld hiervan is insuline, een eiwit dat gebruikt wordt voor de behandeling van diabetes 
(suikerziekte). Insuline werd oorspronkelijk uit de alvleesklier van geslachte varkens en 
runderen gehaald, maar wordt nu gemaakt met behulp van de bacterie Escherichia coli. Het 
voordeel hiervan is dat in tegenstelling tot insuline uit varkens en koeien, de insuline gemaakt 
door E. coli identiek is aan die van de mens. Dit voorkomt dat ons immuunsysteem het 
insuline als lichaamsvreemd herkent en vernietigd wordt. Daarnaast is door E. coli-
geproduceerde insuline vele malen goedkoper. Er bestaan verschillende productiesystemen en 
veel biofarmaceutica worden met behulp van E. coli gemaakt, maar ook de gist 
Saccharomyces cerevisiae en dierlijke cellijnen worden vaak gebruikt. Elk productiesysteem 
heeft voor- en nadelen en het gewenste eiwit bepaald welk systeem gebruikt kan en zal 
worden. Onderzoek naar het gebruik van planten heeft in de laatste jaren meer aandacht 
gekregen omdat planten net als E. coli goedkoop in gebruik zijn en net als dierlijke cellen in 
staat zijn complexe eiwitten te maken. Het telen van planten is ook makkelijk op te schalen 
aangezien de infrastructuur al aanwezig is ten behoeve van de voedselproductie.  
Dit proefschrift beschrijft het gebruik van planten voor de productie van een variatie 
aan eiwitten en eiwitcomplexen die gebruikt worden of in de toekomst mogelijk gebruikt 
kunnen worden als biofarmaceutica. Sinds 1982 kunnen planten genetisch gemodificeerd 
worden, waardoor men in staat is elk gewenst eiwit in planten te maken. De genetische 
modificatie kan op verschillende manieren bereikt worden, maar vaak wordt gebruik gemaakt 
van een bacterie genaamd Agrobacterium tumefaciens, die planten van nature kan 
‘transformeren’. Dat doet deze bacterie door enkele van zijn eigen genen in het genoom van 
de plant in te bouwen die er voor zorgen dat de bacterie van nutriënten wordt voorzien. De 
genen die de bacterie overdraagt, kunnen vervangen worden door een gen dat codeert voor 
een door ons gewenst eiwit. Een veel gebruikte plant voor productie van eiwitten is de 
tabaksplant Nicotiana benthamiana. De bladeren van deze tabaksplant kunnen geïnfiltreerd 
worden met een suspensie van Agrobacterium tumefaciens, zoals te zien op de voorkant van 
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dit proefschrift (de donkere delen). Na enkele dagen is de productie van het gewenste eiwit 
waar te nemen. 
De eerste pogingen om biofarmaceutica in planten te maken resulteerden in een te laag 
productieniveau om economisch interessant te zijn. In de laatste twee decennia is de 
efficiëntie van transformatie sterk verbetert en heeft het aanpassen van regulerende elementen 
voor genexpressie voor een sterke verbetering van de productie gezorgd. Tegenwoordig 
bestaan er verschillende productiestrategieën die een hoog productieniveau in planten kunnen 
bewerkstelligen. De meeste ervaring is opgedaan met de productie van antilichamen. Iedereen 
heeft miljarden verschillende antilichamen in zijn/haar lichaam. Elk antilichaam is in staat één 
specifiek molecuul te binden. Vaak zijn antilichamen gericht tegen moleculen afkomstig van 
ziekteverwekkers, maar technieken zijn ontwikkeld om antilichamen te maken die een 
gewenst molecuul kunnen binden. Vanwege deze unieke eigenschap worden antilichamen 
vaak ingezet als biofarmaceutica om ongewenste moleculen in ons lichaam te neutraliseren. 
Elk antilichaam bestaat uit variabele domeinen die de bindingsspecificiteit bepalen en 
constante domeinen die voor interactie met het immuunsysteem zorgen. Er bestaan 
verschillende constante domeinen die het zogenaamde isotype bepalen. De verschillende 
isotypen hebben ieder een specifieke interactie met het immuunsysteem. Antilichamen van het 
IgG isotype worden het meest gebruikt als biofarmaceutica. Over het algemeen kunnen IgG 
antilichamen gemaakt worden in een orde van grootte van grammen per kilogram 
plantmateriaal, maar het productieniveau van antilichaam tot antilichaam kan erg variëren. 
Het productieniveau van andere biofarmaceutica, zoals bijvoorbeeld die van de 
cytokines, blijft vaak achter in vergelijking met de productie van antilichamen. Cytokine is de 
verzamelnaam van een grote groep eiwitten die een rol spelen in de signalering tussen cellen 
van het immuunsysteem. Vele cytokines zouden mogelijk gebruikt kunnen worden voor de 
behandeling van auto-immuunziekten en chronische ontstekingen. Hun korte levensduur 
suggereert dat ze van nature instabiel zijn, wat wordt aangenomen als de hoofdreden voor de 
achterblijvende productie.  
In hoofdstuk 2 beschrijven wij de productie van interleukine-10 (IL-10), een cytokine 
met ontstekingsremmende eigenschappen. We laten zien dat humaan IL-10, in tegenstelling 
tot muis IL-10, multimeriseert in planten. Zowel humaan als muis IL-10 vormen onder normale 
omstandigheden homodimeren (twee dezelfde eiwitmoleculen die aan elkaar binden). Voor 
IL-10 gaat dit als in een yin-yang teken; het eerste deel van het IL-10 eiwit wordt uitgewisseld 
met het tweede deel van een ander IL-10 eiwit en visa versa, een mechanisme dat 3D ‘domain 
swapping’ wordt genoemd. In tegenstelling tot muis IL-10 beperkt zich dit voor humaan IL-10 
echter niet tot twee eiwitten, maar wordt een soort ketting gevormd. Hierbij bind het eerste 
domein van eiwit 1 met het tweede domein van eiwit 2, maar bind het eerste domein van 
eiwit 2 met het tweede domein van eiwit 3 etc. Door IL-10 te fuseren met groen fluorescent 
eiwit werd de multimerisatie gevisualiseerd en hiermee konden we aantonen dat humaan IL-
10 granules vormt ter grote van organellen in de cel (tot wel 0.005 millimeter groot). We 
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ontdekten dat de formatie van granules van muis IL-10 werd voorkomen door een 
suikermolecuul (N-glycaan) die op het eiwit gezet wordt tijdens de productie (een proces wat 
N-glycosylering wordt genoemd). Door er voor te zorgen dat ook humaan IL-10 een 
suikermolecuul kreeg, werd de formatie van granules grotendeels voorkomen. Door het 
invoegen van een extra stuk flexibele linker tussen het eerste en tweede domein van humaan 
IL-10 kon het eerste domein uitgewisseld worden met het tweede domein van hetzelfde eiwit. 
Op deze manier vormt zich een stabiele monomeer. Deze strategie voorkwam de formatie van 
granules volledig en resulteerde in een 30 keer hogere opbrengst van humaan IL-10.  
In de volgende twee hoofdstukken hebben we onze focus verschoven naar de 
productie van antilichamen. De productie van het IgA isotype heeft vooralsnog niet veel 
aandacht gekregen als potentieel biofarmaceutisch eiwit. Desalniettemin maken de unieke 
eigenschappen van IgA het een interessant eiwit voor therapeutische doeleinden. IgA is in staat 
neutrofielen (de meest voorkomende witte bloedcellen) te rekruteren en deze cellen zouden 
ingezet kunnen worden om bijvoorbeeld kanker te bestrijden. Daarnaast kan IgA door IgG en 
IgE geïnduceerde immuunreacties onderdrukken en zou dus als ontstekingsremmer kunnen 
functioneren. Daarom hebben wij de productie van humaan IgA in planten vergeleken met die 
van humaan IgG (hoofdstuk 3). Drie antilichamen (Infliximab, Adalimumab en Ustekinumab) 
die veelvuldig gebruikt worden in de kliniek om chronische ontstekingen te behandelen (zoals 
de ziekte van Crohn en reumatoïde artritis) werden als IgG en IgA geproduceerd. Alle 
antilichamen bereikten een vergelijkbaar hoog productieniveau, dit in tegenstelling tot wat we 
op basis van de literatuur hadden verwacht. De grote variatie in opbrengst beschreven in de 
literatuur wordt daarom waarschijnlijk vaker veroorzaakt door verschillen in 
productiesystemen en experimentele condities, en minder vaak door intrinsieke verschillen 
van antilichamen.  
Daarentegen hebben we wel wezenlijke verschillen tussen IgG en IgA gevonden met 
betrekking tot de uitscheiding en N-glycosylering. Vergeleken met IgG werd IgA aanzienlijk 
minder uitgescheiden door plantencellen. Dit is wellicht een gevolg van het feit dat IgA 
waarschijnlijk naar de vacuole wordt gedirigeerd. Voor muis IgA is aangetoond dat het eiwit 
naar de vacuole gaat door de aanwezigheid van een signaal in het staartstuk van het eiwit. 
Humaan IgA heeft een vergelijkbaar signaal en zou dus ook in de vacuole terecht kunnen 
komen. Daarnaast draagt plant-geproduceerd IgA ook hoofdzakelijk andere N-glycanen 
vergeleken met plant-geproduceerd IgG. De voornaamste N-glycaan op IgA miste het voor 
planten kenmerkende suikerresidu α1,3-fucose en het eindstandige suikerresidu N-
acetylglucosamine (GlcNAc). Dat er geen α1,3-fucose toegevoegd wordt, komt wellicht door 
slechte bereikbaarheid van de N-glycaan voor het enzym om dit suikerresidu er aan te 
koppelen. De afwezigheid van een van de eindstandige GlcNAcs is mogelijk ook een gevolg 
van inefficiënte koppeling van dit suikerresidu of het gevolg van (gedeeltelijke) afsplitsing door 
het enzym β-hexosaminidase. Het is nog onduidelijk of humaan IgA, net als muis IgA, naar de 
vacuole wordt gestuurd, of dit een rol speelt in de afwezigheid van de eindstandige GlcNAc 
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en welke inherente eiwiteigenschappen hier aan ten grondslag liggen. Wel hebben we 
aangetoond dat N-glycosylering van het staartstuk van humaan IgA niet altijd plaats vindt, wat 
de vorming van het eiwitcomplex secretoir (s)IgA zou kunnen beperken (hoofdstuk 4). 
In hoofdstuk 4 beschrijven we de productie van sIgA. Dit grote eiwitcomplex bestaat 
uit twee IgA moleculen die met elkaar verbonden zijn via een J-keten met daaromheen 
gevouwen een eiwit dat de secretoire component wordt genoemd. De uitdaging voor het 
maken van sIgA is dat de assemblage van vier verschillende eiwitten (de zware keten, de lichte 
keten (samen IgA), de J-keten en het secretoire component) een 4:4:1:1 ratio behoeft. 
Voorgaande studies hebben aangetoond dat productie van sIgA in planten mogelijk is, maar de 
productie ging altijd gepaard met de aanwezigheid van een grote hoeveelheid monomeer IgA 
en andere tussenvormen van het complex. Een ongelijke productie of stabiliteit van de 
individuele eiwitten zouden de aanwezigheid van deze tussenvormen kunnen verklaren. Wij 
hebben echter laten zien dat de koppeling van de J-keten aan de IgA moleculen de limiterende 
stap is voor de vorming van het complex en niet de productiestrategie. We veronderstellen dat 
de eerder waargenomen partiële N-glycosylering van het staartstuk van IgA ten grondslag ligt 
aan de inefficiënte koppeling van de J-keten.  
In hoofdstuk 5 besteden we aandacht aan het aanpassen van de N-glycosylering in 
planten. Als model eiwit maken we gebruik van omega-1, een eiwit dat uitgescheiden wordt 
door de eieren van de humaan parasitaire worm Schistosoma mansoni. De biologische 
activiteit van omega-1 is afhankelijk van zijn N-glycanen die opname door humane 
dendritische cellen bewerkstelligen. Omega-1 is een immuun-modulatoir eiwit met 
therapeutische potentie, maar kan niet in voldoende hoeveelheden geïsoleerd worden uit 
natuurlijke bronnen. Daarom hebben wij een productiesysteem opgezet om omega-1 met zijn 
natuurlijke N-glycaan te maken in planten. De N-glycanen van omega-1 dragen ‘Lewis X’ 
motieven die bestaan uit een eindstandige GlcNAc met daaraan een β1,4-galactose en α1,3-
fucose gekoppeld. Deze suikerresiduen worden door de enzymen β1,4-galactosyltransferase 
en α1,3-fucosyltransferase IXa toegevoegd en deze enzymen komen van nature niet voor in 
planten. De gelijktijdige productie van deze enzymen met omega-1 resulteerde in een N-
glycaan profiel dat vergelijkbaar was met natuurlijk omega-1.  
We ontdekten ook dat ~90% van het geproduceerde omega-1 werd uitgescheiden door 
plantencellen. Hierdoor was de zuivering van dit eiwit relatief eenvoudig. Dit demonstreert dat 
planten prima in staat zijn eiwitten op grote schaal uit te scheiden, waar het tegenovergestelde 
in het verleden werd gesuggereerd. Ondanks het feit dat we dezelfde strategie gebruikt hebben 
om secretie van IgG en omega-1 door plantencellen te bewerkstelligen, werd maximaal 28% 
IgG uitgescheiden tegenover ~90% omega-1. Welke inherente eiwiteigenschappen 
uitscheiding beïnvloeden is nog onbekend. Meer onderzoek naar de secretie van eiwitten door 
plantencellen zou een oplossing kunnen bieden voor de moeizame zuivering van eiwitten uit 
planten, het huidige knelpunt van veruit de meeste plant-productiesystemen.  
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In hoofdstuk 6 beschrijven we niet de productie van een specifiek eiwit, maar richten 
we ons op een algemeen aspect van eiwitproductie; de vertaling van gen naar eiwit. Eiwitten 
worden gecodeerd door genen die opgebouwd zijn uit vier verschillende bouwstenen; de 
nucleotiden cytosine (C), guanine (G), adenine (A) en thymine (T). De combinatie van drie 
nucleotiden wordt een codon genoemd en codeert voor een specifiek aminozuur. Aminozuren 
worden in een keten geschakeld en kunnen vervolgens met elkaar interacties aangaan om zo 
een eiwit te vormen. Eukaryote eiwitten kunnen maximaal 20 verschillende aminozuren 
bevatten en elk aminozuur kan door 1, 2, 4 of 6 codons gecodeerd worden. In andere 
woorden maximaal 6 codons coderen voor hetzelfde aminozuur. Het gebruik van de 
verschillende codons is nooit gelijk en welk codon het meest gebruikt wordt is afhankelijk van 
de soort. Je zou dus kunnen spreken van ‘dialecten’ tussen verschillende soorten. Hoe minder 
verwant de soorten zijn, hoe groter het verschil in het dialect. Omdat de soorten die gebruikt 
worden om menselijke eiwitten te maken een ander dialect hebben dan mensen, vinden deze 
soorten het soms moeilijk de menselijke genen te ‘verstaan’. Als gevolg hiervan zal er minder 
van het eiwit gemaakt worden dan wellicht mogelijk is. Daarom zijn vele verschillende 
methodes ontwikkeld om menselijke genen te ‘vertalen’ naar het dialect van producerende 
soorten. Echter zijn de resultaten behaald met deze methodes erg variabel. Ook wij hebben 
een strategie ontwikkeld voor de vertaling van genen die verrassend succesvol bleek. Onze 
strategie is niet gebaseerd op het dialect van ons productie platform N. benthamiana, maar het 
dialect in een bepaalde set genen uit verschillende ver-verwante plantensoorten; namelijk de 
genen die erg veel gebruikt worden. Uit voorgaand onderzoek was gebleken dat verschillende 
plantensoorten, inclusief ver-verwante plantensoorten, allemaal met hetzelfde dialect spreken 
als het hun veel gebruikte genen betreft. Onze strategie, gebaseerd op dit ‘veel gesproken’ 
dialect, resulteerde in aanzienlijk hogere eiwitproductie in planten. We laten dit niet alleen 
zien voor een menselijk eiwit, maar ook voor een kippen- en kwalleneiwit. Dit stimuleerde het 
bestuderen van veel gebruikte genen in niet-plantensoorten en we ontdekten dat dit veel 
gesproken dialect van planten grotendeels gedeeld wordt door ver-verwante soorten uit 
verschillende biologische rijken. We leveren daarnaast ook indirect bewijs voor een 
onderliggende selectiedruk.  
In dit proefschrift laten wij zien dat naast het aanpassen van het ‘dialect’ van genen het 
aanpassen van regulerende elementen waarschijnlijk niet meer zal leiden tot significante 
productietoename, maar dat veel eiwitten eiwit-specifieke productie-knelpunten hebben. De 
opbrengst van humaan IL-10 werd beperkt door multimerisatie, sIgA complexvorming wordt 
mogelijk beperkt door de inefficiënte N-glycosylering van het staartstuk van IgA, zowel IgA als 
IgG worden inefficiënt uitgescheiden vergeleken met omega-1 en vertoonde IgA een afwijkend 
N-glycaan profiel ten opzichte van IgG. Daarom is meer kennis vereist over hoe eiwit-
inherente eigenschappen de kwaliteit en opbrengst van eiwitten beïnvloeden. Daarbij is 
productie van eiwitten in N. benthamiana een ideaal wetenschappelijk instrument om deze 
eiwit-inherente eigenschappen en hun effect op eiwit opbrengst te onderzoeken. !
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